




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 6 :</b>  <b>A61B 8/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/08597</b>  <b>(43) International Publication Date:</b> 25 February 1999 (25.02.99)
<b>(21) International Application Number:</b> PCT/US98/17240  <b>(22) International Filing Date:</b> 19 August 1998 (19.08.98)  <b>(30) Priority Data:</b> 08/914,527      19 August 1997 (19.08.97)      US 09/096,857      12 June 1998 (12.06.98)      US  <b>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications</b> US      08/914,527 (CIP) Filed on      19 August 1997 (19.08.97) US      09/096,857 (CIP) Filed on      12 June 1998 (12.06.98)  <b>(71)(72) Applicants and Inventors:</b> MENDLEIN, John, D. [US/US]; 680 Neptune Avenue, Leucadia, CA 92024 (US). LANG, Philipp [DE/US]; 225 Lincoln Way #206, San Francisco, CA 94122 (US).  <b>(74) Agent:</b> KIM, Stanley, H.; Gray Cary Ware & Freidenrich, Suite 1600, 4365 Executive Drive, San Diego, CA 92121 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> MULTI-SITE ULTRASOUND METHODS AND DEVICES, PARTICULARLY FOR MEASUREMENT OF FLUID REGULATION		
<b>(57) Abstract</b>  The present invention provides for methods, and devices for ultrasound monitoring especially capillary related interstitial thickness. The invention also includes methods of measuring capillary related interstitial fluid as well as cardiac, vascular, and renal function. Specific devices, particularly probes (520, 600) are provided for such methods.		



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

**MULTI-SITE ULTRASOUND METHODS AND DEVICES,  
PARTICULARLY FOR MEASUREMENT OF FLUID REGULATION**

**TECHNICAL FIELD**

5           The invention relates to the multi-site ultrasound methods, compositions and devices, particularly methods, compositions and devices that provide for the measurement and monitoring of fluid regulation, especially a capillary related edema layer in a human.

**BACKGROUND**

10           For over thirty years ultrasound has been used as a safe and effective diagnostic tool. During this time many different types of ultrasound methods and devices have been developed, such as imaging techniques, Doppler flow methods, and speed of sound measurements, as well as their respective devices. Clinicians use such  
15   methods and devices in a variety of clinical settings that range from obstetrics to cardiology.

          Imaging methods and devices can provide details of the topography of various tissues. Although ultrasound techniques cannot typically interrogate the range of tissues with the same anatomical detail as state of the art nuclear magnetic resonance  
20   imaging techniques and devices, ultrasound imaging is extremely cost effective and easy to operate by comparison. For many imaging situations, ultrasound is often preferred over magnetic resonance imaging for patient management because ultrasound imaging provides relatively fast imaging times and sufficient interrogation of anatomic details using comparatively inexpensive devices and operation costs.

25           Doppler flow methods and devices can provide information about blood flow in tissues. Doppler systems have been used from many years to inexpensively monitor blood flow in the vessels of the body. Doppler systems can also be combined with imaging techniques to probe additional details of vessel function, such as velocity profiles across the vessel.

30           Because ultrasound techniques have been extensively used for many years, the side effects of ultrasound are not an issue for clinicians. The safety of ultrasound

is well recognized in the field of medical imaging and diagnostics. As Bushberg et al points out:

“Ultrasound has established a remarkable safety record related to potential bioeffects caused by the exposure to mechanical radiation used at the typical intensity levels for diagnostic imaging and Doppler exams. In fact, there has never been any confirmed bioeffects on either patients or operators of diagnostic ultrasound procedures.” *The Essential Physics of Medical Imaging*, Bushberg, J. T., et al, Chapter 12, page 414 (1994).

Despite the widespread use of ultrasound as a safe and effective diagnostic tool many types of ultrasound technology have not been developed or clinical applications of existing ultrasound technology have not been recognized. Many areas remain unexplored and the inventors of the present invention offer new ultrasound technologies and applications to provide better patient management for clinicians, particularly for fluid regulation.

Fluid regulation comprises a critical component of human physiology. The inability to properly maintain fluid compartments and fluid transport underlies a myriad of human medical conditions. Yet, despite the importance of fluid regulation, and its role in potentially life threatening conditions (e.g. edema), accurate, simple and reliable assessments of fluid regulation are not available to the clinician or patient alike. Traditionally, evaluation methods have been related to edema, which include visual inspection of the extremities, tissue palpation by a clinician, and measurement of the circumference of the extremity. Although these methods are familiar assessments to clinicians, none of these methods is quantitative and all suffer from tremendous variability due to inter- and intra-clinician variability of the measurements.

Visual inspection of the affected body region yields information on changes in the color and texture of the skin. Skin changes in patients with edema include discoloration and ulceration. Unfortunately, such skin changes occur typically only in patients with long-standing, chronic edema and are not useful for diagnosing early or discrete edema. Furthermore, skin changes are difficult to assess on a quantitative scale and are not useful for monitoring a response to treatment of edema or the underlying cause of the edema.



Visual inspection can also yield information on arteries and veins, e.g. varicose veins may be visible and may be identified as a potential cause for capillary related edema. Such identification of vascular pathology, unfortunately, is only qualitative, is limited to assessment of the vascular system, and cannot provide information on the patient's fluid status or on cardiac, renal or hepatic performance.

Manual palpation can be used to evaluate edema. For manual palpation, a finger is pressed gently but firmly into the patient's skin and subjacent tissue. The depth of the resultant indentation and persistence of the indentation after the finger has been released yield information on the severity of the edema. A semiquantitative scale can be used to assess the severity of the edema, typically consisting of five different grades: 0.) absent, I.) slight, II.) mild, III.) moderate, and IV.) severe (see Bates et al., J.B. Lippincott, 1995). Results obtained with manual palpation are, however, subjective and difficult to reproduce.

Circumference measurements of appendage regions and limbs have also been employed for assessing edema. These measurements of changes in circumference of a limb or an appendage region are limited to detecting large increases in interstitial fluid. Subtle increases or also decreases in interstitial fluid in early or mild forms of capillary related edema will be masked since the change in circumference induced by the interstitial fluid shift (usually on the order of few millimeters or less) will be small compared to the overall circumference of the appendage region or limb (usually on the order of several centimeters or decimeters).

In addition, tracer and biochemical assays are available to a clinician to study fluid and solute regulation. Such analytical techniques, although often quantitative, typically require time consuming steps, special sample preparation or equipment, trained operators, or invasive sample removal. Often such techniques are limited only to providing information at the time point of sample removal.

Consequently, the present inventors have recognized the need, among other things, to provide reliable, quantitative and accurate ultrasound devices and methods for such applications, particularly multi-site devices. The methods and devices provided herein permit continuous, cost effective monitoring and accurate measurement of fluid regulation, including capillary related interstitial fluid, in patients in a variety of diverse clinical settings.

**TABLE OF CONTENTS**

	<b>TECHNICAL FIELD.....</b>	<b>1</b>
	<b>BACKGROUND.....</b>	<b>1</b>
	<b>SUMMARY.....</b>	<b>5</b>
5	<b>BRIEF DESCRIPTION OF FIGURES .....</b>	<b>11</b>
	<b>DETAILED DESCRIPTION OF THE INVENTION.....</b>	<b>13</b>
	<b>1.0 ABBREVIATIONS AND DEFINITIONS .....</b>	<b>13</b>
	<b>2.0 INTRODUCTION.....</b>	<b>31</b>
	<b>3.0 METHODS AND DEVICES FOR MULTI-SITE MONITORING.....</b>	<b>34</b>
10	<i>Multi-probe Sets.....</i>	<i>35</i>
	<i>Multi-site Monitoring .....</i>	<i>37</i>
	<i>Anatomical Maps from Multi-probe Sets .....</i>	<i>38</i>
	<i>Multi-site Monitoring Time Course and Sites .....</i>	<i>41</i>
	<i>Other Multi-site Devices.....</i>	<i>42</i>
15	<b>4.0 ULTRASOUND PROBES FOR IN SITU MEASUREMENTS .....</b>	<b>44</b>
	<i>Examples of Advantages of the Invention.....</i>	<i>52</i>
	<i>Considerations Related to Acoustic Power .....</i>	<i>52</i>
	<i>Other Applications.....</i>	<i>54</i>
	<b>5.0 METHODS AND DEVICES FOR MULTI-SITE MONITORING</b>	
20	<b>OF FLUID REGULATION .....</b>	<b>54</b>
	<i>Application Sites .....</i>	<i>59</i>
	<i>Application to Medical Treatment .....</i>	<i>61</i>
	<i>Different Types of Monitoring .....</i>	<i>70</i>
	<i>Calculations and Standard .....</i>	<i>72</i>
25	<i>Empirical Methods for Determining Standards .....</i>	<i>77</i>
	<b>6.0 METHODS AND DEVICES FOR MULTI-SITE MONITORING</b>	
	<b>OF CAPILLARY RELATED EDEMA.....</b>	<b>80</b>
	<i>Anatomical Regions .....</i>	<i>81</i>
	<i>Use in Medical Conditions and Treatment.....</i>	<i>83</i>
30	<i>Devices for Testing for Capillary Related Edema.....</i>	<i>88</i>
	<i>Calculations and Standards.....</i>	<i>89</i>
	<b>7.0 METHODS AND DEVICES FOR MULTI-SITE MONITORING</b>	
	<b>OF VASCULAR PERFORMANCE.....</b>	<b>89</b>
	<b>8.0 METHODS AND DEVICES FOR MULTI-SITE MONITORING</b>	
35	<b>OF CARDIAC PERFORMANCE.....</b>	<b>99</b>
	<b>9.0 METHODS AND DEVICES FOR MULTI-SITE MONITORING</b>	
	<b>OF RENAL DISORDERS AND FUNCTION.....</b>	<b>105</b>
	<b>EXAMPLES .....</b>	<b>109</b>
40	<b>GENERAL MATERIALS AND METHODS .....</b>	<b>109</b>
	<b>EXAMPLE 1: ULTRASONOGRAPHIC MEASUREMENT</b>	
	<b>OF TISSUE THICKNESS IN AN IN VITRO</b>	
	<b>MODEL OF CAPILLARY RELATED EDEMA.....</b>	<b>110</b>

**EXAMPLE 2: ULTRASONOGRAPHIC MEASUREMENT  
OF THICKNESS OF CAPILLARY RELATED  
EDEMA IN A MODEL OF VENOUS  
INSUFFICIENCY AND RIGHT VENTRICULAR  
CARDIAC FAILURE ..... 113**

**EXAMPLE 3: ULTRASONOGRAPHIC MEASUREMENT  
OF THICKNESS OF PRETIBIAL EDEMA IN  
A MODEL OF CAPILLARY RELATED EDEMA  
SECONDARY TO ABNORMAL COLLOID OSMOTIC  
PRESSURE AND/OR RENAL FAILURE ..... 124**

10	<b>PUBLICATIONS.....</b>	<b>127</b>
	<b>U.S. PATENT DOCUMENTS.....</b>	<b>127</b>
	<b>FOREIGN PATENT DOCUMENTS.....</b>	<b>127</b>
	<b>OTHER PUBLICATIONS.....</b>	<b>127</b>
15	<b>CLAIMS.....</b>	<b>129</b>
	<b>ABSTRACT .....</b>	<b>150</b>

20

### **SUMMARY**

The present invention recognizes for the first time that ultrasound can be applied to the measurement of fluid regulation using multiple ultrasound probes. The invention finds particular application for convenient and cost effective measurements in a variety of clinical settings. Previously, it was not recognized that diagnostic ultrasound measurements of fluid regulation were possible, or precise. Nor was it recognized that clinically rapid shifts in fluid regulation, especially in capillary related interstitial fluid distribution in tissues, could be monitored using ultrasound methods or devices. The invention includes monitoring of fluid regulation in a subject using ultrasound wave devices and methods as described herein. Aspects of the invention are directed to continuous or intermittent monitoring, such as capillary related edema monitoring in a human. Selected aspects of multi-site ultrasound probes can also be used in areas other than monitoring fluid regulation as described herein.

In one embodiment, the invention includes a method of multi-site monitoring of capillary related edema in a subject. The method includes: a) positioning an ultrasound probe on an epidermal surface of at least two anatomical regions of a subject in need of capillary related edema detection, b) applying at least one ultrasound pulse to a subcutaneous layer of the at least two anatomical regions, c)

recording a least one ultrasound signal from each of the at least two anatomical locations, and d) detecting the presence or absence of a capillary related edema layer in the subcutaneous layer in each of the at least two anatomical regions from the ultrasound signals of step (c). Typically, the method includes detecting a capillary related edema layer that extends from an inner surface of skin to either a bone or fat surface in the tibia region. Preferably, the method uses at least three ultrasound probes positioned at three or more anatomical regions.

Often such methods will be applicable to patients having diabetes, compromised renal function or compromised cardiac function will benefit from such examinations. The method can also include a medical treatment and examination before, after or in parallel (or a combination thereof) with such a treatment. Typically, such a subject will be a human desiring a capillary related interstitial fluid assessment because a clinician wishes to use the invention as a part of a diagnosis.

The invention also includes a multi-site ultrasound system for monitoring capillary related edema. The system includes at least two ultrasound probes each comprising a connection to separately (or integratively) and concurrently connect each ultrasound probe to a computational unit. Each connection permits signals to pass between each ultrasound probe and the computational unit. The computational unit typically comprises at least one chip to process signals from the at least two ultrasound probes, to send instructions to the at least two ultrasound probes, and to monitor capillary related edema from at least two anatomical locations. Each probe may also have a chip to facilitate interrogation. Preferably, the multi-site ultrasound system comprises at least three or four ultrasound probes. The multi-site ultrasound system's computational unit may be designed to measure or calculate an ILT (interstitial layer thickness). Usually, the computational unit has instructions for concurrently or parallel monitoring from the at least two anatomical locations during clinically relevant time periods. The computational unit may include instructions for continuous monitoring. A standard thickness for skin layer thickness may be stored in the computational unit for calculations or as a reference thickness.

The invention also includes a therapeutic kit, comprising: a multi-site ultrasound system for monitoring capillary related edema, comprising at least two multi-site ultrasound probes, a computational unit for estimating capillary related

edema based on monitoring of capillary related edema based at two or more anatomical regions; and

a health care product in at least one dosage; wherein the multi-site ultrasound system can monitor for a therapeutic effect of the at least one dosage.

5           In another embodiment the invention includes a method of multi-site monitoring of capillary related interstitial layer thickness. The method comprises: transmitting at least one ultrasound pulse to at least two anatomical regions in a subject in need of capillary related interstitial fluid assessment, recording at least one ultrasound signal from each of the at least two anatomical regions, and determining a  
10   capillary related interstitial layer thickness from a first reflective surface to an internal reflective surface from each of the at least two anatomical regions, wherein the capillary related interstitial layer thicknesses are an assessment of capillary related interstitial fluid. Typically, the first reflective surface is a probe-skin interface and the internal reflective surface is from a bone. Such methods are particularly  
15   useful for monitoring fluid regulation during surgery, administration of a general anesthetic, or intubation or a combination thereof.

In addition, the method applies to emergency room situations and trauma care. The steps of the method can be repeated during a clinical relevant time period after the trauma and sequential capillary related interstitial layer thicknesses are determined to  
20   help assess fluid regulation in the patient. Usually, the recording occurs at clinically relevant time intervals over at least about a 4 hour time period. Preferably, each of the at least two ultrasound probes has a surface area no more than about 2 cm<sup>2</sup>.

The inventors were also the first to recognize that ultrasound methods and devices could be applied to the assessment of different aspects of integrated cardiac,  
25   vascular, or renal function related to fluid regulation. Numerous aspects of the present invention circumvent many of the disadvantages of the current techniques for evaluating dynamic performance of the heart or vascular system.

For example, the present invention provides for a noninvasive assessment of vascular performance that is relatively inexpensive, easily performed by a clinician  
30   (not necessarily a physician trained in ultrasound techniques) and can integrate tissue effects into the assessment, especially capillary related tissue effects. Typically, a test of vascular performance, includes two basic steps: reducing or increasing blood flow

(or pressure) to a tissue in a subject in need of vascular performance assessment (step (a)), and multi-site monitoring of capillary related interstitial layer or ILT of the tissue (step (b)). Monitoring ILT with ultrasound probes can be before, after or concurrent with reducing or increasing blood flow in step (a).

- 5 Other techniques and devices are described herein for assessments of cardiac, renal, and capillary function. Such aspects of the invention can also be used to assess the effect of medical treatments on such physiological functions.

The invention also provides for the first time methods and devices for multi-site monitoring of different anatomical regions either concurrently or at predetermined  
10 time intervals. Monitoring anatomical changes during clinically relevant time periods or continuous monitoring provides an important diagnostic tool for detecting short or rapid changes in tissue structure, particularly interstitial layer thickness. In contrast to previous work, the invention is able to measure rapid changes in capillary related interstitial fluid volume or ILT and monitor capillary related interstitial fluid volume  
15 or ILT from different anatomical regions simultaneously or within short time frames to compare capillary related interstitial fluid volume or ILTs from different regions. The sensitivity of this method to changes ILT can be quite sensitive, such as less than about 1 to 2 millimeters.

In one aspect, the invention provides for a method of multi-site monitoring of  
20 ILT. The method comprises transmitting an ultrasound pulse from a first ultrasound probe to a first anatomical region and transmitting an ultrasound pulse from a second ultrasound probe to a second anatomical region. The method includes recording ultrasound signals from a first ultrasound probe to a first anatomical region and recording ultrasound signals from a second ultrasound probe to a second anatomical  
25 region. The method also includes monitoring interstitial layer thickness from the first and second, or more, anatomical regions. Typically, the method is practiced by monitoring from the first anatomical region concurrently with monitoring from the second anatomical region.

Another related aspect of the invention includes a multi-probe set that may be  
30 used for multi-site monitoring. The multi-probe set comprises a first ultrasound probe comprising a first output port, the first ultrasound probe adapted for continuous or in situ monitoring at a first anatomical region and a second ultrasound probe

comprising a second output port, the second ultrasound probe adapted for continuous or in situ monitoring at a second anatomical region. Such output ports can often transmit signals to the probe (e.g. out from the signal processing unit), as well as from the probe. The set can include an ultrasound system to concurrently process  
5 first signals from the first ultrasound probe and second signals from the second ultrasound probe. Systems or sets with more than two probes can also be used. Each probe in the set can be adapted for a particular anatomical region or indication. For example, the anatomical region can be selected from the group consisting of the forehead region, anterior tibia region, foot region, distal radius region, elbow region,  
10 presternal region and temporal bone region. Preferably, the ultrasound probe is a micro-transducer adapted for monitoring interstitial layer thickness or A scan.

The invention provides for the first time micro-transducers applied to the skin of a subject for ultrasound measurements of tissue structure. Typically, the micro-transducers are adapted for either monitoring ILT or capillary related edema, usually  
15 on the skin in a predetermined anatomical region. As described herein, the micro-transducers are typically small about 10 to 20 mm<sup>2</sup> or less in surface area, not hand-held but rather attachable to the skin surface, and lightweight. Preferably, micro-transducers are isolated and not connected to an ultrasound system or display by a conductive wire (i.e. wireless), as described herein. In use, the micro-transducers are  
20 usually secured to the skin of a subject for continuous monitoring of the interrogated region.

The invention also provides for a compact ultrasound probe for in situ ultrasound measurements. Such a compact probe will typically comprise: at least one ultrasound crystal in acoustic communication with an acoustic coupling material, an  
25 ultrasound crystal holder adapted for securing the acoustic coupling material to a surface of an object or subject for in situ ultrasound measurements, and a connection for connecting the at least one ultrasound crystal to an ultrasound output or recording system, wherein the connection is compatible with securing the ultrasound probe for in situ ultrasound measurements. Preferably, the probe is adapted for A scan and not  
30 adapted for B scan. The compact ultrasound probes usually include a chip to facilitate signal processing or transmission. The connection can comprise an electrical coupling for transmitting electrical signals to an ultrasound computational

unit. The electrical coupling is sufficiently light to permit the ultrasound probe to rest on the subject without substantial interference with ultrasound interrogation and ultrasound probe placement and the subject is a human. Preferably, the probe is wireless. The connection may be an infra red coupling for transmitting signals to an ultrasound computational unit. The infra red coupling is sufficiently light to permit the ultrasound probe to rest on the subject without substantial interference with interrogation and ultrasound probe placement and the subject is a human. The connection may be a radio frequency coupling for transmitting signals to an ultrasound computational unit. The radio frequency coupling is sufficiently light to permit the ultrasound probe to rest on the subject without substantial interference with interrogation and ultrasound probe placement and the subject is a human. Preferably, the coupling material has a surface area of about  $2\text{cm}^2$  or less.

The invention also provides for a multi-probe set with a control chip, preferably etched-silicon micro-circuit, in each probe to facilitate interrogation or reduce noise. Typically, multi-probe set comprises: a first ultrasound probe comprising a first output port, a first chip for controlling operation of the first ultrasound probe and the chip may optionally include a program for multi-site monitoring or A scan and a first housing or frame for the first ultrasound probe and the first chip, wherein the first ultrasound probe adapted for continuous or in situ monitoring at a first anatomical region, and a second ultrasound probe comprising a second output port and a second chip for controlling operation of the second ultrasound probe and the chip may optionally include a program for multi-site monitoring or A scan and a second housing or frame for the first and second ultrasound probes and the chip, wherein the second ultrasound probe adapted for continuous or in situ monitoring at a second anatomical region.

The invention also provides for a probe or multi-probe set equipped with radio frequency transmitter(s) to relay signals between a probe and a command unit, such as an ultrasound system. A radio frequency linkable, ultrasound medical probe, typically comprises: a first ultrasound probe comprising a first output port and an ultrasound source and detector, said first ultrasound probe is adapted for in situ monitoring, preferably at a first anatomical region. The first output port comprises a first radio frequency transmitter for connecting said first ultrasound probe to a signal



processing unit. The first ultrasound probe can be adapted for multi-site monitoring. A set can include additional such probes as described herein.

The invention also provides for a remote sensing or isolated, medical probe that emits wave form energy into, or receives wave form energy from, a tissue. A remote sensing, medical probe typically comprises a medical probe selected from the group consisting of a MRI probe, an ultrasound probe, a radioactivity probe and a photon probe. The remote sensing, medical probe also includes a first radio frequency transmitter, whereby said first radio frequency transmitter can connect said medical probe to a signal processing unit. The remote sensing, medical probe may optionally a probe of human physiology, such as a temperature, oxygen, pH, conductivity, electrical or salinity probe. Such dual or multi-functional monitoring probes are particularly useful devices for in situ monitoring of patients.

#### **BRIEF DESCRIPTION OF THE FIGURES**

**FIG. 1 A-C** show an example of capillary related interstitial fluid accumulation. **FIG. 1A** shows normal leg tissue prior to an increase in capillary related interstitial layer thickness. Skin is "S". Tibia is "T". Fibula is "F". Muscle is "M" and interstitial layer is "IL". The probe interrogation site **100** is a preferred site for monitoring capillary related changes in ILT. The tissue plane **110** is approximately illustrated by the arrows. **FIG. 1B** and **C** illustrate a small but progressive increase in ILT around **100** over time.

**FIG. 2 A-C** shows a magnified view of probe interrogation site **100** from **FIG. 1**. IL is located between skin **200** (dotted layer) and muscle or bone **210** (cross-hatched layer). **FIG. 2B** and **C** illustrate that IL (wave-line layer) increases dramatically due to an increase in capillary related interstitial fluid.

**FIG. 3** shows selected, exemplary anatomical regions that can be used for ultrasound monitoring of capillary related interstitial fluid and capillary related edema in a human in need of such monitoring. Exemplary ultrasound interrogation sites include but are not limited to the forehead region **300**, the temporal region **310**, the forearm region **320**, the humeral region **330**, the presternal region **340**, the lateral chest wall region **350**, the lateral abdominal region **360**, the tibial region **370**, and the

foot region **380**. The exemplary regions illustrated in **FIG. 3** can be used alone or in combination, as described herein.

**FIG. 4** is a magnified view of the tibial region **370** demonstrating the proximal third of the tibia region **400**, the mid-tibia region **410**, the distal third of the tibia  
5 region **420**, and the medial malleolus region **430**.

**FIG. 5A** and **B** show embodiments of the invention comprising an ultrasound transducer secured to a subject or a tissue surface with an adhesive probe holder, which is preferably used for intermittent or continuous recording. The ultrasound transducer can be electrically coupled to an ultrasound computational unit (not shown)  
10 using a lightweight wire **500**. An electrical connector **510** connects the computational unit and the ultrasound transducer **520** using an electrical connecting socket or connector means **530**. The ultrasound transducer **520** is optionally seated inside a positioning frame **540**. The undersurface of the positioning frame consists of an acoustic coupler **550**. The positioning frame is attached to the subject or tissue  
15 surface using an adhesive **560**. The adhesive **560** can acoustically couple the ultrasound probe to the skin of the subject or the interrogated tissue surface **570**. The adhesive **560** can also be interspersed with an acoustic coupling material, such as a gel (not shown). Tibia is "T". Fibula is "F". Muscle is "M" and interstitial layer is "IL".

**FIG. 5B** shows that the ultrasound transducer **520** can also be coupled to an  
20 ultrasound computational unit (not shown) using an infrared coupler or a radio frequency coupler **580** or other connector means that transmits signals **590** to an ultrasound computational unit.

**FIG. 6** shows one embodiment of the invention comprising an ultrasound transducer **600** attached to a separate positioning frame **620** with an attachment  
25 member **610**. The extending members **630** of the positioning frame are attached to securing members **640** to secure the frame to the skin away from the interrogation site. The securing members are secured to the skin using an adhesive or other anatomical region attachment means (not shown). The ultrasound transducer is electrically coupled to an ultrasound computational unit (not shown) using a light  
30 weight wire **650**. Alternatively, the ultrasound transducer can be coupled to an ultrasound computational unit using an infrared or radio frequency coupler (not shown).

## **DETAILED DESCRIPTION OF THE INVENTION**

### **1.0 ABBREVIATIONS AND DEFINITIONS**

*ABBREVIATIONS* include first reflective distance (FRD), interstitial fluid (IF), interstitial fluid content (IFC) interstitial fluid layer (IFL), interstitial fluid monitoring  
5 (IFM), interstitial layer thickness (ILT), interstitial fluid volume (IFV) and shortest reflective distance (SRD).

*Acoustic communication* refers to the passage of ultrasound waves between two points in a predetermined manner. Usually, this is accomplished by selecting a desired pathway between the two points that permits the passage of ultrasound waves  
10 either directly or indirectly. Direct passage of ultrasound waves would occur, for instance, when an ultrasound crystal is directly disposed to (usually touching) an acoustic coupling material, such as a composite. Indirect passage of ultrasound waves would occur, for instance, when an ultrasound crystal is located at a predetermined distance from an acoustic coupling material or when a number of acoustic coupling  
15 materials, often heterogenous materials, form two or more layers.

*Acoustic coupler* refers to a connection or plurality of connections between an ultrasound crystal and a substance that reflects or passes ultrasound pulses and is not part of the device. The acoustic coupler will permit passage of ultrasound waves. It is desirable for such couplers to minimize attenuation of ultrasound pulses or signals and  
20 to minimize changes in the physical properties of an ultrasound wave, such as wave amplitude, frequency, shape and wavelength. Typically, an ultrasound coupler will either comprise a gel or other substantially soft material, such as a pliable polymer matrix, that can transmit ultrasound pulses. Alternatively, an ultrasound sound coupler can be a substantially solid material, such as a polymer matrix, that can  
25 transmit ultrasound pulses. An ultrasound coupler is usually selected based on its acoustic impedance match between the object being interrogated and the ultrasound crystal(s). If a reflective surface is desired, for instance as a spatial marker, a larger impedance difference is selected compared to situations where it is advantageous to minimize a reflective surface to avoid a sharp reflective surface.

30 *Acoustic coupling material* is a material that passes ultrasound waves, usually from a probe to a subject or tissue to be interrogated. It is usually not a living material and is most often a polymer or gel.

*Anatomical region* refers to a site on the surface of the skin, tumor, organ or other definable biomass that can be identified by an anatomical feature or location. Usually, such a region will be definable according to standard medical reference methodology, such as that found in Williams et al., Gray's Anatomy, 1980.

5        *Appendage region* refers to a site on the surface of a limb of a subject. Examples of appendage regions include a variety of sites on a leg or an arm, such as a humeral or tibia region.

*A - scan* refers to an ultrasound technique where an ultrasound source transmits an ultrasound wave into an object, such as patient's body, and the amplitude  
10 of the returning echoes (signals) are recorded as a function of time. Only structures that lie along the direction of propagation are interrogated. As echoes return from interfaces within the object or tissue, the transducer crystal produces a voltage that is proportional to the echo intensity. The sequence of signal acquisition and processing of A - scan data in a modern ultrasound instrument usually occurs in six major steps:

15        *Detection* of the echo (signal) occurs via mechanical deformation of the piezoelectric crystal and is converted to an electric signal having a small voltage.

*Pre-amplification* of the electronic signal from the crystal, into a more useful range of voltages is usually necessary to ensure appropriate signal  
20 processing.

*Time Gain Compensation* compensates for the attenuation of the ultrasound signal with time, which arises from travel distance. Time gain compensation may be user-adjustable and may be changed to meet the needs of the specific application. Usually, the ideal time gain compensation curve  
25 corrects the signal for the depth of the reflective boundary. Time gain compensation works by increasing the amplification factor of the signal as a function of time after the ultrasound pulse has been emitted. Thus, reflective boundaries having equal abilities to reflect ultrasound waves will have equal ultrasound signals, regardless of the depth of the boundary.

30        *Compression* of the time compensated signal can be accomplished using logarithmic amplification to reduce the large dynamic range (range of smallest to largest signals) of the echo amplitudes. Small signals are made

larger and large signals are made smaller. This step provides a convenient scale for display of the amplitude variations on the limited gray scale range of a monitor.

*Rectification, demodulation and envelope detection* of the high  
5 frequency electronic signal permits the sampling and digitization of the echo amplitude free of variations induced by the sinusoidal nature of the waveform.

*Rejection* level adjustment sets the threshold of signal amplitudes that are permitted to enter a data storage, processing or display system. Rejection of lower signal amplitudes reduces noise levels from scattered ultrasound  
10 signals.

*Blood* refers to whole blood. Blood does not refer to red blood cell concentrates.

*Blood flow* refers to blood movement in a blood vessel (e.g., coronary, vein, artery, venole, arteriole, shunt, or capillary). Blood flow is usually associated with  
15 blood entering or leaving a tissue or definable anatomical region, such as an appendage or a specific vessel (e.g., artery, vein, naturally occurring and non-naturally occurring shunt, or coronary).

*B - scan* refers to an ultrasound technique where the amplitude of the detected returning echo is recorded as a function of the transmission time, the relative location  
20 of the detector in the probe and the signal amplitude. This is often represented by the brightness of a visual element, such as a pixel, in a two-dimensional image. The position of the pixel along the y-axis represents the depth, i.e. half the time for the echo to return to the transducer (for one half of the distance traveled). The position along the x-axis represents the location of the returning echoes relative to the long  
25 axis of the transducer, i.e. the location of the pixel either in a superoinferior or mediolateral direction or a combination of both. The display of multiple adjacent scan lines creates a composite two-dimensional image that portrays the general contour of internal organs.

*Cardiac performance* refers to at least one physical functioning property of the  
30 heart at rest, such as an EKG, ST segment, QRS wave, estimated cardiac output, estimated contractility, afterload or preload. Dynamic cardiac performance refers to at least one physical functioning property of the heart during a physiological challenge,

such as physical exercise (e.g. predetermined physical exercise or uncontrolled exercise), mental stress, medical treatment or diagnostic maneuvers (e.g. breath holding).

*Chip* refers to any current and future electronic compact hardware device within a computational unit that can be used as an aid in controlling the components of an ultrasound unit including: 1) timing and synchronizing trigger pulses and subsequent transmission of ultrasound waves, 2) measuring and analyzing incoming ultrasound signals, 3) determining the shortest reflective distance generated from ultrasound signals reflected from multiple different ultrasound waves emitted at different transmission angles, 4) estimating body fat and edema using various equations, 5) measuring various anatomical landmarks, 6) comparing data to predetermined standards and data cut-offs (e.g. electronic filtering), 7) generating anatomical maps of ultrasound parameters, and 8) performing multiple other simple and complex calculations. Chips are preferably integrated circuits, usually etched-silicon circuits, of micron dimension or less.

*Clinically relevant time period* refers to a period of time when changes in physiology are expected or detected. Such periods can be on the order of seconds (e.g., 5 to 300 seconds or less) for rapid physiological changes, such as changing position from sitting to standing; minutes (e.g. about 2 to 40 minutes or less) for relatively rapid physiological changes, such as shock or inflammation; and hours to days (e.g. about .5 to 4 hours or about 0.5 days to 1 week or more) for slow physiological changes, such as altitude acclimation, long term medical treatment that might require weeks or months to detect a change, and diet acclimation.

*Computational unit* refers to any current or future software, chip or other device used for calculations, such as reflective distance calculations, now developed or developed in the future. The computational unit may be designed to determine the shortest reflective distance when two or more ultrasound sources are employed at different transmission angles. The computational unit may be designed to control the ultrasound generator or source, for defining or varying the firing rate and pulse repetition rate (as well as other parameters related to the ultrasound generator or source), for measuring the reflected signal, for image reconstruction in B-scan mode and for filtering and thresholding of the ultrasound signal. Other applications of the

computational unit to the methods and devices described herein will be recognized by those skilled in the art. The computational unit may be used for any other application related to this technology that may be facilitated with use of computer software or hardware.

5           *Crystal* refers to the material used in the ultrasound transducer to transmit ultrasound waves and includes any current and future material used for this purpose. Crystals typically consist of lead zirconate titanate, barium lead titanate, lead metaniobate, lithium sulfate and polyvinylidene fluoride or a combination thereof. A crystal is typically a piezoelectric material, but any material that will contract and  
10   expand when an external voltage is applied can be used, if such a material can generate ultrasound waves described herein and known in the art. Crystals emit ultrasound waves because the rapid mechanical contraction and expansion of the material moves the medium to generate ultrasound waves. Conversely, when incoming ultrasound waves deform the crystal, a current is induced in the material.  
15   The materials then emits an electrical discharge that can be measured and, ultimately, with B-scan technology be used to reconstruct an image. Crystals or combinations of crystals with dipoles that approximate the acoustic impedance of human tissue are preferred, so as to reduce the impedance mismatch at the tissue/probe interface.

*C - scan* refers to an ultrasound technique where additional gating electronics  
20   are incorporated into a B-scan to eliminate interference from underlying or overlying structures by scanning at a constant-depth. An interface reflects part of the ultrasound beam energy. All interfaces along the scan line may contribute to the measurement. The gating electronics of the C - mode rejects all returning echoes except those received during a specified time interval. Thus, only scan data obtained from a  
25   specific depth range are recorded. Induced signals outside the allowed period are not amplified and, thus, are not processed and displayed. C-mode-like methods are also described herein for A-scan techniques and devices in order to reduce the probe/skin interface reflection.

*Detector* refers to any structure capable of measuring an ultrasound wave or  
30   pulse, currently known or developed in the future. Crystals containing dipoles are typically used to measure ultrasound waves. Crystals, such as piezoelectric crystals, shift in dipole orientation in response to an applied electric current. If the applied

electric current fluctuates, the crystals vibrate to cause an ultrasound wave in a medium. Conversely, crystals vibrate in response to an ultrasound wave that mechanically deforms the crystals, which changes dipole alignment within the crystal. This, in turn, changes the charge distribution to generate an electric current across a crystal's surface. Electrodes connected to electronic circuitry sense a potential difference across the crystal in relation to the incident mechanical pressure.

*Echogenicity* refers to the brightness of a tissue in an ultrasound image relative to the adjacent tissues, typically on a B-scan image. Echogenicity is dependent on the amount of ultrasound waves reflected by the tissue. Certain tissues are more echogenic than other tissues. Fatty tissue, for example, is more echogenic than muscle tissue. For identical imaging parameters, fatty tissue will thus appear brighter than muscle tissue. Consequently, image brightness can be used to identify different tissues.

*Grip* refers to a portion of a probe that is grasped by an operator. As described herein, most grip designs permit a human to self measure anatomical regions that are normally difficult to accurately interrogate using a handheld probe designed to be operated by a person that is not the subject.

*Heart failure* refers to the pathophysiologic state in which an abnormality of cardiac function is responsible for the failure of the heart to pump blood at a rate commensurate with the requirements of the metabolizing tissues and/or in which the heart can do so only from an abnormally high filling pressure. *Compensated heart failure* refers to a condition in which the heart functions at an altered, but stable physiologic state, e.g. at a different but stable point on the Frank-Starling-curve, through an increase in preload or after development of myocardial hypertrophy.

*Decompensated heart failure* refers to a condition in which the heart functions at an altered and unstable physiologic state in which cardiac function and related or dependent physiologic functions deteriorate progressively, slowly or rapidly. Compensated or decompensated heart failure can result in multiple complications, such as fluid regulation (including a progressive increase in capillary related edema), progressive renal failure, or progressive ischemic tissue damage.

*Linear array* refers to a transducer design where the crystals are arranged in a linear fashion along one or more axes. Crystals can be fired in sequential, as well as



non-sequential and simultaneous firing patterns or a combination thereof. With sequential firing, each crystal can produce an ultrasound beam and receive a returning echo for data collection. The number of crystals in one array usually determines the number of lines of sight for each recording. With segmental firing, a group or segment  
5 of crystals can be activated simultaneously resulting in a deeper near field and a less divergent far field compared with sequential activation. A segmental linear array produces, however, a smaller number of lines of sight when compared to a sequential linear array with the same number of crystals.

*Lymphedema* refers to a condition that can be congenital or acquired and is  
10 characterized by abnormal lymphatic drainage from damage to, or obstruction of, the lymph vessels. Causes of secondary lymphedema, include bacterial lymphangitis, surgery, radiation, and trauma. Unlike capillary related edema, which can develop within minutes or few hours, lymphedema develops slowly over days and months. In chronic stages of lymphedema, the affected body part has a woody texture and the  
15 tissues become fibrotic and indurated.

*Mechanically connected* refers to a connection between two or more mechanical components, such as an ultrasound source having at least two transmission positions. A mechanical connection between two transmission positions may be accomplished using a mechanical motor to rotate or move an ultrasound source.  
20 Optionally, the ultrasound source can be rotated or moved on a track.

*Mechanical motor* refers to any device that can move the ultrasound source from a first to a second position and, if desired, to additional positions. A mechanical motor may employ a spring-like mechanism to move the ultrasound source from said first to said second position. A mechanical motor may also employ a hydraulic, a  
25 magnetic, an electromagnetic mechanism or any other current and future mechanism that is capable of moving the ultrasound source from a first to a second position.

*Medical condition* refers to a physiological state of a subject, usually a human, that is not normal and would usually benefit from, or require, medical treatment. Such states may arise from a variety of conditions, including diseases, physiological  
30 challenges, trauma, infection, stress, drug abuse, and accelerated aging.

*Medical treatment* refers to an action intended to confer a medical or physiological benefit on a subject, including surgery, catheterization, drug

administration (e.g. either by the subject or by a health care worker), exercise, diet and non-invasive medical techniques (e.g. ultrasound and intravenous administration of electrolytes or osmotically active substances).

*Myxedema* refers to an infiltrative lesion of the skin of the pretibial area.

- 5    Myxedema can occur in patients with autoimmune thyroid disease, such as Graves' disease. Unlike capillary related edema, pretibial myxedema results from deposition of mucin in the dermis. Myxedema develops slowly over months and years. The affected area is demarcated from normal skin by the fact that it is raised, thickened, and may be pruritic and hyperpigmented. The lesions are usually discrete assuming a plaque-like or nodular configuration.

*Non-orthogonal probe alignment* refers to alignment of the probe at an angle other than 90 degrees relative to the object or tissue plane to be measured, such as the probe/skin interface or the subcutaneous fat/muscle interface.

- 15    *Parallax adjustment* refers to a correction of distance measurements for probe mis-alignment. Parallax will result when the ultrasound transducer is placed on the skin in a non-orthogonal orientation thereby creating a transmission angle smaller or greater than 90 degrees. As the difference between the ideal transmission angle of 90 degrees, i.e. perpendicular probe alignment, and the actual transmission angle increases, the ultrasound beam has to travel along an increasingly longer path through the object thereby artifactually overestimating the actual object or tissue layer thickness. A parallax adjustment, i.e. a correction of artifactually elongated distance measurements can, however, be obtained by transmitting multiple ultrasound waves at different transmission angles. The ultrasound wave that has the transmission angle that is closest to 90 degrees will yield the smallest parallax error and therefore provide the best parallax adjustment.

- 25    *Plane* refers to the surface of a cross-sectional area of tissue interrogated by an ultrasound probe. In ultrasound, the portion of the tissue included in the measurement or image is more accurately referred to as a volume. The x-dimension of this volume reflects the length of the tissue plane, i.e. the length of imaged tissue. The x-dimension typically varies between 1 and 10 cm or more. The y-dimension reflects tissue depth from the plane, e.g. the distance from the skin surface to a reflection point in the tissue. The y-dimension (or depth of the interrogation) depends, among other

things, on the type of transducer, the type of tissue, and the frequency with which the ultrasound beam is transmitted. With higher frequencies, tissue penetration decreases and the maximum depth from the tissue plane will decrease. The y-dimension typically varies between 1 and 30 cm. The z-dimension corresponds to the width of the plane that is interrogated. It typically varies between 1 and 15-20 mm.

*Potential fluid space* refers to a compartment of the body that may fill with fluid, including blood, under certain conditions. Such conditions include medical conditions, such as trauma, blood vessel breakdown (e.g., partial or complete), breakdown (e.g., partial or complete) of epithelium and infection. Potential fluid spaces include the subarachnoid, subdural, epidural, mediastinal, perinephric, peritoneal or pleural spaces.

*Self measurement* refers to the ability of a subject to monitor or measure a portion of a subject's body, preferably in real time.

*Shortest reflective distance* refers to the shortest distance between the surface of an ultrasound transducer and a particular layer interface in a object, such as a transducer and a subjacent tissue interface that can be measured with ultrasound. The shortest reflective distance represents the best approximation of the distance measured by ultrasound of the true anatomic distance between the surface of a transducer and a subjacent tissue interface, such as the fat/muscle interface. Skin thickness can also be measured or estimated and subtracted from the shortest reflective distance to calculate the fat layer thickness, as described herein. The shortest reflective distance can be measured when an ultrasound transducer is oriented to the tissue interface in an orthogonal fashion. The reflective distance can be calculated as:

$$RD = \text{SOS} \times t/2, \quad [\text{Eq. 1}]$$

where RD is the reflective distance, SOS is the speed of sound in a given medium and t is the time interval between transmission of the ultrasound wave and return of the signal to the transducer. The shortest reflective distance can be determined by selecting the appropriate RD as described herein.

The shortest reflective distance can be determined by using at least two or preferably multiple ultrasound pulses, where an ultrasound source provides a pulse at a predefined transmission angle. Transmission angles from an ultrasound source

typically differ by at least 1 degree. Reflective distances between an ultrasound source and the tissue interface in question will be measured using the formulae described herein or developed in the art. The ultrasound source that has the transmission angle that is closest to 90 degrees will usually yield the smallest value for reflective distance. This value is least affected by parallax between the probe and the tissue interface and is referred to as shortest reflective distance. *Calculation of shortest reflective distance* refers to electronic or mathematical determination of the shortest reflective distance using the methods described herein. Reflective distance will be calculated for ultrasound waves obtained at various transmission angles. A computational unit can then determine which wave yielded the smallest RD value in order to select the shortest reflective distance.

*Skin* refers to the external tissue layer in humans and animals consisting of epidermis and dermis.

*Skin related definitions:*

*Epidermis* refers to the outer, protective, nonvascular layer of the skin of vertebrates, covering the dermis. The epidermis consists histologically of five layers, i.e. the stratum corneum, the stratum lucidum, the stratum granulosum, the stratum spinosum, and the stratum basale.

*Dermis* refers to the sensitive connective tissue layer of the skin located below the epidermis, containing nerve endings, sweat and sebaceous glands, and blood and lymph vessels. Histologically, the dermis consists of a papillary layer and a reticular layer. The papillary layer contains the vessels and nerve endings supplying the epidermis. The reticular consists predominantly of elastic fibers and collagen.

*Subcutaneous tissue layer* refers to a tissue layer located below the skin. This tissue layer is typically characterized by a loose meshwork of connective tissue such as collagen and elastic fibers. It is rich in small vessels, e.g., arterioles and venules, and capillaries. In edematous states, the subcutaneous tissue layer can expand extensively. Edema will expand the space between the cells and may also result in diffuse swelling of the cells. Owing to its loose cellular network and abundant amount of capillaries, the subcutaneous tissue layer is often the first or one of the first locations affected

by early, developing edema. The relative amount of the different tissues will vary depending on the anatomic location. In the anterior tibial region, for example, connective tissue predominates, while in the abdominal or buttocks region adipose tissue will predominate. If it is desired to quantitatively measure interstitial layer thickness, it is preferable to select sites that contain predominantly connective tissue and vessels, since these sites can potentially change more rapidly or and expand to a greater extent than sites predominantly containing adipose tissue.

*Tibia related definitions:*

*Anterior aspect of the tibia* refers to the surface of the tibia facing in anterior direction. The cross-section of the tibia is triangular with an anteriorly, a laterally, and a posteriorly facing surface. The laterally and posteriorly facing surfaces are covered by several centimeters of muscle tissue. The anterior surface of the tibia, however, is only covered by skin and, in healthy, non-edematous subjects, a thin subcutaneous tissue layer. This subcutaneous tissue layer can enlarge extensively in subjects with capillary related edema. Since there is no interposed muscle layer, the thickness of the subcutaneous tissue/edema layer can be assessed clinically in this location by compressing the tissue against the underlying bone. Cortical bone at the anterior aspect of the tibia is also a strong ultrasound reflector demonstrating a sharply defined reflective interface in the ultrasound image thereby facilitating measurements of the thickness of the subcutaneous tissue/edema layer.

*Proximal third of the tibia* refers to a measurement site at the anterior aspect of the upper tibia. The medial knee joint space and the medial malleolus are localized by manual palpation. The distance between the medial knee joint space and the medial malleolus is measured with a tape measure and subdivided into three equidistant portions, upper, middle, and lower. Alternatively, the distance between the lateral knee joint space and the lateral malleolus can be measured and subdivided into three equidistant portions. The border between the midportion and the upper portion defines the proximal third of the tibia site.

*Mid-tibia* refers to a measurement site at the anterior aspect of the tibia halfway between the medial knee joint space and the medial malleolus or, alternatively, the lateral knee joint space and the lateral malleolus.

5        *Distal third of the tibia* refers to a measurement site at the anterior aspect of the lower tibia. The border between the midportion, as measured above (see “proximal third of the tibia”), and the lower portion defines the distal third of the tibia site.

10       *Lateral malleolus* refers to a bony protuberance at the lateral aspect of the ankle joint. The lateral malleolus is formed by the fibula and represents the lateral portion of the ankle mortise.

*Medial malleolus* refers to a bony protuberance at the medial aspect of the ankle joint. The medial malleolus is formed by the tibia and represents the medial portion of the ankle mortise.

15       *Therapeutic agent* refers to an active substance that produces a beneficial effect in a subject when administered in a therapeutically effective amount using a therapeutically effective modality. Such agents include active substances directed to specific physiological processes or systems, such as, but not limited to, diuretic, hepatic, pulmonary, vascular, muscular, cardiac or diabetic agents. Usually, such agents will modify the physiological performance of a target tissue or cell in order to  
20       shift the physiological performance of the target tissue or cell towards a more homeostatic physiological state. Such agents can be administered in as collection of active substances or therapeutic agents.

*Therapeutic kit* refers to a collection of components that can be used in a medical treatment.

25       *Therapeutic dosage* refers to a dosage considered to be sufficient to produce an intended effect.

*Therapeutically effective modality* refers to a manner in which a medical treatment is performed and is considered to be sufficient to produce an intended effect.

*Tissue related definitions:*

*Fat/fascia interface* refers to the border between the proximal surface of the subcutaneous fat tissue layer and a potential distal surface of the fascial tissue layer.

5           *Fat/muscle interface* refers to the border between the proximal surface of the subcutaneous fat tissue layer and the distal surface of the muscle tissue layer.

10           *Inner border of subcutaneous fat tissue* refers to the interface between the subcutaneous fat and the subjacent muscle, if present, or the interface between the subcutaneous fat and the subjacent fascia, if present.

*Muscle/bone interface* refers to the border between the proximal surface of the muscle tissue layer and the distal surface of the subjacent layer of bone, e.g. the femur in the thigh, the tibia or fibula in the calf, the humerus in the upper arm, or the radius or ulna in the forearm.

15           *Muscle/internal organ interface* refers to the border between the proximal surface of the muscle tissue layer and the adjacent distal surface of the internal organs.

*Outer border of subcutaneous fat tissue* refers to the interface between the patient's skin and the subcutaneous fat.

20           *Skin/fat interface* refers to the border between the proximal surface of the skin layer and the distal surface of the subcutaneous fat tissue layer.

*Tissue* refers to an organized biomaterial usually composed of cells. For dietary purposes, a distinction is made between fatty tissue and lean tissue. Fatty tissue is composed of adipose cells, while lean tissue includes all other  
25           tissues except for bone.

*Tissue volume* may contain several different layers of tissue, such as skin, subcutaneous fat, fascia, muscle, bone, internal organs and other tissues. Ideally, an ultrasound generator is oriented in an orthogonal fashion relative to the interrogated tissue. However, when an ultrasound generator is oriented to  
30           the skin in a non-orthogonal fashion, i.e. when the transmission angle is less than 90 degrees, a parallax can result that will artifactually increase the apparent thickness of the interrogated tissue layers.

*Tissue Swelling related definitions:*

*Edema* refers to a pathologic accumulation of fluid within or between body tissues. Edema fluid can accumulate in potential fluid spaces, e.g. the pleural space, the pericardial space, and the intraperitoneal space. Edema fluid can accumulate in the interstitial space (e.g., in extracellular location) between tissue cells thereby expanding the interstitial space. Edema fluid can also accumulate within the cells, i.e. in an intracellular location (e.g., in toxic, metabolic, infectious, inflammatory, and autoimmune disorders). Causes of edema include, but are not limited to, impairment of vascular, cardiac, renal, and hepatic function, neurologic disorders, metabolic disorders, trauma, burns, tissue damage, changes in intravascular and intracellular colloid osmotic pressure, overhydration, e.g. in transfusion therapy or parenteral nutrition, exposure to toxic substance, e.g. inhalational or by ingestion, and drugs (see also Tables 3 and 4).

*Capillary related edema* refers to an abnormal fluid imbalance arising from capillaries and leading to abnormal local fluid retention. Capillary related edema results from an abnormal physiological function or physiological challenge to the venous system, arterial system, cardiovascular system, renal system, hepatic system, pulmonary system or other non-circulatory, internal organ systems normally involved in homeostasis of normal fluid retention. The present invention is particularly applicable to the systemic aspects of capillary related edema. For clarity, capillary related edema does not refer to pretibial myxedema, which is a lesion in the dermis that leads to tissue swelling. Pretibial myxedema is associated with abnormal mucin production in the dermis that disrupts the surrounding tissue. Any water associated with mucin that might be considered related to pretibial myxedema is not considered capillary related edema, as mucin is an extracellular protein, which in pretibial myxedema, is not considered to be associated with an internal organ system normally involved in homeostasis of normal fluid retention. For further clarity, capillary related edema does not refer to tissue swelling associated with the lymph system. Venous or arterial systems do not refer to the lymphatic system. Potential capillary related



edema layer refers to an anatomical region where capillary related edema might occur.

*Edema detection* refers to the determination of abnormal fluid retention in a subject or a subject's tissue. In many instances edema detection can occur without detecting or knowing the underlying cases of the edema. Often edema detection will lead to additional tests to determine the cause or cause of the edema. For clarity, edema detection does not refer to detection of tissue swelling primarily associated with pretibial myxedema or a malfunctioning of the lymphatic system.

*Capillary related interstitial fluid* refers to fluid between internal tissues of the body that is on the outside of cells and arising from capillaries. Usually, this fluid is subcutaneous, which makes it easier to examine. Capillary related interstitial fluid, however, may also be found in any tissue or layer, unless otherwise indicated herein. Capillary related interstitial fluid is usually comprised of water, body salts and extracellular biomolecules, such as proteins or sugars. Intracellular biomolecules may be found in capillary related interstitial fluid, especially adjacent to traumatized or compromised tissue. For clarity, capillary related interstitial fluid does not refer to 1) blood in either blood vessels or blood released in a potential fluid space of the body (e.g., the subarachnoid, subdural, epidural, or pleural space) by a traumatic, abrupt or accidental lesion (including an aneurysm) of a blood vessel, 2) ascites in the intraperitoneal cavity, 3) fluid in the pleural space (e.g., pleural effusion), 4) fluid in the fetus, 5) fluid in the dermis, 6) fluid in the mouth and 7) fluid, usually blood or pericardial effusion, in the pericardium.

*Interstitial fluid content (IFC)* refers to an amount of interstitial fluid in a given anatomical region. IFC can be expressed as  $\text{mm}^2$  when derived as the measured thickness of the interstitial fluid layer and multiplied by length of the area interrogated. IFC can be used to estimate total size of an interstitial fluid layer or interstitial fluid volume.

*Interstitial fluid layer (IFL)* refers to layer of interstitial fluid that forms a stratum either within or around an internal tissue. Often such layers substantially circumscribe a tissue, especially a tissue of an appendage or an

organ. Such layers can also be localized and appear as pockets or lakes of fluid apposite or interspersed in a tissue. For clarity, IFL does not refer to a stratum formed by pretibial myxedema, which is a lesion in the dermis that leads to tissue swelling. Pretibial myxedema is associated with abnormal mucin production in the dermis that disrupts the surrounding tissue.

*Interstitial fluid volume (IFV)* refers to a volume of interstitial fluid in a subject or a tissue. Usually this term is used in reference to the IFV of an entire human, which may change in response to various physiological challenges, such as medical conditions or treatments. The methods and devices described herein can assess IFV qualitatively both on the level of the entire subject or a portion thereof, such as a tissue. The methods and devices described herein can also measure IFV quantitatively both on the level of the entire subject (indirect measurement by estimate as described herein) or a portion thereof, such as a tissue (indirect or direct measurement depending on the tissue).

*Transmission angle* refers to the angle of an ultrasound beam that intersects the object or tissue plane. The transmission angle is normally measured with respect to the object or tissue plane. The object or tissue plane has a reference angle of zero degrees.

For example, as the transmission angle increases toward 90 degrees relative to the tissue plane, the ultrasound beam approaches an orthogonal position relative to the tissue plane. Preferably, ultrasound measurements of the fat/muscle or fat/bone interface are performed when the ultrasound beam is orthogonal to the plane of the tissue. Operator error, however, often leads to a parallax between the object or tissue plane and the probe. Tissue/probe parallax most often occurs when an operator fails to place the outer probe surface parallel to the tissue plane. Thus, the operator inadvertently creates a transmission angle less than ninety degrees with respect to the tissue plane, i.e. not orthogonal to the tissue plane, that skews the ultrasound beam and the return signal. The resultant skewing creates a parallax when using an ultrasound beam to measure tissue thickness, such as subcutaneous fat thickness or any other thickness measurement of a layer in an object.

Non-orthogonal ultrasound beam transmission creates an apparent displacement of the ultrasound beam compared to an ultrasound beam transmitted at 90 degrees with respect to the tissue plane. The return signal, which is a fraction of an ultrasound beam that is reflected at a tissue interface, travels through the tissue along a longer distance when returning back to the ultrasound detector compared to a return signal that originated from a beam transmitted orthogonal to the tissue plane. To increase the accuracy of the measurement of tissue thickness, preferably the transmission angle is between 90 to 60 degrees, more preferably 90 to 80 degrees. Lower transmission angles can be used, as low as 1 degree, but are not preferred due to the large error associated with the distance measurements of the fat/muscle or fat/bone interface. Such errors can be compensated for by techniques previously described, U.S. patent application number 08/731,821, filed October 21, 1996 (Lang et al).

*Transmission frequency* refers to the frequency of the ultrasound wave that is being transmitted from the ultrasound source. Transmission frequency typically ranges between 0.2MHz and 25MHz. Higher frequencies usually provide higher spatial resolution. Tissue penetration decreases with higher frequencies, especially in dense fat tissue. Lower transmission frequencies are generally characterized by lower spatial resolution with improved tissue penetration. Methods and devices for optimizing and matching transmission frequencies to the measured object's acoustic properties are described herein.

*Vascular performance* refers to the ability of a blood vessel to conduct blood away from or towards the heart.

*Venous performance* refers to the ability of a venous vessel (e.g., a vein) to return blood towards the heart.

*Ultrasound pulse* refers to any ultrasound wave transmitted by an ultrasound source. Typically, the pulse will have a predetermined amplitude, frequency, and wave shape. Ultrasound pulses may range in frequency between about 20kHz and 20MHz or higher. Preferably, for ILT measurements pulses range from about 2.5 MHz to 25 MHz and more preferably from about 3.5 to 10 MHz. Ultrasound pulses may consist of sine waves with single frequency or varying frequencies, as well as single amplitudes and varying amplitudes. In addition to sine waves, square waves or

any other wave pattern may be employed. Square waves may be obtained by adding single-frequency sine waves to other sine waves. The summation of waves can then result in a square wave pattern.

*Ultrasound signal* refers to any ultrasound wave measured by an ultrasound  
5 detector after it has been reflected from the interface of an object or tissue.

Ultrasound signals may range in frequency between 20kHz and 20Mhz or higher. Preferably, for ILT measurements signals range from 2.5 Mhz to 25 Mhz.

*Ultrasound source* refers to any structure capable of generating an ultrasound wave or pulse, currently known or developed in the future. Crystals containing  
10 dipoles are typically used to generate an ultrasound wave above 20 khz. Crystals, such as piezoelectric crystals, that vibrate in response to an electric current applied to the crystal can be used as an ultrasound source. As referred to herein, an ultrasound source usually has a particular transmission angle associated with it. Consequently, a single ultrasound generator, as defined herein, can be used at different transmission  
15 angles to form more than one ultrasound pulse at different transmission angles. An ultrasound generator can include single or multiple ultrasound sources that can be arranged at different angles to produce ultrasound beams (or pulses) with variable transmission angles. In some ultrasound generators, multiple ultrasound sources may be arranged in a linear fashion. This arrangement of ultrasound sources is also  
20 referred to as a linear array. With linear arrays, ultrasound sources are typically fired sequentially, although simultaneous firing of groups of adjacent ultrasound sources or other firing patterns of individual or groups of ultrasound sources with various time delays can be achieved as described herein or developed in the art. The time delay between individual or group firings can be used to vary the depth of the beam in an  
25 object.

*Ultrasound transmission parallax* refers to an error in the measurement of distances between two distinct layers in an object, such as tissue, resulting from non-orthogonal probe placement. Ideally, the probe is oriented orthogonal to the object or tissue to be measured. In this fashion, the distance between two tissue layers  
30 measured on the ultrasound will more accurately reflect the true anatomic distance. However, if the probe is applied to the skin at an angle smaller or greater than 90 degrees, artifactual elongation of all measured distances will result. The difference

between the distance measured with ultrasound and the true anatomic distance at the point where the probe is placed will increase the more the probe-to-skin angle differs from 90 degrees.

Generally, tissue thickness, especially capillary related interstitial fluid layer,  
5 can be measured using more than one ultrasound source (e.g. at least a first and second ultrasound source) to permit multiple transmission angles or one ultrasound source positioned at different transmission angles. The use of multiple transmission angles facilitates the determination of the shortest reflective distance. If only one transmission angle is used to calculate the shortest reflective distance, the shortest  
10 reflective distance could have a considerable ultrasound transmission parallax error associated with it.

*Ultrasound wave* refers to either an ultrasound signal or pulse.

## 2.0 INTRODUCTION

15 The inventors of the present invention recognized, among other things, a need in the ultrasound field for transducers of small size for application on the surfaces of objects, particularly the surface of an interrogated subject. Transducers of the invention can provide for accurate probes of tissues at very specific anatomical locations. Such transducers can offer many advantages including, low cost of  
20 manufacture, enhanced recording specificity, convenience and hygiene of disposable articles and automated, continuous ultrasound monitoring. The inventors also discovered a need for transducers for continuous or in situ monitoring on the surface of an object, often referred to herein as "in situ monitoring." In addition, the inventors also discovered a need for transducers for testing at multiple sites on the surface of an  
25 object, often referred to herein as "multi-site monitoring."

The present invention also recognized for the first time that ultrasound can be applied to the convenient and cost effective measurement of fluid regulation using multiple ultrasound probes. The invention includes continuous or intermittent monitoring of fluid regulation in a subject, such as capillary related edema assessment  
30 in a human, using ultrasound wave devices and methods as described herein for the embodiments of the invention. Previously, it was not recognized that diagnostic ultrasound measurements of fluid regulation were possible or precise. Nor was it

recognized that clinically rapid shifts in fluid distribution (including capillary related interstitial fluid) in tissues could be monitored using ultrasound methods or devices. Previous work also failed to recognize that capillary related interstitial fluid layers in a tissue could be monitored over time and, if desired, accurately quantitated, as  
5 described herein. The inventors were also the first to recognize that multi-site ultrasound methods and devices could be applied to the assessment of different aspects of integrated cardiovascular function, including venous performance and dynamic cardiac performance. Nor was it previously recognized that multi-site ultrasound probes dedicated to measurement of fluid regulation, particularly remote,  
10 multi-site probes of capillary related edema, could accurately determine fluid regulation status, as described herein. It was also not previously recognized that ultrasound devices dedicated to continuous multi-site ultrasound monitoring of interstitial fluid, particularly small remote probes located on a subject, could accurately determine interstitial fluid status, as described herein.

15        *Section 3* primarily describes various aspects of transducers of the invention, which are applicable to many ultrasound techniques, including the in situ monitoring and multi-site monitoring. *Section 4* also includes descriptions of the surface micro-transducers of the invention, as well as various associated devices.

*Sections 5 through 9* reveal exemplary applications of the multi-site  
20 monitoring and associated devices of the invention. *Section 5* primarily describes applications related to the convenient and cost effective measurement of fluid regulation and capillary related interstitial fluid, including continuous or intermittent monitoring of capillary related interstitial fluid in a subject. *Section 6* primarily describes applications related to the convenient and cost effective measurement of  
25 capillary related edema. Previously, it was not recognized that diagnostic ultrasound measurements of capillary related interstitial fluid and edema were possible or precise. Nor was it recognized that clinically rapid shifts in capillary related interstitial fluid distribution in tissues could be monitored using ultrasound methods or devices. Devices and methods of the invention address such clinical settings.

30        *Sections 6, 7, and 9* primarily describe specific clinical areas applicable to the present invention, including methods and devices for evaluating vascular

performance, cardiac performance, and renal function, respectively, especially in relation to fluid regulation.

By way of introduction, and not limitation of the various embodiments of the invention, the invention includes at least eight general aspects:

- 5           1)     an ultrasonic method of measuring fluid regulation, including capillary related interstitial fluid layer thickness in a subject, particularly a capillary related edema layer, by determining the distance between reflective surfaces (e.g., bone or fat) and skin with multiple ultrasound probes,
- 10          2)     an ultrasonic method of detecting capillary related edema by determining the distance between the reflective surfaces of bone and skin at predetermined anatomical sites with a plurality of ultrasound probes,
- 15          3)     an ultrasonic method of assessing vascular performance by clinically challenging or enhancing vascular performance and measuring capillary related interstitial fluid in a tissue that is clinically relevant to either the challenge or enhancement of vascular performance with multiple ultrasound probes,
- 20          4)     an ultrasonic method of assessing cardiac performance by clinically challenging or enhancing cardiac performance and measuring capillary related interstitial fluid in a tissue that is clinically relevant to either the challenge or enhancement of cardiac performance with multiple ultrasound probes,
- 25          5)     an ultrasonic method of detecting capillary related interstitial fluid volumes in humans by measuring capillary related interstitial fluid in a tissue with multi-site ultrasound probes prior to, before or concurrent with a medical condition or treatment,
- 30          6)     a collection of small, ultrasound probes for measuring anatomical changes, fluid regulation (including capillary related edema) and rapid measurements,
- 7)     a dedicated ultrasound system for measuring fluid regulation with multiple ultrasound probes, and ,
- 8)     an ultrasound probe(s) for in situ ultrasound monitoring, particularly of interstitial fluid layers.

These aspects of the invention, as well as others described herein, can be achieved using the methods and devices described herein. To gain a full appreciation of the scope of the invention, it will be further recognized that various aspects of the invention can be combined to make desirable embodiments of the invention. For example, the invention includes an interstitial fluid monitor (IFM) that can desirably include characteristics of aspects (1), (2), and (8) to create a system for periodic or continuous monitoring of patient interstitial fluid. Such combinations result in particularly useful and robust embodiments of the invention.

### 10           **3.0 METHODS AND DEVICES FOR MULTI-SITE MONITORING**

Previously, ultrasound probes and methods focused primarily on single anatomical site measurement and imaging. Typically, probes were gripped by an operator, applied to the anatomical site, manually held in position, signals recorded from a manually maintained position and the probe withdrawn. The probe used in such situations was connected to an ultrasound computational unit by a bulky wire that often complicated probe placement.

The present invention provides for methods and devices for multi-site monitoring, particularly ultrasound multi-site monitoring. The inventors recognized that many types of physiological processes could be monitored by interrogating in parallel multiple anatomical sites with multiple probes. By monitoring multiple anatomical sites information is obtained about each anatomical site for comparison between sites. This permits monitoring of body processes from both an integrated perspective, as well as a differential diagnosis perspective. For many medical conditions and changes in physiological processes will cause different anatomical sites to respond differently. The invention typically uses a probe of physiological function or anatomy that is capable of detecting changes in physiological function or anatomy over a clinically relevant time period. Consequently, such changes in physiological function or anatomy can be captured as clinically useful information, such as a tool for diagnosis, treatment, or continuous patient monitoring.

30           The inventors recognized that changes in physiological processes and anatomical sites of the body can be monitored using ultrasound, particularly rapid or subtle changes in physiological processes and anatomical sites. Surprisingly, the



inventors could measure very small changes in ILT (interstitial layer thickness), as well as relatively rapid changes in ILT at different anatomical sites (see Examples). Such changes are illustrated in FIGS. 1 and 2, as further described in *Section 5*. Many different interrogation sites may be chosen as described herein and illustrated in  
5 FIGS. 3 and 4 with da Vinci's drawing of the male anatomy, which is further described in *Section 5*. Different anatomical sites also responded differently to physiological challenges. The inventors have also provided examples of multi-site monitoring in different therapeutic areas, including vascular, cardiac and renal, as described in *Section 7, 8 and 9*, respectively. A particularly important application of  
10 multi-site monitoring is critical and emergency care situations where it is manifest to measure rapid changes in body function and anatomy as described in *Section 5 and 6*.

#### *Multi-probe Sets*

One aspect of the invention includes a multi-probe set, comprising a first probe of physiological function or anatomy that is capable of detecting changes in  
15 physiological function or anatomy over a clinically relevant time period and comprising a first output port, wherein the first probe is adapted for continuous or in situ monitoring at a first anatomical region, and a second probe of physiological function or anatomy that is capable of detecting changes in physiological function or anatomy over a clinically relevant time period and comprising a second output port,  
20 wherein the second probe is adapted for continuous or in situ monitoring at a second anatomical region. The first and second probes may also be adapted for multi-site monitoring. Examples of such probes are described herein, including FIG. 5, which is further described in *Section 4*.

Another aspect of the invention includes a multi-probe set, comprising a first  
25 ultrasound probe comprising a first output port. The first ultrasound probe is adapted for continuous or in situ monitoring at a first anatomical region. The set includes a second ultrasound probe comprising a second output port. The second ultrasound probe is adapted for continuous or in situ monitoring at a second anatomical region. The output ports can connect the probes to an ultrasound system. Typically, the  
30 ultrasound system is for multi-site processing which includes receiving first signals from the first ultrasound probe and second signals from the second ultrasound probe. Usually the probes are adapted for in situ monitoring, e.g. monitoring at a particular

site over periods of time relatively longer than manual placement of a probe. The probes can be designed for monitoring anatomical distances or imaging or detecting ultrasound contrast agents. For instance the probes can be either A scan or B scan. Typically, the probes of a multi-probe set are not adapted as “listening” and “transmitting” probe pairs, where the first probe listens for the signals sent by the second probe, unless specifically stated so. Typically, each probe can transmit and receive ultrasound signals. Although some probes can be designed with certain crystals or arrays that only transmit or receive ultrasound signals. Preferably, each probe is wireless or includes a chip or has both features.

10           The set can include an ultrasound system to process (e.g. concurrently) first signals from the first ultrasound probe and second signals from the second ultrasound probe. Systems with more probes can also be used. Each probe in the set can be adapted for a particular anatomical region or indication. For example, the anatomical region can be selected from the group consisting of the forehead region, anterior tibia region, foot region, distal radius region, elbow region, presternal region and temporal bone region. Preferably, the ultrasound probe is a micro-transducer adapted for monitoring interstitial layer thickness. Additional probes can be added to the system or supplied as a kit with multi-probes that includes directions for use and appropriate packaging. The multi-probe set, for example, can include a third ultrasound probe comprising a third output port, said third ultrasound probe adapted for continuous or in situ monitoring at a third anatomical region. The multi-site methods, as well as multi-site probe sets, may be used with other methods known in the ultrasound art, such as Doppler based measurements, speed of sound measurements, imaging measurements (including ultrasound imaging for surgical procedures (e.g., trocar assisted surgery)), echogenicity measurements and ultrasound measurements using contrast agents.

Each probe of a multi-probe set can optionally include a sensor or feedback unit. For instance, the first and second ultrasound probes may each further comprise an acoustic power feedback system to monitor and modulate probe energy output as further described herein. A probe may also include other probes of physiological function, such as an oxymeter to monitor tissue oxygen levels, a thermometer to monitor tissue temperature, a blood pressure probe to measure blood pressure, a heart

rate probe to monitor heart rate or a flow probe to monitor blood flow.

Temperature data can be used in a regulating system to adjust the calculated speed of sound or other ultrasound properties affected by temperature.

Typically, the probes are adapted to record ultrasound signals from a particular anatomical region. Such an anatomical region may be selected from the group consisting of the forehead region, anterior tibia region, foot region, distal radius region, elbow region, presternal region and temporal bone region. Other anatomical regions and applications at region are described herein. Adapting a probe to such regions can include, providing a probe surface area in relation to the anatomical regions to be interrogated; providing a crystal frequency (or multiple frequency probe) to match the anticipated tissue interrogation depth or other acoustical properties, providing a contoured probe surface to match the anatomical region; or providing a probe dedicated to monitoring signals for a specific type of ultrasound measurement in the desired anatomical regions (such as imaging or ILT measurements).

#### *Multi-site Monitoring*

The invention also provides for the first time methods and devices for multi-site monitoring of different anatomical regions either concurrently or at predetermined time intervals. Monitoring anatomical changes during clinically relevant time periods or continuous monitoring provides important diagnostic tools for detecting short or rapid changes in tissue structure, particularly interstitial layer thickness. In contrast to previous work, the invention is able to measure rapid changes in ILT and monitor ILT from different anatomical regions simultaneously or within short time frames to compare ILT from different regions. Other time courses and monitoring regimes are described herein.

In one aspect, the invention provides for a method of multi-site monitoring of ILT. The method comprises transmitting an ultrasound pulse from a first ultrasound probe to a first anatomical region and transmitting an ultrasound pulse from a second ultrasound probe to a second anatomical region. The method includes recording ultrasound signals from a first ultrasound probe to a first anatomical region and recording ultrasound signals from a second ultrasound probe to a second anatomical region. The method also includes monitoring interstitial layer thickness from the first and second anatomical regions. The order of the transmitting, recording and

monitoring from different regions can be sequential, intermixed, continuous or a combination thereof or any other sequence that permits monitoring. Typically, the method is practiced by monitoring from the first anatomical region concurrently with monitoring from the second anatomical region.

5           Transmitting steps can be sequentially performed. For example transmitting from one probe is within about 10 seconds of transmitting from another probe. Transmitting is usually automatically controlled by a computational unit in a ultrasound system or a chip. The method steps often are repeated over time to monitor changes in tissue structure. Typically, the steps of transmitting and recording  
10           are repeated about every 30 to 600 seconds. Monitoring can be concurrent or at pre-selected time periods.

          The first and second ultrasound probes can be micro-transducers, as described herein. Any other suitable probe known in the art or developed in the future or described herein can also be used. Often the method will include the use of three,  
15           four, five, six or more probes. The use of multiple probes enables comparing interstitial layer thickness from the first and second anatomical regions or more regions. Concurrent comparisons provide valuable information on fluid shifts in the body. By monitoring such shifts, the clinician can address the situation with the appropriate action. The method also includes determining the rate of change over  
20           time of an interstitial layer thickness from two or more anatomical regions. Such methods are particularly sensitive and give diagnostic indications of rapid fluid shifts.

#### *Anatomical Maps of Multi-probes Sets*

          The invention also includes anatomical maps from multi-probe sets, such as maps of fluid regulation or related measurements such as ILT, capillary related  
25           interstitial layer, capillary related interstitial volume or capillary related interstitial content. Such maps can be created using the multi-site devices and techniques described herein. Generally, an anatomical map provides information on the ultrasonic properties determined at multiple anatomical locations. Such ultrasonic properties are typically measured using multiple probes as described herein. Such  
30           ultrasonic properties include reflective distances, echogenicity, broadband attenuation, speed of sound, ILT, capillary related interstitial layer thickness, capillary related interstitial volume or capillary related interstitial content or combination thereof.

Preferably, an anatomical map is presented with reference to an anatomical landmark(s), either internal or external, or a representation of the subject's body, such as an anatomical representation of a human.

Such anatomical maps offer a variety of advantages to the clinician not previously recognized. First, whole body patterns of ultrasonic properties can be visualized. Multiple interrogation sites can provide information from divergent or related anatomical regions for comparison or to evaluate trends (such as temporal changes). Multiple multi-site probes can permit concurrent interrogation of multiple sites or continuous interrogation at multiple sites. Such information can be used to create real time or clinically relevant time frame maps of human physiology. Such maps can be used to evaluate data collected by all of the methods described herein, known in the art or developed in the future.

Second, temporal patterns of changes in whole body physiology can be more easily recognized using anatomical maps. For example, changes in fluid regulation as indicated by shift in ILT can be monitored at multiple interrogation sites to see shift in the anatomical location of bodily fluids. Such shifts are particularly important to monitor in the medical conditions and diagnostic applications described herein, especially general anesthetic, surgical, cardiac performance, trauma, long-term care (e.g. bed ridden) and emergency room applications.

For example, changes in fluid regulation as indicated by shift in ILT can be monitored at multiple interrogation sites to see shift in the anatomical location of bodily fluids. Such shifts are particularly important to monitor in the medical conditions and diagnostic applications described herein, especially general anesthetic, surgical, cardiac performance, trauma, long-term care (e.g. bed ridden) and emergency room applications.

Third, anatomical patterns of changes in whole body physiology can be more easily recognized using anatomical maps. Many medical conditions, medical treatments and health care methods can change the ultrasonic properties of the human body in one anatomical region to a greater extent than in a second anatomical, third or fourth or more anatomical regions. Consequently, anatomical maps, especially representations a whole body, permit assessment of tissues specific or selective

effective effects of many medical conditions, medical treatments and health care methods.

Anatomical maps using multi-site monitoring can be generated using methods and devices described herein. For instance, the computational unit is designed to process ultrasonic signals received from multiple ultrasonic transducers to generate an anatomical map of an anatomical region(s) or whole body for fluid regulation. Additionally, ultrasonic identification of an anatomical landmark(s) within an anatomical region(s) or whole body can be used to generate reference points for the map. A or B scan maps of landmarks may be superimposed, e.g. by color encoding, onto maps of other ultrasonic properties. The map can show computer-stored coordinates to locate an anatomic landmark within the anatomical region or body for reference. Also, the external location of a transducer(s) can be noted on the map to properly locate the transducer information in reference to other anatomical locations. Typically, anatomical maps for ILT can show changes in ILT of less than about 1 to about 5 percent of the tissue thickness.

In many embodiments of the invention, it will be particularly useful to compare ultrasonic properties from multiple sites in a body or within an anatomical region. The same sites may be compared at different times (intra-site comparison) or one or more sites may be compared (inter-site comparison) or a combination thereof. In some instances such as clinical settings where rapid changes in fluid regulation need to be monitored, maps illustrating the rate of change of fluid regulation at different anatomical locations will be particularly useful for guiding treatment.

For instance, an intra-site comparison can be used during a single site interrogation protocol that entails multiple interrogations of the same region with reference to a particular anatomical site. The computational unit can also further comprise a database comprising reference anatomical maps and the computational unit is further designed to compare the anatomical map with the reference anatomical map. The reference anatomical map may be historic (from the same or another patient, generated as part of an interrogation protocol), or theoretical or any other type of desired reference map. The reference map can include a reference anatomical landmark, or if desired the landmark may be stored alone.

Multi-site monitoring is useful for detecting physiological changes in ultrasonic properties, particularly shift in fluid balance. Changes in fluid regulation can be manifested in a variety of patterns. For example, shifts in fluid balance can be systemic leading to general changes in ILT in anatomical regions. Shifts in fluid balance can be manifested in dependent regions of the body leading to general increases in ILT in anatomical regions where gravity influences fluid retention in tissues, such as the legs. Other shifts in fluid balance can be manifested in specific locations of the body leading to specific changes in ILT in a specific anatomical region(s).

*Multi-site Monitoring Time Course and Sites*

The multi-site monitoring can take place over a variety of time frames as described herein for various indications and other methods. Typically, the time frame is hours to days. Often the micro-transducers of the invention are secured to the skin for continuous monitoring during at least about a 1 to 24 hour period. Many anatomical regions can be used such the regions described herein. Preferably, the anatomical region is selected from the group consisting of the forehead region, anterior tibia region, foot region, distal radius region, elbow region, presternal region and temporal bone region. Micro-transducers or other probes can be secured to the skin over such regions for continuous monitoring during a clinically relevant time period.

The sites listed in Table 1 and shown in FIG. 3 and 4 can also be used in combination. By using combinations of probe sites (i.e. multi-site monitoring), fluid movement throughout the body can be monitored. This permits monitoring fluid shifts from fluid compartments of the body. Multi-site monitoring also permits exquisitely sensitive monitoring of physiological processes related to capillary related edema, such as processes that either induce, prevent or reduce capillary related edema, as well as therapeutic treatments thereof. The invention includes multi-site monitoring of interstitial fluid during space flight. The invention includes multi-site interstitial fluid monitoring for 1) blood in either blood vessels or blood released in a potential fluid space of the body (e.g., the subarachnoid, subdural, epidural, or pleural space) by a traumatic, abrupt or accidental lesion (including an aneurysm) of a blood vessel, 2) ascites in the intraperitoneal cavity, 3) fluid in the pleural space (e.g.,

pleural effusion), 4) fluid in the fetus and 5) fluid in the pericardium, usually blood or pericardial effusion. Different sites on the body can be used as a clinical measure of changes in various physiological states. By comparing values from different sites, assessment of fluid shifts between different fluid compartments can be evaluated.

5           *Other Multi-site Devices*

The invention also includes a multi-site probe designed with a connection for a multi-site monitoring system. A multi-site probe includes an ultrasound transducer and a signal connection for communicating signals to and from a multi-site monitoring system. Typically, the transducer will be adapted for ILT or fluid  
10 regulation monitoring. The signal connection permits monitoring of anatomical region without an operator holding the ultrasound transducer or a mechanical arm holding the ultrasound transducer that is typically part of a large mechanical positioning unit. The connection may be those described herein, those known in the art or developed in the future.

15           For instance, the signal connection on the transducer may be an electrical coupling on the probe that can connect to a wire(s) of a weight that permits the wire(s) to rest on the subject without substantial interference with interrogation and probe placement. The wires connect preferably to a system designed to measure ILT. The wire(s) may transmit instructions for monitoring fluid regulation at the desired  
20 anatomical site.

In another example, the signal connection on the transducer may be an infra red coupling on the probe that can provide a connection with an infra red coupling that is part of an ultrasound system. This type of connection permits probe  
25 interrogation of a desired anatomical region without substantial interference with interrogation and probe placement. The infra red coupling preferably connects to a system designed to measure ILT. The infra red coupling may transmit instructions for monitoring fluid regulation at the desired anatomical site.

In another example, the signal connection for the transducer may be an infra red coupling on the probe that can provide a connection with an infra red coupling  
30 that is part of an ultrasound system. This type of connection permits probe interrogation of a desired anatomical region without substantial interference with interrogation and probe placement. The infra red coupling preferably connects to a



system designed to measure ILT. The infra red coupling may transmit instructions for monitoring fluid regulation at the desired anatomical site.

In another example, the signal connection for the transducer may be a radio-frequency coupling on the probe that can provide a connection with an infra red coupling that is part of an ultrasound system. A radio frequency coupling connection permits probe interrogation of a desired anatomical region without substantial interference with interrogation and probe placement. For each multi-site probe used in a collection of probes, each radio frequency coupling can have a different frequency to code each probe. The infra red coupling preferably connects to a system designed to measure ILT. The infra red coupling may transmit instructions for monitoring fluid regulation at the desired anatomical site.

The invention also includes a multi-site probe designed with a connection for a multi-site monitoring system. Such multi-site probes may also include an adhesive for securing the probe to the surface of the skin. For example, the probe may be circular with an annulus of an adhesive surface (e.g. film) substantially surrounding the probe. Such probes may include a coupling gel primarily located on the probe surface, thereby allowing the adhesive surface to attach to the skin.

The invention also includes adhesive films (or surface) for securing ultrasound probes. Typically, an adhesive film is adapted and shaped to accommodate a probe and to permit securing the probe to the skin without substantially interfering with interrogation. The adhesive film or surface may be part of a frame to hold the probe. Preferably, the adhesive film or surface includes a transmission film that may or may not have an adhesive.

The transmission surface permits the probe to interrogate a tissue. Typically, the transmission film is part of a frame to hold the probe, as described herein, and preferably includes a coupling gel on one or both sides of transmission film to facilitate transmission. The entire interrogation film (including an interrogation film of both an adhesive film and a transmission film) or interrogation frame (including an interrogation film of both an adhesive film or surface and a transmission film or surface) can be supplied as sterile components in a sterile container for opening prior to use and may be disposable. Such interrogation films and interrogation frames offer the advantages of promoting more sterile conditions for interrogation, ease of use for

applying a coupling gel, greater reproducibility when used with a predefined amount of coupling gel, less chance of transmission of disease when probes are re-used, and stable securing of multi-site probes to the skin. Such device can be easily made by applying the adhesive and/or the coupling gel to a film or frame. Although, the gel on the transmission film will often have sufficient adhesion to the probe (usually due to surface tension effects) to secure it to a film, the film or frame may also be fastened to the probe using a fastening system described herein, known in the art or developed in the future.

#### 4.0 ULTRASOUND PROBES FOR IN SITU MEASUREMENTS

The invention provides for the first time micro-transducers for ultrasound measurements and imaging. Typically, the micro-transducers are adapted for either monitoring capillary related ILT or capillary related edema, usually on the skin in a predetermined anatomical region. As described herein, the micro-transducers are typically small about 10 to 20 mm<sup>2</sup> or less in surface area, not hand-held but rather attachable to the skin surface, and lightweight. Preferably, micro-transducers are isolated and not connected to an ultrasound system or display by a conductive wire, as described herein. In use, the micro-transducers are usually secured to the skin of a subject for continuous monitoring of the interrogated region. These types of probes offer the advantage of being particularly well suited for in situ measurements, such as measurements not requiring an operator to hold the probe in place.

The size and shape of the micro-transducer can be sculpted to maximize the ability of the micro-transducer to detect the desired signals in a particular anatomical region. In the case of monitoring capillary related ILT, the size of the micro-transducer is generally considerably smaller than the anatomical region to be interrogated. As the size of the cross sectional area of the micro-transducer increases, a larger area is monitored, which in some applications is desirable because a greater surface area can produce better signal averaging. If the micro-transducer surface, however, is larger than the anatomical region to be interrogated the signal quality will diminish. A smaller cross sectional area also increases the selectivity of interrogation to a specific area. Consequently, micro-transducer size is generally tailored to fit a particular anatomical region. In some applications, it will also be desirable to have a

micro-transducer that specifically interrogates a smaller region in order to improve sensitivity. In some anatomical regions, such as the tibial region, a focused interrogation, in terms of surface area, can permit more sensitive measurements. Typically, the ultrasound micro-transducer has a surface area of no more than about 3 cm<sup>2</sup>, preferably about 3 cm<sup>2</sup>, and more preferably about 2 cm<sup>2</sup>.

The micro-transducer may also be adapted to snugly fit a particular anatomical region. While a flat, planar and relatively stiff micro-transducer is desirable in many applications and easy to manufacture, other shapes and flexibility properties find application with the present invention. Micro-transducers may be disposed with a curved surface to either aid in capturing a better ultrasound recording or aid in securing the micro-transducer to the skin or both. For instance, in the anterior tibial region, a micro-transducer can be slightly curved to aid in fixing the micro-transducer to the skin of the leg or to aid in providing a better geometric arrangement for transmitting or receiving signals. The crystals of the micro-transducer may only be disposed over a portion of the micro-transducer surface. Micro-transducers may be disposed with a flexible housing or surface to permit the micro-transducers to be slightly "bent." The flexible nature of the micro-transducers preferably allows the housing or surface to be bent and the induced bend to be maintained, especially in embodiments where the micro-transducers may be contoured to a particular skin surface. In other embodiments, a flexible micro-transducer housing that returns to its original shape are preferred for applications where the surface needs not to be contoured but the micro-transducer might be subjected to accidental mechanical deformation by either the subject or the operator. Plastics known in the plastic art can be used for either application. Shortest reflective distance techniques can also be applied to accommodate varying angles that may be induced by non-planar micro-transducer surfaces.

The micro-transducer interrogation frequency can be selected to match the interrogated tissue. As the interrogation frequency of the micro-transducer decreases, generally, the ability to resolve reflective surfaces at deeper depths improves. At fairly deep interrogation depths (e.g., greater than about 20 to 30 mm) shorter frequency micro-transducers are desirable (e.g., about 5 to 15 MHz). Even shorter frequency micro-transducer, are desirable for interrogating particularly thick tissues

(e.g., extremely thick appendages or large subjects), such as .5 to 3 MHz micro-transducers.

As the tissue thickness increases, a relatively small change in ILT (e.g., about .5 mm) will become a smaller percentage of total ILT. This can lead in some instances to decreases in the signal-to-noise ratio and make it more difficult to determine ILTs at deep interrogation depths. In such instances, as well as others, it will be desirable to provide a tunable micro-transducer that can transmit multiple micro-transducer frequencies. The micro-transducer can then either be adjusted by the operator to use the best frequency for the interrogation depth selected or the micro-transducer or the ultrasound system to which it is electrically coupled can automatically adjust the micro-transducer to the best frequency. For instance, the micro-transducer can be designed with four ultrasound sources with different basic frequencies and the micro-transducer or the ultrasound system to which it is connected can provide a micro-circuit to switch to the appropriate ultrasound source based on the type or quality of signals being received. Preferred frequencies include about 1, 3 and 5 MHz.

A higher micro-transducer frequency, in general, will improve micro-transducer interrogation of shallow interrogation depths (e.g., about 1 to 30 mm). Generally, micro-transducers above 18 MHz are preferred (e.g., about 20 to 30 MHz) for shallow interrogation depths. Most of the micro-transducers with these frequencies are for monitoring capillary related ILT in anatomical regions where bone is very close to the skin, such as in small, and often thin, subjects (particularly younger subjects) and in the head or the cranium. Even in the tibial regions, however, where bone can be relatively close to the skin, especially in thin legged subjects, other interrogation frequencies will be desirable. Consequently, it will be desirable to match micro-transducer frequency to the tissue depth or anticipated depth of interrogation to improve the sensitivity of monitoring or testing.

Generally, micro-transducers can be constructed that are extremely sensitive. Micro-transducers can typically detect percentage changes in capillary related ILT on the order of about 10 percent or higher, preferably about 5 percent or higher, and more preferably about 1 percent or higher. Consequently, with shorter clinically relevant time periods it is desirable to provide high sensitivity micro-transducers in order to

detect small changes in ILT over time. Such micro-transducers are particularly applicable to multi-site monitoring, continuous monitoring, and critical care monitoring.

Typically, a micro-transducer can measure changes in a capillary related ILT as small as about .2 to 1.0 mm. Smaller and larger changes in ILT can also be measured. Preferably, a universal micro-transducer can measure changes in capillary related ILT across a broad range of thicknesses of about .5 to 50mm, more preferably about .2 to 80mm and most preferably about .2 to 120 mm. Preferably, an anatomical region specific micro-transducer can measure changes in capillary related ILT across a selective range of thicknesses at a specific interrogation depth range. Such micro-transducers can measure changes in thickness of about .2 to 30 mm at an interrogation depth of about 1 to 50 mm, about .4 to 50 mm at an interrogation depth of about 2 to 75 mm and about 1 to 50 mm at an interrogation depth of about 2 to 100 mm.

One aspect of the invention includes a compact micro-transducer for in situ ultrasound measurements, comprising: at least one ultrasound crystal in acoustic communication with an acoustic coupling material, an ultrasound crystal holder adapted for securing the acoustic coupling material to a surface of an object or subject for in situ ultrasound measurements, and an electrical coupling electrically connecting the at least one ultrasound crystal and to an ultrasound output or recording system. The electrical coupling is disposed to allow the micro-transducer to be secured for in situ ultrasound measurements. Typically, the micro-transducer uses a plurality of crystals. A small number of crystals are often desirable to reduce weight and mass if the circuitry is included in the micro-transducer. Preferably, a computer chip is included in the micro-transducer to facilitate signal transmission, reception or processing, or a combination thereof. The electrical connections, housing and micro-transducer materials can also be selected to reduce weight. Micro-transducer weights generally range between 5 and 150 grams, although larger and smaller micro-transducers can be used as well. Preferably, the micro-transducer is light to reduce pressure on the skin for continuous monitoring. Micro-transducer weights are preferably about 50 grams or less and more preferably about 25 grams or less. The micro-transducer can also be adapted for continuous monitoring applications in the skin. The time of continuous monitoring will vary depending on the clinically

relevant time period. In some embodiments the acoustic coupling material and the ultrasound crystal holder are flexible.

Micro-transducers can be secured to skin using any means compatible with ultrasound transmission and detection. Typically, the micro-transducer can be lightly  
5 and securely taped to the skin using standard adhesive tape or adhesives that can provide for both secure attachment to the skin, as well as acoustic coupling as shown in FIG. 5A and B. Although securely fastened to the skin, the pressure of the micro-transducer should be minimized to avoid artifacts. In the initial minutes of  
10 monitoring, signals may vary due to short term skin effects or pressure effects. Such effects can be minimized or avoided by using biocompatible or hypoallergenic materials and minimum skin pressure.

In some embodiments, the micro-transducer can include a separate positioning frame, generally only about 10 to 20 percent larger than the micro-transducer, that holds the micro-transducer. As shown in FIG. 6, the frame 620 can have extending  
15 members 640 that can be secured to the skin and away from the interrogation site in order to reduce artifacts associated with probe placement. The structure of the frame can resemble a spider, where the body of the frame 620 secures the micro-transducer 600 and the legs of the positioning frame 630 secure the frame to the skin application site. Such spider embodiments of the positioning frame are particularly useful for  
20 securing the micro-transducer to an appendage region either by taping the legs or adjusting the legs to interlock. The positioning frame may be disposable and optionally include a sterile film disposed in the frame so as to provide a sterile micro-transducer surface. Acoustic coupling materials can be applied to either side of the film to enhance acoustic communication. The positioning frame can also include  
25 other fastening systems known in the art, such as velcro.

Alternatively the micro-transducer can be secured with adhesive coating. The adhesive coating can be applied to the skin of the subject or as part of the micro-transducer. Preferably, when acoustic coupling materials are applied to the skin, such as a gel, an adhesive can be included in the acoustic coupling materials to secure the  
30 micro-transducer.

In another embodiment the ultrasound crystal holder is adapted to attach to a securing member that secures an appendage of the human and secures the ultrasound

crystal holder. This embodiment can immobilize the appendage and/or the micro-transducer. The acoustical coupling material can be secured in acoustical contact with the surface of the skin. An acoustic coupling gel can be optionally applied between the surface of the skin and the acoustical coupling material.

5           A micro-transducer can transmit signals that it receives to an ultrasound system for display or processing. Typically, a micro-transducer is electrically coupled to a system. Preferably, a lightweight wire for transmitting electrical signals to an ultrasound computational unit is used. A micro-transducer can also be coupled with an infrared coupler to an ultrasound computational unit. More preferably, a  
10 micro-transducer is coupled using a radio frequency coupler that transmits signals to an ultrasound computational unit. Radio frequency and infrared coupling offers a number of advantages including reducing the weight of the micro-transducer by not requiring wires, permitting greater movement capabilities for either the subject or operator, and remote sensing. Radio frequency (RF) technology can be applied to the  
15 transducer of the invention in a number of ways as described herein, known in the transmission arts or developed in the future. RF technology described herein is not limited to ultrasound devices and may be applied as tags, for device and as devices to transmit information (signals) from one locations to another, particularly for small devices that have power requirements or send information recorded by the device in  
20 situ or both.

Active RF systems may be used with devices of the invention. Typically, the ultrasound transducer unit comprises RF transmitting/receiving circuitry and an antenna(s) to transmit RF signals to and from the ultrasound transducer and an energy source to power the circuitry to provide for RF and ultrasound transmission from the  
25 transducer unit. The energy source may be a battery or photoelectric transducer to produce energy for use or storage or both, or suitable energy sources known in the art or developed in the future, especially those for lightweight applications.

Active RF systems may also be designed in what is fondly termed by the inventors as the diver-boat configuration. Like multiple oyster divers tethered to a  
30 boat that holds the pearls, in the diver-boat configuration multiple diagnostic probes are electrically connected to an active RF system that transmits RF signals to a command unit that may be part of an diagnostic system, such as a multi-site

ultrasound system. Conversely, the active RF system that receives RF signals from the command unit and electrically transmits them to the ultrasound probes. Typically, the diver-boat configuration comprises an active RF system and at least two ultrasound probes or other number of probes as described herein. Such probes can be connected to the active RF system, which can act as a relay station, via lightweight wires as described herein for other embodiments of the invention. This configuration offers the advantage of not necessarily relying on an energy source within the probe unit, thereby reducing weight of the probe unit. It also minimizes the amount of RF components needed for manufacturing the probe units.

Passive RF systems may also be used with devices of the invention. Typically, the ultrasound transducer unit comprises transmitting/receiving circuitry and an antenna(s) to transmit signals to and from the transducer and a RF based power unit to power the circuitry to provide for transmission from the transducer. For example, a rectifier may be included in the ultrasound transducer unit to convert a portion of the RF signal received by an antenna(e) to a direct current. Such energy may be used to drive the circuitry in the ultrasound transducer unit, including 1) to control of ultrasonic transmission, 2) current to drive an ultrasonic source and 3) current to drive the RF transmission related to the ultrasound signals detected by the transducer. Typically, in passive systems, or in active/passive systems described herein, the RF signal train will comprise an identification sequence to identify the ultrasound transducer, a power sequence to power the ultrasound transducer unit, an instruction sequence to instruct the ultrasound transducer unit to transmit or record or both and additional power sequences as needed. Internal circuitry of the transducer can also be included, to minimize power requirements of the ultrasound transducer unit.

Alternatively, a combination of a passive and active system may be used. For example, a lightweight energy source may be initially activated by a circuit(s) that responds, directly or indirectly, to the appropriate RF energy or RF based power units described herein, known in the art or developed in the future. This permits the use of a small, lightweight energy source, such as a battery or photoelectric transducer to produce energy for use or storage or both, due to conservation of energy achieved by



the switching on and off of the energy source by the RF signal received from the command RF unit.

In another embodiment of the invention, a combination of a passive and active systems may be used to generate a RF relay system. One consideration with passive systems is transmission range. In order to enhance transmission range of a passive system, an active RF system can be used to relay RF signals to and from the ultrasound transducer with a passive RF system. The RF relay system includes a sufficient power supply and amplifier (if necessary) to broadcast RF signals back to the command unit (e.g. the ultrasound monitoring system) and broadcast RF signals to the ultrasound transducer unit. This embodiment is particular useful for lightweight, passive based devices that may have difficulty transmitting distances of more than about 2 to 3 feet. Such devices would include some of the ultrasound transducer units of the invention herein, but could also include other types of devices, particular those that monitor or that generate signals. Such relay systems will find particular application in bed, examination table, surgery table and emergency room monitoring where a patient is typically confined to one location and one or more relay systems can cover the necessary distances for monitoring using multiple probe from head to toe. In addition, multiple relay systems can be used to transfer information even greater distances.

In addition, a number of different radio frequency technologies that are known in the art of radio frequency transmission can be applied to the devices of the invention herein or combined or modified by the radio frequency techniques described herein, including active systems described in U.S. patent 4,274,083; passive systems described in U.S. patents 4,654,658; and 4,730,188; active/passive systems 4,724,247; systems and antennae described in U.S. patents 5,572,226 (Tuttle), 5,697,061 (Krueger et al), 5,550,547 (Chan et al), 5,473,330 (Lauro et al), 5,528,222 (Moskowitz et al), 5,305,008 (Turner et al), 5,341,375 (Buchholz et al), and 5,218,187 (Koenck et al).

Another aspect of the invention includes a micro-transducer comprising an acoustic surface acoustically coupled to an ultrasound source, wherein the acoustic surface and the ultrasound source are disposed in a frame adapted for directly or indirectly securing the micro-transducer to a skin. Typically, the micro-transducer is

adapted for monitoring interstitial thickness. Preferably, the micro-transducer has surface area of about  $3\text{cm}^2$  or less. Preferably, the micro-transducer is about 1 cm or less in thickness. To eliminate the inconvenience and weight of wiring to the micro-transducer the micro-transducer can transmit signals to an ultrasound system using  
5 infrared or radio frequency signals. The micro-transducer can be disposable. The micro-transducer can be sterile and further comprises a covering to protect the unit from contamination. The micro-transducer can also be connected to an ultrasound system with a coupling means for transmitting signals as known in the art or developed in the future.

10 Micro-transducers of the invention do not include ultrasound probes adapted for Doppler measurements in vessels and other ultrasound probes adapted for positioning on the surface of a body cavity (e.g. vaginal probes).

#### *Examples of Advantages of the Invention*

The design and small size of the transducers of the invention can enable 1)  
15 interrogation of ultrasonically detectable events in a specific, predefined anatomical region, 2) highly directed imaging or reflective distance measurements in the interrogated anatomical region, 3) reduced manufacturing costs due to the fewer number of ultrasound sources required for interrogation, 4) monitoring of dynamic events within the anatomical region over time, 5) reduction in probe interference and  
20 artifacts compared to prior art devices, 7) in situ monitoring, 8) multi-site monitoring, 9) automated monitoring and 10) remote monitoring.

#### *Considerations Related to Acoustic Power*

Ultrasound pulses can potentially heat tissue due to compression and rarefaction of the medium. The amount of heat generated in the tissue is related to the  
25 amount of acoustic energy per unit time (intensity), as well as the spatial distribution of the acoustic power. For ultrasound pulses, the intensity is expressed as milliwatts/ $\text{cm}^2$ . A number of parameters have been used to describe intensity or power per unit area:

Isp: (spatial peak intensity) is the highest intensity in the beam ( $\text{mW}/\text{cm}^2$ );  
30 Isa: (spatial average intensity) is the average intensity a given area, usually measured over the area of the transducer ( $\text{mW}/\text{cm}^2$ );

Ipa: (pulse average intensity) is the average intensity over a repetition period ( $\text{mW}/\text{cm}^2$ );

Itp: (temporal peak intensity) is the highest intensity temporally in the beam ( $\text{mW}/\text{cm}^2$ );

5 Ita: (time averaged intensity) is the average over the time the transducer is active ( $\text{mW}/\text{cm}^2$ );

Isata: (spatial and temporal average) is the Ita combined with the Isa a measure of average intensity in a given time for the transducer surface area ( $\text{mW}/\text{cm}^2$ ).

10 Isapa: (spatial average-pulse average intensity) is the Isata divided by the duty cycle ( $\text{mW}/\text{cm}^2$ ), wherein duty cycle = pulse duration (number of pulse cycles divided by the transducer frequency, e.g. 4 cycles with a center frequency of 4 MHz is a duration of  $1\mu\text{sec}$  (time)) divided by the pulse repetition period (time);

15 Ispta: (spatial peak-temporal average intensity) is the Isata x ( $I_{\text{sp}}/I_{\text{sa}}$ ) ( $\text{mW}/\text{cm}^2$ ); and

Isppa: (spatial peak-pulse average intensity) is the Ista x ( $I_{\text{sp}}/I_{\text{sa}}$ ) ( $\text{mW}/\text{cm}^2$ ).

Typically,  $I_{\text{sppa}} > I_{\text{spta}} > I_{\text{sapa}} > I_{\text{sata}}$  for ultrasound intensity levels. Values for Ista in diagnostic imaging are typically below  $100\text{mW}/\text{cm}^2$ , while the Ista in some Doppler techniques exceed  $200\text{mW}/\text{cm}^2$ . Cavitation effects can occur at extremely  
20 high levels, such as  $1\text{kW}/\text{cm}^2$ , and should be avoided due possible mechanical or free radical damage to the tissue.

One aspect of the invention includes a feedback system to monitor the effects of acoustic power on an interrogated tissue. The feedback system includes a sensor for a detectable change in an ultrasound or physiological property of the tissue. The  
25 sensor detects a change in an ultrasound or physiological property of the tissue related to acoustic power. The feedback system can include a predetermined threshold level for the property being monitored by the sensor. If the property being measured reaches the predetermined threshold, the feedback system will adjust the acoustic power output of the transducer accordingly. Thus, by setting a threshold level for  
30 changes in tissue properties acoustic power can be modulated to avoid undesired effects from total acoustic power exposure on a tissue.

Alternatively, the feedback system may include a threshold for acoustic power. If the acoustic power threshold is reached during interrogation, the ultrasound transmission can be abated or modulated appropriately to optimize or reduce exposure to acoustic power. Threshold for acoustic power can correspond to Isppa, Ispta, Isapa or Isata for ultrasound intensity levels. The threshold may also be based on the integration of acoustic energy transmitted into a tissue over time. By tracking the amount of acoustic energy used for interrogating the tissue over time, the integral of acoustic energy can be calculated and the total amount of applied acoustic energy can be determined.

In addition, transducer units may include a temperature gauge(s) to determine skin of tissue temperature. Such temperature probes can assess heating effect of acoustic power, as well as offering additional patient information at the interrogated anatomical region. Other types of probes may be included in the ultrasound transducers described herein, including skin conductivity probes, pH probes, blood pressure probes, pulse probes, hemoglobin probes, salinity probes, spectrophotometric probes and electrical stimulator probes.

#### *Other Applications*

Many of the examples the inventors provide concern ultrasound probes and techniques. Multi-site monitoring can be applied however, to other types of multi-probe monitoring including, skin electrolyte composition, skin conductivity, skin temperature, tissue oxygen levels, blood pressure, drugs and biochemical components. Such multi-site monitoring does not include monitoring of action potentials of neuronal conductivity either of single neurons, or of tissues (e.g. EKG).

## **5.0 METHODS AND DEVICES FOR MULTI-SITE MONITORING OF FLUID REGULATION**

Multicellular, living organisms with more than one body compartment tightly regulate the interstitial fluid that baths their cells. Such organisms manage their interstitial fluid using a variety of physiological mechanisms that can include adjusting excretory, secretory, and circulatory processes. These physiological processes, as well as others, have evolved to compensate for small and rapid changes

in capillary related interstitial fluid that can dramatically alter homeostasis due to physiological challenges and responses.

The invention recognizes for the first time that fluid regulation can be assessed with ultrasound techniques by interrogating a tissue of interest at multiple ultrasound probe locations. Typically, at each interrogation site distances are ultrasonically measured between reflective interfaces within the tissue of interest that anatomically correspond to capillary related interstitial fluid or capillary related interstitial fluid layers. Because interfaces between different biological layers arise due to differences in the relative amounts of water and biomaterials in such layers, the ultrasound methods and devices described herein can advantageously utilize such differences to qualitatively or quantitatively measure fluid regulation and capillary related interstitial fluid in the tissue of interest or whole body.

The invention's methods and devices are broadly applicable to any tissue or body, including internal organs, having one or more reflective interface(s) that can be interrogated using ultrasound. Usually, such interfaces will arise from differences in water or biomaterial content, such as interfaces between bone and muscle layer, skin layer and fat layer, cell mass and interstitium, tumor and interstitium, or bone and interstitial layer. Consequently, the present invention finds broad application in a variety of settings in health care and health management.

By way of example, and not limitation, **FIG. 1 A-C** illustrates capillary related interstitial fluid accumulation. **FIG. 1A** shows normal leg tissue prior to an increase capillary related interstitial layer thickness. Skin is "S." Tibia is "T." Fibula is "F." Muscle is "M" and interstitial layer is "IL." The probe interrogation site **100** is a preferred site for monitoring capillary related changes in ILT. The tissue plane **110** is approximately illustrated by arrows. **FIG. 1B** and **C** illustrate a small but progressive increases in ILT around **100** over time. Such changes in ILT can be measured using the devices and methods of the present invention for assessing fluid regulation.

Increases in ILT are further illustrated in **FIG. 2A** and **B**, which is a closer view of interrogation site **100**. Skin **200** shows little change in thickness over time due to an increase in capillary related interstitial fluid. In contrast, the IL thickness changes dramatically due to an increase in capillary related interstitial fluid. Bone

210 and skin 200 (skin/bone interface) typically provide reflective surfaces for detecting ILT.

In one embodiment, the invention includes a method of measuring fluid regulation capillary related interstitial fluid comprising: transmitting at least one  
5 ultrasound signal to a tissue in a subject in need of fluid regulation assessment at least two or more anatomical sites, recording at least one ultrasound signal from each one of said at least two or more anatomical sites, and determining a capillary related interstitial layer thickness from a first reflective surface to a second, usually an internal, reflective surface at each one of said at least two or more anatomical sites,  
10 wherein the capillary related interstitial layer thickness from each one of said at least two or more anatomical sites is an assessment of fluid regulation. Often the capillary related interstitial layer thickness from each one of said at least two or more anatomical sites are compared to determine if fluid shifts are occurring in the subject. Typically, such a subject will be a human desiring a fluid regulation assessment  
15 because a clinician wishes to use the invention as a part of a diagnosis of the subject's fluid regulation capability. Often such diagnosis will relate to a clinician's desire to assess capillary related interstitial fluid to determine the status of a subject's homeostasis to ensure that the subject's physiological mechanisms are functioning appropriately. In the case of self-measurement, such measurements will often relate  
20 to the subject's desire to monitor changes in homeostatic physiological mechanisms in their own body for health, medical, athletic, or intellectual reasons.

The transmitting step requires transmitting at least one ultrasound signal with sufficient power to permit the signal to travel in the tissue of interest. Typically, the transmitted signal will be reflected off an interface that separates two layers that  
25 contain differing amounts of water and biomaterials. Any suitable frequency, as described herein or in the future or known in the art can be used. The frequencies used can be selected for maximum transmission and reflective performance, and lowest noise by recording signals from a tissue at different frequencies. Thus, for a particular tissue, the frequency with the best properties can be selected and a  
30 dedicated probe can be constructed using such a frequency. Typically, the frequencies used will range from 0.2 to 20 MHz, preferably from .5 to 8 MHz and more preferably from 0.5 to 4 MHz.

The transmitting step is desirably practiced using multiple signals from multiple probes. A plurality of signals can be transmitted and their return signals ("echoes") from reflective interfaces recorded from each probe at each anatomical site. Signal averaging will improve the accuracy of the measurements and can be conducted over a relatively short period of time. Generally, multiple signals for signal averaging will be transmitted in less than 1 to 2 seconds and more often in less than 100 to 300 milliseconds and preferably in less than 50 milliseconds.

The transmitting step can be optionally practiced using multiple signals over longer lengths of time that would not typically be used for signal averaging. Such lengths of time permit monitoring of shifts or changes in fluid regulation. For example, water can shift from blood into capillary related interstitial fluid (or vice versa) and change the amount of capillary related interstitial fluid in a tissue. Such shifts can result from changes in physiological processes or regulated parameters, such as ion transport, oncotic pressure of the capillary related interstitial fluid, oncotic pressure of blood, the amount of osmotically active substances in the capillary related interstitial fluid or blood, extracellular pH or intracellular pH. By transmitting ultrasound signals over lengths of time that correspond to such physiological events, changes in fluid regulation can be assessed and compared to normal or standard values and over time. Most physiological events will occur over a much longer time frame than required for signal averaging. Typically, such monitoring will occur over minutes, hours, days and even in some instances, as described herein, it will be desirable to monitor subjects over months or years. In addition, such transmitting may be continuous, or over a clinically relevant time period nearly continuous, in order to monitor real time changes in fluid regulation.

The recording step typically requires recording multiple signals from multiple probes. Usually, the signal will be a reflected signal from a reflective interface. Desirably, a plurality of reflected signals are averaged for a particular probe, as described for transmitted signals or known in the art. The returning signals can be optionally filtered or sampled to remove noise and scatter. For example, if a layer(s) at a predictable (or estimated) distance from the probe is present that produces scatter and is not relevant for determining capillary related interstitial fluid volume, return signals can be appropriately sampled to remove such scattering by preferentially

recording the signal at times not corresponding to the return signal times from the interfering layer(s). Such methods, as well as shortest reflective distance measurements, are also described in PCT patent application PCT/US97/18993 filed October 21, 1997, which is herein incorporated by reference.

5           A, B or C scan modes of ultrasound interrogation and recording can be used  
with the methods and devices of the invention. Preferably, A scan systems will be  
used to provide relatively inexpensive diagnostic tools. Because most applications  
only require detecting the distance between layers that contain capillary related  
interstitial fluid or the thickness of a capillary related interstitial fluid layer,  
10       information relating to a third dimension is often not necessary.

The determining step requires determining a capillary related interstitial layer thickness from a first reflective layer and a second reflective layer from multiple probes at their respective anatomical sites. Typically, signals from the first and second reflective layer will be detected by an ultrasound detector at different times.

15 The difference in time of reception between the signal from the first reflective layer and the signal from the second reflective layer can be used to determine the time required for sound to travel from the medium between first and second reflective layers. For example, capillary related interstitial layer thickness can be a reflection of transmission times as described by the following calculation:

$$20 \qquad \text{ILT} \propto (\tau_2 - \tau_1) \div 2 \qquad [\text{Eq. 2}]$$

wherein ILT is the interstitial layer thickness,  $\propto$  refers to a relationship of proportion (and can include the relationship of equality if calculated using the appropriate factor(s)),  $\tau_2$  is the time of transmission of the ultrasound signal from an ultrasound probe (the transmitting signal) to the second reflective layer and back to an ultrasound probe (detecting the return signal), and  $\tau_1$  is the time of transmission of the ultrasound signal from an ultrasound probe (transmitting the signal) to the first reflective layer and back to a ultrasound probe (detecting the return signal). ILT for this type of calculation can be expressed in relation to transmission time.

ILT can also be calculated in terms of actual distance, such as centimeters  
 30 (cm). For example, the transmission time related to the ILT in [Eq. 2], which is units  
 of time, can be multiplied by the speed of sound in the medium being measured. If  
 more than one medium is being interrogated and more than two reflective layers are



being interrogated, then the speed of sound for each medium can be incorporated into the calculation. The speed of sound for various tissues and substances typically varies from 331 to 5000 (meters/second), such as air (331), water (1430), saltwater (1510), fat (1450), soft tissue (1540), blood (1585), muscle (1585), PZT-4 transducer (4000), skull bone (4080) and metal (5000) (all in meters per second). Speed of sound in a medium can also be measured empirically, by separating two ultrasound probes by a predetermined distance with the medium of interest between the two probes and transmitting and detecting ultrasound signals between the two probes. Such measurements can be relatively easily accomplished, especially with appendages, and can increase the information content of the data.

It is not, however, necessary to record signals reflected from the first reflective layer. In some instances, the first reflective layer will be a predictable transmission time and distance from the ultrasound probe and such a predictable transmission time or distance can be used in [Eq. 2] to estimate the ILT. As described in further detail herein standard transmission times and ILTs can be estimated by sampling subjects or by providing predetermined standards. Thus, capillary related interstitial layer thickness can be qualitatively or quantitatively determined. Nor is it necessary, even for quantitative calculations, to calculate an exact value for the interstitial layer because a delta (i.e. change) in ITL may be all that is clinically relevant.

This embodiment of the invention can be applied to a variety of application sites and medical treatments as described herein, developed in the future or known in the art. This embodiment of the invention also can be used with many different types of suitable probes, systems, and methods relating to ultrasound measurements, and calculations and biological standards, as described herein, developed in the future or known in the art.

#### *Application Sites*

Fluid regulation can be measured in any tissue or at anatomical site(s) (e.g. continuously) that contains within it at least one reflective surface and a sufficient amount of water or other acoustic medium to permit ultrasound signals to penetrate and return through the tissue for detection. Often the first reflective surface is the probe-skin interface and the internal reflective surface is a bone-ILT interface. An internal reflective surface refers to a reflective surface on the inside of the body that is

not accessible from the outside and is in contact with interstitial fluid. **Table 1** shows a number of potential reflective surface combinations for potential application sites for ultrasound probes and some potential diagnostic applications for assessing certain physiological functions that can be related to fluid regulation. **Table 1** is by no means exhaustive, it is only illustrative of the many potential sites and reflective surfaces to monitor fluid regulation or capillary related interstitial fluid. **Table 1** also includes some embodiments of the invention not associated with capillary related interstitial fluid monitoring, such as ascites and cranial edema. Typically, the subjects will be humans, however, the present invention may be used with other animals, especially large mammals in veterinary settings.

**Table 1**

First Reflective Surface	Second Reflective Surface	Probe Site	Diagnostic Application
Skin	Bone	Leg (preferably mid, anterior tibia)	Heart, renal, and circulatory function
Skin	Bone	Arm (preferably distal radius or ulna)	Heart, renal, or circulatory function
Skin or bone or chest wall muscles	Lung tissue or pleural surface	Chest (preferably mid axillary line, e.g. between 10 <sup>th</sup> /11 <sup>th</sup> rib)	Pulmonary edema, pleural effusion, heart and circulatory function
Skin or muscle	Bone	Presternal	Heart, renal, and circulatory function
Skin	Traumatized tissue	Skin above internal trauma site	Trauma, progression of trauma or healing
Skin or muscle or liver tissue or splenic tissue	Liver tissue or splenic tissue or abdominal fat	Skin above left or right paracolic gutter	Ascites, heart failure, renal failure, cirrhosis
Skin	Bone	Cranium (preferably temporal bone, forehead or nuchal region)	Head trauma, cerebral edema, heart function

The sites listed in **Table 1** can also be used in combination. By using combinations of probe sites (i.e. multi-site monitoring), fluid movement throughout the body can be monitored. This permits monitoring fluid shifts from fluid compartments of the body. Multi-site monitoring also permits exquisitely sensitive monitoring of physiological processes related to edema, capillary related interstitial fluid shifts and other fluid related changes in the body, such as processes that either

induce, prevent or reduce fluid shifts, as well as therapeutic treatments thereof. Multi-site monitoring is further described in detail herein, particularly in the section relating to monitoring physiological functions and in situ probes.

By way of example, and not of limitation, FIG. 3 and 4 illustrates selected sites that can be used for ultrasound monitoring of fluid regulation, capillary related interstitial fluid and capillary related edema as well as other methods described herein. FIG. 3 shows a human subject in need of monitoring of capillary related interstitial fluid. Exemplary ultrasound interrogation sites include, but are not limited to, the forehead region 300, the temporal region 310, the forearm region 320, the humeral region 330, the presternal region 340, the lateral chest wall region 350, the lateral abdominal region 360, the tibial region 370, and the foot region 380.

FIG. 4 is a magnified view of the tibial region demonstrating the proximal third of the tibia site 400, the mid-tibia site 410, the distal third of the tibia site 420, and the medial malleolus site 430. FIG. 3 and 4 are by no means exhaustive, it is only illustrative of the many potential regions and sites that are available to monitor fluid regulation and capillary related interstitial fluid. The exemplary regions and sites illustrated in FIG. 3 and 4, as well as others described herein, can be used alone or in combination for interrogation.

#### *Application to Medical Treatments*

Medical treatments often affect fluid regulation, such as maintenance of interstitial fluid levels. Often medical treatments are designed to modulate the function of an organ or physiological process in order to improve fluid homeostasis. There are numerous examples of drugs designed to modulate heart, renal or pulmonary function and, as a consequence, improve fluid homeostasis. Often when such medical treatments are initiated, it is difficult to establish a baseline for fluid homeostasis other than a general diagnosis of abnormal or pathological fluid imbalance or fluid retention that may or may not be associated with another diagnosed medical condition. Methods and devices of the invention can assist in measuring the effectiveness of medical treatments, as well as distinguishing the causes or causes of inadequate fluid regulation.

For example, a patient may have pronounced fluid retention in the extremities resulting from right ventricular failure. A clinician when posed with this medical

situation might prescribe a drug to improve cardiac performance. The effectiveness of the medical treatment could be measured by examining the patient, similar to the original examination. Often the original examination will only involve a physical examination that may be difficult to directly compare to the second examination, especially the amount of fluid retention in the extremities. Although examination of heart function may be easier to compare between first and second examinations because heart function is often more quantifiable, patients may show changes in systemic function that suggest improvement without measurable improvement in cardiac performance.

10 In this case, comparing the first and second examination results using traditional methods has a number of drawbacks. The medical treatment for right ventricular failure might not actually improve right ventricular performance even though heart rate may be lowered or contractility improved. Cardiac improvements apparent from traditional methods may also lead to false positive indications because actually improvement water retention in the extremities may not have occurred. Comparing systemic effects in the first and second examination may also be complicated by the fact that the clinician conducting the first examination may not be the same clinician as the one conducting the second examination.

20 It is therefore desirable to compare measurements of fluid retention in a manner that is more easily repeated upon a second examination, less influenced by variability between clinicians, more reproducible, and more quantifiable than physical examination. The methods and device of the present invention permit measurement of fluid retention in a manner that is more easily repeated upon a second examination, less influenced by variability between clinicians, more reproducible, and relatively more quantifiable than physical or traditional examination techniques.

25 The steps of (a) transmitting, (b) recording, and (c) determining related to the method monitoring fluid regulation or capillary related interstitial fluid can be performed as multiple patient examinations over different time spans. This is an advantage over the prior art, since this technique can generate values for the interstitial layer(s) that can be compared over time and is less susceptible to inter-clinician and intra-clinician variation. For example, steps of transmitting, recording and determining can be conducted as a baseline for patient monitoring. Such an

examination could occur prior to a medical treatment. In the first examination, a first capillary related interstitial layer thickness(es) is determined. In a subsequent examination, steps (a), (b), and (c) are repeated. Examinations subsequent to the first examination could occur after, or simultaneous to, the medical treatment. The timing of subsequent examinations can be any desired by the subject, operator, or clinician. Usually, examination will be periodic or during a predetermined clinically relevant time period.

Routine periodic examinations, such as part of an annual examination, can monitor long term changes in the physiology due a number of medical conditions, such as those described herein. Such periodic examinations can be applied to other methods described herein, such as methods related to monitoring vascular or cardiac performance during a clinically induced stress.

Examinations during a clinically relevant time period can be used to monitor the progress of expected changes in a subject's physiology. Clinically relevant time periods usually relate to a medical treatment regime or medical conditions. The method includes comparing a second capillary related interstitial layer thickness from single or multiple sites (measured in the subsequent examination) to the first capillary related interstitial layer thickness from single or multiple sites (measured in a prior examination). The change in capillary related interstitial layer thickness can be indicative in a change in the physiological condition of the subject, such as fluid regulation. For instance, if the second capillary related interstitial layer thickness is larger than the first capillary related interstitial layer thickness, then the medical treatment, or medical condition, has usually induced an increase in capillary related interstitial fluid. As a second alternative, if the first capillary related interstitial layer thickness is larger than the second capillary related interstitial layer thickness, then the medical treatment, or medical condition, has usually induced a decrease in capillary related interstitial fluid. As a third alternative, if the first capillary related interstitial layer thickness is equal to the second capillary related interstitial layer thickness, then the medical treatment, or medical condition, has usually induced no change in capillary related interstitial fluid. This type of comparative monitoring, subsequent to a first examination, can be applied to a monitor a number of medical conditions or assess a number of medical treatments.

A desirable aspect of periodic or clinically relevant monitoring is to determine if a change in capillary related interstitial layer thickness relates to more than one physiological change. For example, a change in capillary related interstitial layer thickness may be induced by both short term and long term physiological changes. In such a subject the short term effect can be assessed by inducing physiological changes in the subject that would alter capillary related interstitial layer thickness at the relevant anatomical region in a relatively short examination period (e.g., within about 40 to 120 minutes). Depending on the outcome of such assessment, the clinician can weigh the relative contribution of long term and short term effects on interstitial layer thickness. Preferably, the same type of monitoring was previously performed on the subject so a comparison can be made. Generally, the more rapid or greater the change in interstitial layer thickness, compared to an expected or previous reading, the greater the short term effect. The subsequent diagnosis can then be guided by the relative contributions of short and long term effects.

For example, a typical short term effect on capillary related interstitial layer thickness in the tibial region is prolonged standing (e.g., 4 to 6 hours of continuous standing). A subject monitored using the tibial monitor methods described herein, for instance, may be responding to anti-diuretic treatments to reduce capillary related interstitial fluid volume while contemporaneously responding to shorter term effects of standing upright. In such a subject the effect of standing upright for a prolonged period of time can be assessed by inducing physiological changes in the subject that would alter tibial capillary related interstitial layer thickness in a relatively short examination period. For example, by monitoring tibial capillary related interstitial layer thickness in the upright position and in the prone, or leg raised positions, the short-term effect of standing upright can be assessed. Rapid changes in tibial capillary related interstitial layer thickness can be generally influenced by short-term effects. In some instances, such as in physiological changes in capillary permeability, will be preferably to measure the rate of change in capillary related interstitial layer thickness, as it will be a more sensitive and reliable measurement. Note, however the methods described herein, where rapid changes in tibial interstitial thickness can be indicative of increased capillary permeability, compromised venous valves, or insufficient cardiac output. Preferably, a baseline is established for

capillary related interstitial layer thickness so comparisons can be made in subsequent measurements.

One of the most common clinical settings for a method of measuring capillary related interstitial layer thickness is the assessment of the efficacy or side-effects of medical treatments. Monitoring regimes can be conveniently and appropriately tailored using the methods described herein to evaluate the progress of treatment. Typically, a drug will be administered to a subject and the steps (a) transmitting, (b) recording, and (c) determining related to the method of monitoring fluid regulation or capillary related interstitial fluid are repeated at predetermined intervals as an assessment of capillary related interstitial fluid balance of the subject over a clinically relevant time period. Preferably, baseline monitoring prior to drug administration is also conducted.

Typical drugs amenable to such treatment monitoring include cardiovascular agents and renal agents. Other drugs include anti-hypertensives, diuretics, anticoagulants, and vasoactive substances (see also **Table 3**). Clinicians, however, can use the method with any drug, particularly those drugs thought to change capillary related interstitial fluid levels either as a treatment for altering capillary related interstitial fluid levels or for monitoring side-effects of drugs that may alter capillary related interstitial fluid levels in undesired or unintended ways.

Another common clinical setting for a method of measuring capillary related interstitial layer thickness is to assess the efficacy or side-effects of a medical treatment comprising surgical procedures and treatments. Typically, a surgical treatment will be provided to the subject and the steps of (a) transmitting, (b) recording, and (c) determining related to the method of monitoring fluid regulation or capillary related interstitial fluid are repeated at predetermined intervals as an assessment of capillary related interstitial fluid balance of the subject over a clinically relevant time period. Preferably, baseline monitoring prior to surgical treatment is also conducted. The surgical treatment may be directed, in whole or in part, to modulating capillary related interstitial fluid levels.

Examples of such surgical treatments include cardiac surgery (e.g., cardiac valve replacement and coronary bypass graft surgery), renal surgery (e.g., surgical or interventional radiologic repair of renal artery stenosis or urinary outflow stenosis),

renal and hepatic transplantation, pulmonary arterial embolectomy, peripheral venous or arterial embolectomy, and peripheral vascular surgical and interventional radiologic procedures (e.g., stripping of varicose veins, sclerotherapy, bypass grafting, and thrombolytic therapy), as well as others known in the art or developed in the future.

5 Usually, the clinically relevant time period for monitoring of the efficacy of surgical treatments will be periodically over about days to months.

In other indications related to surgical treatments, monitoring of the side-effects of surgical treatments will be desired. Side effects of surgical treatments include blood loss, cardiac arrest, fat and air embolism, heart failure, hepatic failure, 10 hepatic or renal ischemia and infarction, hypoxic tissue damage, intestinal ischemia and infarction, mechanical tissue damage, myocardial ischemia or infarction, myolysis, pulmonary edema, pulmonary embolism, renal failure, urinary obstruction, respiratory arrest, sepsis, shock, spinal cord injury, over-hydration or dehydration, fluid retention in dependent anatomical regions, lower or upper extremity venous 15 thrombosis, and arterial dissection and/or occlusion.

Usually, the clinically relevant time period for monitoring of the side-effects of surgical treatments will be during the surgical procedure or treatment and periodically over about 24 to 96 hours post procedure or treatment. The use of multi-site monitoring and continuous monitoring, as described in further detail herein, will 20 be particularly applicable in this clinical setting.

Multi-site monitoring and continuous monitoring can be used to prevent the progression of capillary related interstitial fluid retention, especially in specific anatomical regions during and post surgical treatment, such as the forehead, the temporal region, the occiput, the nuchal region, the cervical region, the thoracic 25 region, the low back region, sacral region, and buttocks region, the sternal region, the anterior or the lateral chest wall, the anterior or the lateral abdominal wall, the humerus region, the forearm region, the hand, the thigh, the tibial region, the calf, the medial and lateral malleolus, the foot, and preferably any such dependent anatomical region (see also FIG. 3 and 4).

30 Another common clinical setting for a method of measuring capillary related interstitial layer thickness is to assess the efficacy or side-effects of a medical treatment comprising general anesthetic procedures and treatments. Typically, a



general anesthetic procedure or treatment will be provided to the subject and the steps (a) transmitting, (b) recording, and (c) determining related to the method of monitoring fluid regulation or capillary related interstitial fluid are repeated at predetermined intervals as an assessment of capillary related interstitial fluid balance of the subject over a clinically relevant time period. Usually, the clinically relevant time period will be during a general anesthetic procedure or treatment and periodically over about 24 to 72 hours post procedure or treatment. Preferably, baseline monitoring prior to general anesthetic procedure or treatment is also conducted. Side-effects of general anesthetic procedures or treatments include hypoxic or embolic brain damage, cardiac arrest, drug-induced complications, heart failure, hypoxic tissue damage, intestinal ischemia and infarction, myocardial ischemia or infarction, myolysis, pulmonary edema, pulmonary embolism, renal failure, respiratory arrest, line sepsis, shock, over-hydration or dehydration, and lower or upper extremity arterial or venous thrombosis.

The use of multi-site monitoring and continuous monitoring, as described in further detail herein, will be particularly applicable to general anesthetic procedures and treatments. Multi-site monitoring and continuous monitoring can be used to prevent the progression of capillary related interstitial fluid retention under such conditions, especially in specific anatomical regions during and post general anesthetic procedure or treatment, such as the forehead, the temporal region, the occiput, the nuchal region, the cervical region, the thoracic region, the sternal region, the anterior or the lateral chest wall, the anterior or the lateral abdominal wall, the humerus region, the elbow region, the forearm region, the hand, the thigh, the tibial region, the calf, the medial and lateral malleolus, the foot, and dependent anatomical regions (see also FIG. 3 and 4).

Intubation of a subject is another common clinical setting to apply a method of measuring fluid regulation or capillary related interstitial layer thickness to assess the efficacy or side-effects associated with this medical treatment. Typically, an intubation procedure will be provided to the subject and the steps of (a) transmitting, (b) recording, and (c) determining related to the method of monitoring capillary related interstitial fluid are repeated at predetermined intervals as an assessment of capillary related interstitial fluid balance of the subject over a clinically relevant time

period. Usually, the clinically relevant time period will be during an intubation procedure and periodically over about 24 to 72 hours post procedure or treatment. Preferably, baseline monitoring prior to an intubation procedure is also conducted. Side effects of intubation procedures include airway obstruction, airway damage, barotrauma, gastric intubation, tracheal or bronchial perforation, tracheopleural and bronchopleural fistula, tracheoesophageal fistula, hepatic or renal ischemia and infarction, hypoxic brain damage, hypoxic tissue damage, intestinal ischemia and infarction, myocardial ischemia or infarction, pulmonary edema, respiratory arrest, spinal cord and cervical spine injury, and tetraparesis or paraparesis. The use of multi-site monitoring and continuous monitoring, as described in further detail herein, will be particularly applicable in this clinical setting. Multi-site monitoring and continuous monitoring can be used to prevent the progression of capillary related interstitial fluid retention in intubation, especially in specific anatomical regions post intubation procedure, such as the forehead, the temporal region, the cervical region, the thoracic region, the low back region, the sternal region, the anterior or the lateral chest wall, the anterior or the lateral abdominal wall, the humerus region, the elbow region, the forearm region, the hand, the thigh, the tibial region, the calf, the medial and lateral malleolus, the foot, and dependent anatomical regions (see also FIG. 3 and 4).

Another important application of the present invention is in trauma, intensive or critical care units, or emergency room settings. Such settings normally require critical care procedures of a subject to assess medical conditions that have serious or life threatening consequences. In critical care situations, the steps of (a) transmitting, (b) recording, and (c) determining related to the method of monitoring fluid regulation capillary related interstitial fluid are typically initiated as quickly as possible. In many critical care situations rapid fluid shifts occur and the present invention, in part, because of its sensitivity to small fluid shifts, can warn a clinician of a potentially harmful or life threatening fluid shift.

The method can also be used to monitor the progression or shift of capillary related interstitial fluid that is common in critical care settings. Fluid is often retained in the extremities, the head and neck region, dependent body regions (i.e., regions subjected to fluid accumulation due to gravity) and areas with subcutaneous tissue

rich in vascularized tissue and collagen and elastic fibers, such as the scrotum. It will be desirable to repeat the steps of (a) transmitting, (b) recording, and (c) determining related to the method of measuring fluid regulation and monitoring capillary related interstitial fluid, particularly at predetermined intervals, as an assessment of capillary related interstitial fluid balance of the subject over a clinically relevant time period. Steps (a), (b), and (c) are typically initiated within 36 hours of a trauma or other critical care setting, preferably within about 24 hours, more preferably within about 6 hours and most preferably within about 15 minutes. Typically, a progressive increase in capillary related interstitial layer thickness indicates an increase in capillary related interstitial fluid and a progressive decrease in capillary related interstitial layer thickness indicates a decrease in capillary related interstitial fluid. Monitoring of capillary related interstitial fluid can occur in many critical care situations, including patients with acquired immunodeficiency syndrome (AIDS), autoimmune disorders, burns, bacteremia, cancer leading to local or distant organ failure, cardiac arrest, coma, drowning or near-drowning, drug-induced complications, drug overdose, heart failure, hepatic failure, infections, inhalation of toxic substances, intestinal ischemia and infarction, myocardial ischemia or infarction, poisoning, pulmonary embolism, renal failure, respiratory arrest, trauma, transplant complications, sepsis, shock, and arterial or venous thrombosis. The use of multi-site monitoring and continuous monitoring, as described in further detail herein, will be particularly applicable in this clinical setting.

Multi-site monitoring and continuous monitoring can be used to prevent the progression of capillary related interstitial fluid retention post trauma, or during some other critical care event, in specific anatomical regions, such as the forehead, the temporal region, the occiput, the nuchal region, the cervical region, the thoracic region, the low back region, the sternal region, the anterior or the lateral chest wall, the anterior or the lateral abdominal wall, the humerus region, the elbow region including the olecranon, the forearm region, the hand, the thigh, the tibial region, the calf, the medial and lateral malleolus, the foot, and preferably dependent anatomical regions (see also FIG. 3 and 4).

*Different types of monitoring*

Monitoring of fluid regulation or capillary related interstitial fluid can include any temporal method, including periodic, intermittent, predetermined and continuous. In many instances, at least one ultrasound signal is from an ultrasound probe  
5 positioned on the surface of a tissue. The positioning typically guides the probe to a specific and routinely recognizable anatomical region and permits measurement of an interstitial layer, often between bone and skin. The probe can be positioned to allow for periodic, continuous or intermittent monitoring. The more reproducible the positioning the better the monitoring over time. Thus, the probe is preferably  
10 positioned at approximately the same anatomical site on the surface of the tissue. The transmitting and recording can occur at clinically relevant time intervals. In many settings where the subject is relatively immobile, such as a hospital or convalescent home, and continuous or intermittent monitoring is preferred, the time intervals are over at least about a 4 hour time period. Other acceptable time interval include  
15 monitoring over at least about a 6, 12, 24, 48, 72, or 96 hour time periods. Longer or shorter monitoring periods can also be applied. Usually, the clinical situation the subject has been diagnosed with requires chronic or continual fluid regulation assessment.

The ultrasound probe(s) used for fluid regulation monitoring preferably is  
20 specifically adapted for interstitial fluid assessment. Examples of such specifically adapted probes are described herein for the first time. Preferably, for self-measurement the probe is part of an ultrasound system dedicated to monitoring interstitial fluid assessment. Such systems can be primarily designed to measure interstitial fluid levels, usually based on specific anatomical regions using an  
25 ultrasound probe. Often such systems will include a chip for computing interstitial layer thickness. Equivalently, the calculation of a proxy that approximately simulates interstitial fluid volume or capillary related interstitial fluid thickness based on ultrasound signals may be substituted for computing the ILT thickness. Other features that can be included in dedicated probes are more fully described herein. Although,  
30 imaging systems can be used to practice some embodiments of the invention, it will be preferred to use non-imaging systems that can determine interstitial layer thickness.

Probes known in the art and developed in the future can also be used for practicing methods of the invention.

In one embodiment of the invention, an ultrasound probe can be secured to the subject with an adhesive as shown in **FIG. 5A and B**. This is preferred for methods that use intermittent or continuous recording. The ultrasound transducer can be electrically coupled to an ultrasound computational unit (not shown) using a light weight wire **500**. An electrical connector **510** connects the computational unit and the ultrasound transducer **520** using an electrical connecting socket or connector means **530**. The ultrasound transducer **520** is optionally seated inside a positioning frame **540**. The undersurface of the positioning frame consists of an acoustic coupler **550**. The positioning frame is attached to the subject or tissue surface using an adhesive **560**. Usually, for better acoustical coupling the skin of the subject is hairless or the hair is removed. Although, this is not necessary in most instances. Preferably, the adhesive **560** can acoustically couple the ultrasound probe to the skin of the subject or the interrogated tissue surface **570**. Although, the adhesive can also be interspersed with an acoustic coupling material, such as a gel. An adhesive may also be applied to a securing band that is disposed on at least a portion of the probe that does not contact the skin. The adhesive contacts a region adjacent the probe to secure the probe's position. Preferably the adhesive contacts the skin on either side of the probe.

**FIG. 5B** shows that the ultrasound transducer **520** can also be coupled to an ultrasound computational unit (not shown) using an infrared coupler or a radio frequency coupler **580** or other connector means that transmits signals **590** to an ultrasound computational unit.

**FIG. 6** shows one embodiment of the invention comprising an ultrasound transducer **600** attached to a separate positioning frame **620** with an attachment member **610**. The extending members **630** of the positioning frame are attached to securing members **640** to secure the frame to the skin away from the interrogation site. The securing members are secured to the skin using an adhesive or other anatomical region attachment means. The ultrasound transducer is electrically coupled to an ultrasound computational unit using a light weight wire **650**. Alternatively, the ultrasound transducer can be coupled to an ultrasound computational unit using an infrared or radio frequency coupler.

Dedicated and secured probes can have many different cross sectional areas. As the size of the cross sectional area increases, a larger area is monitored, which in some applications is desirable because a greater surface area can produce better signal averaging. If the probe surface, however, is larger than the anatomical region to be  
5 interrogated the signal quality will diminish. Consequently, probe size can be tailored to fit a particular anatomical region. In some applications it will also be desirable to have a probe that specifically interrogates a smaller region in order to improve sensitivity. In some anatomical regions, such as the tibial region, a focused interrogation, in terms of surface area, can permit more sensitive measurements.  
10 Typically, the ultrasound probe has a surface area of no more than  $7 \text{ cm}^2$ , preferably  $5 \text{ cm}^2$ , and more preferably  $2 \text{ cm}^2$ .

#### *Calculations and Standards*

Calculations relating to capillary related interstitial fluid and layers can be used with the devices and methods of the present invention. Many of the calculations  
15 are related to signal processing, including calculating the ILT, signal averaging, calculating the shortest reflective distance, and threshold setting. Generally, ILT is calculated as follows:

$$\text{FRD} - \text{SRD} \quad [\text{Eq. 3}],$$

wherein FRD (first reflective distance) is calculated as the time of travel from a probe  
20 to a first reflective layer (usually skin) and back to the probe multiplied by the speed of sound in a given tissue(s) and divided by two, and SRD (second reflective distance (such as an internal reflective distance, usually bone) is calculated as the time of travel from a probe to a second reflective layer (usually bone or fat) and back to the probe multiplied by the speed of sound in a given tissue(s) and divided by two.

25 A computational unit can be included in a system to calculate ILT using Eq. 3 or any other calculation that can be used in the methods described herein or known in the art or developed in the future for ultrasound. For instance, it may not be necessary in some applications to use Eq. 3 because the first reflective distance is filtered out by the system and only the second reflective distance is calculated. The second reflective  
30 distance will still often be, even in the absence of a first reflective distance correction, an indicator of ILT, in appendage regions. Skin thickness usually does not change as much as interstitial layer thickness, therefore ILT is often not greatly influenced by

such correction. Skin thickness usually does not provide a large relative contribution to overall tissue thickness. Consequently, ILT is often relatively insensitive to the inclusion of skin thickness in ILT measurements.

Skin thickness can also be standardized and subtracted (see methods described  
5 herein) from the second reflective distance to determine ILT. This is preferred in applications where skin thickness becomes a significant contributor to tissue thickness (e.g., young individuals, tibial regions, and subject of normal or below normal weight). Preferably, the invention does not include a computational unit capable of processing signals for imaging. In the preferred embodiments of the invention, the  
10 system simply processes the signals without reconstructing an image from the signal. By using an A scan type ultrasound system, a dedicated system can be built relatively inexpensively. The invention also includes a computer program product that includes a computer readable storage media that includes a computer program to calculate or estimate ILT using Eq. 3.

15 Determination of a reflective layer will typically constitute either analysing signals for the most intense, narrow signals or by threshold setting. Signals received from the tissue by the detector are processed or stored by the system for subsequent processing. Selection of reflective layers can include determining which signal contains the highest amplitude or averaging a number of signals and determining the  
20 highest amplitude for the averaged signals. Once the highest amplitude has been selected, the travel time associated with the highest amplitude is used to determine the distance to the reflective layer. Either travel times or distances can be used in an electronic or computational filter to remove data with either travel times or distances that are considered a priori as artifacts. For instance data can be excluded with travel  
25 times considered to be too short to be associated with a first reflective layer associated with skin. Often inexperienced operators can inadvertently include an air gap between the probe and skin or not properly apply a coupling gel to the surface of the skin. Such operator errors can lead to anomalous data that includes abnormal short travel times or distances that can be excluded from the analysis by a computational unit.  
30 Optionally, the computational unit can electronically apprise the operator of the potential error by signaling the operator, such as with a bell, flashing light or other error message. The system can also include an override function to enable the

operator to dismiss the error. Upon repetition of the measurement the operator may determine the signal is not in error and wish to override the preprogrammed error function of the system.

Signals received by the detector can be subjected to threshold processing.

5 Typically, threshold processing excludes signals of a predetermined value or range of values. The signal processing can potentially exclude signal either above or below the predetermined threshold value. The predetermined threshold value for a signal can include: 1) predetermined values correlated with, or selected from, anatomical sites and structures (e.g., estimates of actual thicknesses), 2) predetermined values  
10 generated from interrogating the tissue under examination (e.g., generating average values for the tissue under examination), and 3) predetermined values generated from interrogating tissues to determine normative values for different tissues, subject populations, medical conditions, etc. (e.g., generating average values from particular anatomical sites or structures using multiple qualified subjects).

15 A system or detector can exclude signals at different levels of signal detection or processing. For instance, signals can be excluded by time gating, electronic filtering, digital filtering, analog filtering, and amplitude gating. Such filtering can be applied to both B-scan and A-scan devices. Preferably, such filtering is applied to A-scan devices in the form of a simple electronic circuit.

20 Time gating can be used to exclude or filter out signals received by the detector. For example, signals received by crystals can be excluded by switching off the circuit receiving electrical impulses from the crystals during a selected time window. Signals received during this time window are not subjected to further processing. The circuit receiving electrical impulses from the crystals need not be  
25 switched completely off. Instead such circuit can be instructed not to receive signals during the time window, such as by electrical gating of an amplifier receiving signals from the crystals. Alternatively, signals can be time gated by analyzing the signals received by the crystals. Through analysis of the signals as a function of time, signals received during selected time windows can be simply excluded.

30 Electronic circuits or devices can be used to exclude or filter out signals received by the crystals to accomplish electronic filtering. A circuit can be connected to the crystals to exclude signals with unwanted transmission times or amplitudes.



Signals received either too quickly or too slowly can be excluded using circuits with appropriate time responses, such as capacitive devices with different time constants. Signals received with either too small or too large in amplitude can be excluded using circuits with appropriate amplitude responses. For example, avalanche type circuits  
5 can be used. When an electrical threshold is surpassed (e.g., gating current), the current activates an amplifier. The signal current rapidly increases from zero to a value substantially above background. Reverse amplifier circuits can be used to reduce or eliminate signals with amplitudes such as capacitive devices with different time constants. Alternatively, the signals can be digitized as known in the art and  
10 signals excluded based on digital exclusion criteria (either amplitude, timing, or frequency information) that can form part of either a chip (e.g., a programmed chip) or program.

Signals, results of calculations, or signal processing can be displayed on a digital or analog display for the operator or the subject to observe. The display can  
15 also include a predetermined display arrangement that includes symbols or illustrative graphics of pre-selected anatomical features of the interrogated tissue. Results of calculations can then be used in the graphic to display the calculated distances (or other suitable information) associated with the predetermined anatomical features. After the computational unit processes the data, processed information, such as calculated  
20 distances, can then be inserted into the displayed graphic. It will also be desirable to provide display features that show the change in absolute ILT (in mm or cm) over time (or the derivative of absolute ILT as a function of time) or the percent change in ILT over time. Such time based displays will be particularly useful in chronic, continuous, and short term periodic monitoring.

25 The method or the system can further include comparing capillary related interstitial layer thickness with a standard value for capillary related interstitial layer thickness for a particular tissue. A computational unit can compare measured ILTs to ILT standards described herein. By comparing ILT values the clinician or operator can be apprised of the clinical situation. Warning or diagnostic signals can be  
30 programmed into the system to alert the clinician or operator of the possible medical implications of the ILT of fluid regulation evaluation. Diagnostic thresholds can be used to alert operators of sub- or supra-medical thresholds related to medical

conditions. Although, a particular subject may not ultimately require medical treatments if the measured ILT falls below or exceeds a sub- or supra-medical threshold, respectively, such sub- or supra-medical thresholds can provide indications or clinical warning signs that may provoke additional testing either with ultrasound or with other diagnostic tools.

The methods and devices of the invention for detecting ILT can be extremely sensitive. Typically, the present invention can measure changes in ILT as small as about .4 to 1.0 mm. Smaller and larger changes in ILT can also be measured. The ability to detect small changes in ILT is primarily influenced by probe frequency, tissue depth and the strength of the reflective layer interrogated, as described further herein. The higher the probe frequency, in general, will improve probe interrogation of shallow interrogation depths (e.g., about 1 to 20 mm). Generally, probes above 18 MHz are preferred (e.g., about 20 to 30 MHz) for shallow interrogation depths. For deeper interrogation depths (e.g., greater than about 20 mm) shorter frequency probes are desirable (e.g., about 5 to 15 MHz). Even shorter frequency probes, are desirable for interrogating particularly thick tissues (e.g., extremely thick appendages or large subjects). As the tissue thickness increases, a relatively small change in ILT (e.g., about .5 mm) will become a smaller percentage of total ILT. This can lead in some instance to decreases in the signal-to-noise ratio and make it more difficult to determine ILTs at deep interrogation depths. Consequently, it will be desirable to match probe frequency to the tissue depth or anticipated depth of interrogation. Generally, percentage changes in ILT can be measured at about 25 percent or higher, preferably about 10 percent or higher, more preferably about 5 percent or higher, and most preferably about 1 percent or higher. Consequently, with shorter clinically relevant time periods, it is desirable to provide high sensitivity aspects of the invention in order to detect small changes in ILT over time.

For example, the present invention can detect small changes in ILT as function of time. Generally, for physiological processes or challenges that rapidly affect ILT, changes in ILT can be detected in about 1 to 90 or less, preferably about 1 to 30 minutes or less, and more preferably about 5 to 30 minutes or less. At these time frames, the more sensitive aspects of the invention are preferred. Generally, for

physiological processes or challenges that slowly affect ILT less sensitive aspects of the invention can be used.

*Empirical Methods for Determining Standards*

In one embodiment of the invention, ILT measured in a patient is compared to  
5 reference ILT's obtained from a control population (e.g. age-, sex-, race-, or weight-  
matched normal subjects). Reference ILT's can be generated by measuring interstitial  
layer thickness in healthy subjects with normal vascular, cardiac, hepatic, or renal  
function and no other underlying medical condition. Reference ILT's can be  
expressed as but are not limited to, mean and standard deviation or standard error.  
10 Reference ILT's can be obtained independently for pediatric patients and patients 15-  
20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, and 80 and more years of age.  
Reference ILT's for these age groups can be obtained separately for men and women  
and for race (e.g. Asian, African, Caucasian, and Hispanic subjects). Additionally,  
reference ILT's can be obtained for different subject weights within each age, sex, and  
15 racial subgroup. For each subgroup defined in this fashion by age, sex, race, and  
weight, reference ILT's can be measured at various anatomic sites, such as the  
forehead, the temporal region, the occiput, the nuchal region, the cervical region, the  
thoracic region, the low back region, the sacral region, the buttocks region, the sternal  
region, the anterior or the lateral chest wall, the anterior or the lateral abdominal wall,  
20 the humerus region, the elbow region including the region of the olecranon, the  
forearm region, the hand, the thigh, the tibial region, the calf, the medial and lateral  
malleolus, and the foot (see also FIG. 3 and 4). Thus, such ILTs can be used a  
baseline or point of comparison in fluid regulation diagnosis.

Similarly, reference values for skin thickness, e.g. first reflective distance, can  
25 be obtained in healthy subjects with normal vascular, cardiac, hepatic, or renal  
function and no other underlying medical condition. Reference values for skin  
thickness can be obtained independently for pediatric patients and patients 15-20, 20-  
30, 30-40, 40-50, 50-60, 60-70, 70-80, and 80 and more years of age. Reference  
values for skin thickness for these age groups can be obtained separately for men and  
30 women and for race (e.g. Asian, African, Caucasian, and Hispanic subjects).  
Additionally, reference values for skin thickness can be obtained for different subject  
weights within each age, sex, and racial subgroup. For each subgroup defined in this

fashion by age, sex, race, and weight, reference skin thickness can be measured at various anatomic sites such as the forehead, the temporal region, the occiput, the nuchal region, the cervical region, the thoracic region, the low back region, the sacral region, the buttocks region, the sternal region, the anterior or the lateral chest wall, the anterior or the lateral abdominal wall, the humerus region, the elbow region including  
5 the region of the olecranon, the forearm region, the hand, the thigh, the tibial region, the calf, the medial and lateral malleolus, and the foot (see also FIG. 3 and 4).

When reference values of skin thickness have been determined for a given anatomic site, ILT may be calculated by subtracting the reference value of skin  
10 thickness for the patient's age, sex, race and weight group from the measured second reflective distance. Alternatively, reference data for skin thickness published in the literature may be subtracted from the second reflective distance. For example, skin thickness at the dorsal side of the mid-forearm has been reported to be approximately 0.95 mm at age 5 years of age, increasing to 1.2 mm at 45 years of age, and  
15 decreasing to approximately 0.7 mm at 80 years of age. Skin thickness at the ventral side of the forearm has been reported to be 0.8 mm at 5 years of age without significant variation between the first and the seventh decade of life (deRigal et al., J Invest. Dermatol. 1989). Other investigators reported a skin thickness of  $1.3 \text{ mm} \pm 0.2$  at the palm and the dorsum of the hand,  $1.4 \text{ mm} \pm 0.3$  at the forearm,  $1.6 \text{ mm} \pm 0.3$  at  
20 the calf,  $1.9 \text{ mm} \pm 0.4$  at the posterior sole,  $2.0 \text{ mm} \pm 0.3$  at the forehead,  $2.3 \text{ mm} \pm 0.5$  at the lower back (Fornage et al., Radiology 1993).

If skin thickness does not provide a large relative contribution to overall tissue thickness, no correction may be necessary. Alternatively, the device may measure the first reflective distance, e.g. skin thickness, in each individual patient directly and ILT  
25 may then be obtained by subtracting measured first reflective distance from measured second reflective distance.

In another embodiment of the invention, measured ILT can be compared to the control population (e.g. age, sex, race, or weight-matched normal subjects) reference ILT for a given patient. If the measured ILT falls outside a certain range defined  
30 based on the reference ILT, an alarm such as a bell, a flashing light, or a message will be generated by the device indicating that the patient has an ILT and, ultimately, an amount of interstitial fluid lower or higher than the healthy reference population. The

device may be set to generate the alarm when the measured ILT is one, two, or three standard deviations above or below the reference ILT. In this fashion, the device can be used to diagnose capillary related edema. The magnitude of the discrepancy between measured ILT and reference ILT can also give an indication of the severity of interstitial fluid accumulation or depletion.

Normal ILT in healthy subjects will vary significantly depending on the anatomic site. In the pretibial region, normal ILT may range from 0.2 mm to 3 mm. At the dorsum of the foot, normal ILT may range from 0.2 mm to 2 mm. In the thigh, normal ILT may range from 1 mm to 2.5 cm. In the low back, sacral, and buttock region, normal ILT may range from 0.5 mm to 4 cm. In the abdominal region, normal ILT may range from 2 mm to 5 cm. In the sternal and chest wall region, normal ILT may range from 2 mm to 3 cm. In the humeral region, normal ILT may range from 0.5 mm to 1.5 cm. In the forearm region, normal ILT may range from 0.2 to 3 mm. In the forehead and temporal region, normal ILT may range from 0.2 mm to 2 mm. In the occipital region, normal ILT may range from 0.5 mm to 3 mm. In the nuchal region, normal ILT may range from 0.5 mm to 1.5 cm. Values in all of these regions may be significantly higher in obese patients.

ILT will change significantly depending on the patient's fluid status. In patients with a low interstitial fluid volume, e.g. from dehydration, blood loss, or high intracapillary colloid osmotic pressure, ILT's may be as low as about 25% of the control population reference value. In patients with capillary related edema, e.g. patients with heart failure, renal failure, hepatic failure, or venous insufficiency, ILT may increase 20 fold or even more. If the patient's clinical situation deteriorates, e.g. the patient develops heart failure or his condition worsens, ILT can increase by 35% or more within 15 minutes (see Example 2).

Changes in ILT may vary depending on the patient's age. Younger patients are more likely to compensate for a sudden physiological imbalance or challenge, e.g. intra-operative, over-hydration by rapid saline infusion. Thus, increases in ILT may be less significant in younger than in older subjects. However, the elastic properties of the skin and ILT may decrease with age thereby reducing rapid expansion of the ILT in older patients with sudden fluid challenge.

Similarly, expansion or decreases of the ILT may be masked in very obese patients since the change in ILT induced by the interstitial fluid shift may be small compared to the patient's already large ILT prior to the fluid shift.

Different medical conditions may demonstrate regional variations in the amount of capillary related edema and ILT. These regional variations may potentially be useful for differentiating different etiologies of capillary related edema. Capillary related edema secondary to varicosity of the deep calf veins and other veins may be more prominently seen at distal sites such as the foot and calf. Edema induced by abnormal colloid-osmotic pressure as is seen in hepatic disease with associated hypalbuminemia may involve both proximal and distal sites in a more uniform fashion.

Different medical conditions may also show regional variations between dependent and non-dependent body regions. Capillary related edema in venous disorders may preferentially affect the dependent body portions, while capillary related edema in patients with abnormal capillary permeability from allergic reactions may affect both dependent as well as non-dependent body regions.

#### **6.0 METHODS AND DEVICES FOR MULTI-SITE MONITORING OF CAPILLARY RELATED EDEMA**

Edema is a medical condition that primarily relates to inappropriate or compromised regulation of fluid in cells or interstitial compartments. As a secondary consequence of a compromised or faltering physiological process, it is often associated with death in many disease states. Comprised cardiac, capillary, hepatic, or renal function can all lead to edematous states, particularly in the appendages.

Capillary related edema refers to an abnormal fluid imbalance arising from capillaries and leading to abnormal local fluid retention. This type of edema is associated with vast majority of edema related medical conditions. Capillary related edema results from an abnormal physiological function or physiological challenge to the venous system, arterial system, cardiovascular system, renal system, hepatic system, pulmonary system or other non-circulatory, internal organ systems normally involved in homeostasis of normal fluid retention in the capillaries. The present invention is particularly applicable to the systemic aspects of capillary related edema.

Unlike edema, capillary related edema does not refer to lymphatic related edemas, which have a completely different etiology. For example, pretibial myxedema is a lesion in the dermis that leads to tissue swelling and is associated with the disruption of the lymph system.

5           One of the clinically important aspects of the invention are methods and devices for monitoring capillary related edema. One embodiment of the invention includes a method of detecting capillary related edema in a subject. Multiple ultrasound probes are positioned on anatomical regions, such as appendage regions of a subject in need of capillary related edema detection. Positioning is typically on the  
10       surface of the subject's skin. At least one ultrasound pulse is applied to each region at a duration and frequency to permit detection of bodily tissues. At least one ultrasound signal is then recorded with an ultrasound probe from each region. This permits the detection of the presence or absence of a capillary related edema layer in the region from the ultrasound signal(s).

15           *Anatomical regions*

Capillary related interstitial fluid can be measured in any tissue that contains at least one reflective surface and a sufficient amount of water or other acoustic medium to permit ultrasound signals to penetrate and return through the tissue(s) for detection. Preferred anatomical regions are characterized by a first reflective surface comprised  
20       of a skin-ILT interface and second reflective surface comprised of a bone-ILT interface. **Table 2** shows a number of preferred potential application sites for ultrasound probes preferred for certain types of capillary related edema. While these sites are preferred, non-preferred sites can be readily used in most applications and empirical tests can be quickly performed to determine other diagnostically useful  
25       sites. Preferably, probes are adapted for dedicated measurement in these regions.

Probes dedicated to measurement of capillary edema in a particular region may function in other regions, although they have been configured to optimize signals from a particular region, as described herein. **Table 2** is by no means exhaustive, it is  
30       only illustrative of the many potential preferred sites and reflective surfaces to monitor capillary related edema. Particularly preferred sites include the tibia region (even more preferably the proximal tibia), sites where a potential capillary related edema layer extends from the inner surface of the skin to either a fat or bone surface

(especially in the tibia or humeral region), the forehead, the anterior or posterior forearm region, the dorsum of the hand, and the medial or lateral malleolus. Typically, the subjects will be humans, however, the present invention may be used with other animals, especially large mammals in veterinary settings.

5

Table 2

First Reflective Surface	Second Reflective Surface	Probe Site	Type of Capillary Related Edema
Skin	Bone	Leg (preferably mid, anterior tibia)	Cardiac, venous, renal, and hepatic system; hypertension; physiological challenge
Skin	Bone	Arm (preferably distal radius or ulna)	Cardiac, and arterial system: hypertension;
Skin or muscle	Bone	Presternal	Cardiac and arterial system
Skin	Traumatized tissue	Skin above internal trauma site	Trauma
Skin	Bone	Cranium (preferably temporal bone, forehead or nuchal region)	Physiological challenge

The sites listed in Table 2 can also be used in combination. By using combinations of probe sites (i.e. multi-site monitoring), systemic or regional fluid shifts can be assessed. Multi-site monitoring also permits exquisitely sensitive monitoring of physiological processes related to capillary related edema, such as processes that either induce, prevent or reduce capillary related edema, as well as therapeutic treatments thereof. Multi-site monitoring is further described in detail herein, particularly in the section relating to monitoring physiological functions and in situ probes. These aspects of the invention do not necessarily, and preferably do not, include measuring the degree of skin echogenicity. Methods described herein can be used to improve the signal from tissues interrogated for a capillary related edema layer. For instance, the thickness of a capillary edema layer can be measured by determining the shortest reflective distance described herein.



*Use in Medical Conditions and Treatments*

In many instances it will be useful to interrogate tissues for a capillary related edema layer before, concurrent with, or after the diagnosis of a medical condition. Often subjects with diabetes, compromised renal function, compromised vascular  
5 function, or compromised cardiac function have or will have capillary related edema, especially in the appendages. Early traditional clinical signs of capillary related edema may be difficult to register. In contrast, the present invention provides an unparalleled ability to register slight increases in capillary related edema. Early diagnosis of the capillary related edema permits the clinician to follow the progress of  
10 capillary related edema and provide the appropriate clinical response, if warranted (e.g., prescription of diuretics).

A number of medical conditions described herein can produce capillary related edema. The present invention is particularly well suited for testing capillary related edema in medical conditions that increase capillary blood pressure, increase intra-  
15 capillary oncotic pressure, or increase capillary permeability. Such medical conditions include but are not limited to compromised cardiac function (particularly right ventricular failure and valvular insufficiency), compromised renal function (particularly renal failure with decreased urine production, compromised ability to concentrate urine in the distal nephron or improper glomerular filtration, hepatic  
20 failure water load (particularly the rapid administration (e.g., IV) of isotonic or isosmotic fluids) and hypertension. **Table 3** shows a number of potential medical conditions and medical treatments side effects that may cause, in part or in whole, capillary related edema. **Table 3** also indicates the medical conditions in which the present invention is particularly clinical relevant and extremely clinically relevant.  
25 **Table 3** is by no means exhaustive, as it is only illustrative of the many clinically relevant medical settings in which the present invention can be applied.

Table 4

**Selected Drugs That May Induce Capillary Related Edema***Antidiuretic hormone (ADH)**Antimicrobial agents*

(see also under "hepatotoxic drugs" and "nephrotoxic drugs")

*Chemotherapeutic drugs*

(see also under "hepatotoxic drugs" and "nephrotoxic drugs")

*Hepatotoxic drugs and drugs causing impairment of hepatic function*

(e.g. aflatoxine, antiepileptic drugs [e.g. valproic acid], antimicrobial drugs [e.g. rifampicin, fluconazole], antiviral drugs [e.g. vidarabine])

*Hormones*

(e.g. estrogen and estrogen derivatives)

*Immunosuppressive drugs*

(see also under "hepatotoxic drugs" and "nephrotoxic drugs")

*Myocardial depressant agents and cardiotoxic drugs*

(e.g. verapamil, disopyramide, adriamycin, and daunomycin)

*Nephrotoxic drugs and drugs causing impairment of renal function*

(e.g. anticancer drugs [e.g. carboplatin, carmustine, cisplatin, cyclophosphamide, ifosfamide, lomustine, semustine, streptozocin, and thioguanine], antimicrobial agents [e.g. aminoglycosides, amphotericin B, cephalosporines such as cephalotin, cephalexin, cefamandole, pentamidine], antiviral agents [e.g. amantidine, foscarnet], contrast agents for radiologic and other imaging procedures, immunosuppressants [e.g. cyclosporine], non-steroidal antiinflammatory drugs)

*Neuro- and psychopharmacologic drugs**Salt retaining agents*

- As a further example, the present invention may be used for the early
- 5 diagnosis of or for monitoring the progression of capillary related edema in conjunction with a medical treatment. For instance, after testing for capillary related edema it may be advantageous to administer a diuretic agent, a cardiac function agent or a diabetic agent to the subject. Testing for capillary related edema can then be repeated by positioning an ultrasound probe on an appendage region of a subject in
- 10 need of capillary related edema detection after the administration of an agent, and recording ultrasound signals with the ultrasound probe from the appendage region. The therapeutic value of the treatment with respect to the capillary related edema can be then assessed. This aspect of the invention can be used with a number of the medical treatments described herein, particularly those treatments affecting capillary
- 15 related edema in the appendages. Table 5 shows a number of potential medical treatments that may reduce, in part or in whole, capillary related edema. Table 5 is by

- no means exhaustive, as it is only illustrative of the many medical treatments that can apply to capillary related edema. Selected routes of administration for various agents include: intradermal injection, subcutaneous injection, intramuscular injection, intravenous injection, intraperitoneal injection, intracavitational injection (e.g.,
- 5 injection into a pre-existing physiologic or pathologic body cavity), oral, anal, inhalational, nasal spray, and dermal patch. One skilled in the relevant art can easily select the route most likely to be a therapeutically effective modality for a particular agent.

10

**Table 5**

<p>Selected Medications That Can Be Used To Treat Capillary Related <i>Anticholinergics</i> (e.g. atropine sulfate)</p> <p><i>Beta-adrenergic blockers</i></p> <p>(e.g. acebutolol, atenolol, betaxolol, bisoprolol, labetalol, metoprolol tartrate, nadolol, oxprenolol, pindolol, propanolol hydrochloride, sotalol, and timolol maleate)</p>
<p><b>Edema or Its Underlying Cause</b></p>
<p><b>Anticoagulants</b></p> <p>(for treatment of deep venous thrombosis or pulmonary embolism) (e.g. dicumarol, coumarine derivatives, heparin calcium, heparin sodium, and warfarin sodium)</p> <p><b>Antihypertensives</b></p> <p><i>Alpha-adrenergic blockers</i></p> <p>(e.g. bunazosin, phenoxybenzamine hydrochloride, phentolamine mesylate, prazosin hydrochloride, terazosin hydrochloride, tolazoline hydrochloride, and urapidil)</p> <p><i>Angiotensin-converting enzyme inhibitors</i></p> <p>(e.g. benazepril, captopril, enalaprilat, enalapril maleate, fornopril, lisinopril, monopril, perindopril, quinapril, and ramipril)</p> <p><i>Beta-adrenergic blockers</i></p> <p>(see under "cardiovascular agents")</p> <p><i>Calcium channel blockers</i></p> <p>(see under "cardiovascular agents")</p> <p><i>Centrally acting antihypertensives</i></p> <p>(e.g. alphas-methyl-dopa, clonidine, guanfacine, rilmenidine, and guanobenz)</p> <p><i>Monoamine oxidase inhibitors</i></p> <p>(e.g. pargyline hydrochloride)</p> <p><i>Miscellaneous</i></p> <p>(e.g. clonidine hydrochloride, diazoxide, guanabenz acetate, guanadrel sulfate, guanethidine sulfate, guanfacine hydrochloride, hydralazine hydrochloride, mecamylamine hydrochloride, methyl-dopa, metyrosine, minoxidil, nitroprusside sodium, and trimethaphan camsylate)</p> <p><i>Rauwolfia alkaloids</i></p> <p>(e.g. deserpidine, rauwolfia serpentina, rescinnamine, and reserpine)</p>

Table 5 - continued

**Cardiovascular agents**

(see also listing for antihypertensives)

*Antiarrhythmics and miscellaneous*

(e.g. adenosine, amiodarone hydrochloride, bretylium tosylate, disopyramide phosphate, encainide hydrochloride, flecainide acetate, indecainide hydrochloride, lidocaine, lidocaine hydrochloride, mexiletine hydrochloride, molsidomine, procainamide hydrochloride, propafenone hydrochloride, propanolol, quinidine gluconate, quinidine, polygalacturonate, quinidine sulfate, sotalol, and tocainide)

*Calcium channel blockers*

(e.g. amlodipine, diltiazem hydrochloride, felodipine, isradipine, lacadipine, nicardipine, nifedipine, nitrendipine, and verapamil hydrochloride)

*Cardiac glycosides*

(e.g. deslanoside, digitalis glycoside, digitoxin, digoxin, and strophanthin)

*Hydantoin derivatives*

(e.g. phenytoin sodium)

*Nitrates*

(e.g. nitroglycerin, isosorbide, pentaerythritol tetranitrate, and erythrityl tetranitrate)

*Phosphodiesterase inhibitors*

(e.g. methylxanthines)

*Thrombolytics*

(e.g. streptokinase, urokinase, tissue plasminogen activator (tPA), and anisoylated plasminogen streptokinase activator complex (APSAC))

*Vasodilators and vasoconstrictors*

(see under "Antihypertensives" and "Vasoactive Substances")

**Diuretics***Aldosterone antagonists and potassium sparing diuretics*

(e.g. amiloride, canrenone, spironolactone, and triamterene)

*Carbonic anhydrase inhibitors*

(e.g. acetazolamide, acetazolamide sodium, dichlorphenamide, and methazolamide)

*Loop diuretics*

(e.g. bumetanide, ethacrynate sodium, ethacrynic acid, furosemide, and torsemide)

*Miscellaneous*

(e.g. alcohol and caffeine)

*Natural medicinal products*

(e.g. terminalia arjuna and moringo oleifera)

*Osmotic agents*

(e.g. mannitol, glycerin and hyperosmolar solution)

*Plasma expanders*

(e.g. dextran)

*Thiazides*

(e.g. bendroflumethiazide, benzthiazide, chlorothiazide, cyclothiazide, hydrochlorothiazide, hydroflumethiazide, indapamide, methyclothiazide, polythiazide, and trichlormethiazide)

*Thiazide-like agents*

(e.g. chlorthalidone, metolazone, and quinethazone)

*Serum albumin*

Table 5 - continued

*Vasoactive substances*

(e.g. bamethan, bencyclane, bethahistine, cyclandelate, cinnarizine, citicoline, dihydroergocristine, dihydroergotoxine, dipyridamole, ebunamonine, flunarizine, ginko-biloba extracts, horse-chestnut seed extract, isoxsuprine, naftidrofuryl, nicergoline, nicotinic acid derivatives, nylidrin, oxerutins, i.e. hydroxyethyl derivatives of rutin, pentoxifylline, papaverine, piracetam, piribedil, raubasine, suloctidil, and vincamine)

Monitoring of capillary related edema is also particularly relevant in many critical care situations including patients with acquired immunodeficiency syndrome (AIDS), autoimmune disorders, burns, bacteremia, cancer leading to local or distant organ failure, cardiac arrest, coma, drowning or near-drowning, drug-induced complications, drug overdose, heart failure, hepatic failure, infections, inhalation of toxic substances, intestinal ischemia and infarction, myocardial ischemia or infarction, poisoning, prolonged non-ambulatory convalescence, pulmonary embolism, renal failure, respiratory arrest, trauma, transplant complications, sepsis, shock, and arterial or venous thrombosis. The use of multi-site monitoring and continuous monitoring, as described in further detail herein, will be particularly applicable in this clinical setting.

*Devices For Testing for Capillary Related Edema*

Monitoring or testing for capillary related edema can be performed with multiple ultrasound probes connected to an ultrasound system designed for imaging. Although this approach is certainly feasible and offers the clinician the opportunity to perform such diagnostic tests using a multi-use ultrasound system, such systems are not preferred for use with the present invention. Multi-use ultrasound systems, such as those used for pelvic, abdominal, thoracic, cranial, scrotal, thyroid and other small parts, fetal and vascular ultrasound, are expensive and not tailored either at the level of the probe or signal transmission or processing to test for capillary related edema.

Preferably a dedicated ultrasound system is used to test for capillary related edema that has multiple probes. In a dedicated system each probe can be adapted for measuring capillary related edema. The probe frequency can be selected to optimize interrogation of a selected region and to increase the sensitivity of detection of a first and second reflective layer, as described herein. Probe size can also be optimized to

sample a specific area, as described herein. Signal processing can be also be optimized for this particular application as described herein. A scan probe and signals can be used to reduce cost and size of the units. Since many such dedicated systems will be designed to primarily interrogate one particular type of capillary related edema probe site, which has a well known anatomy, imaging will not be necessary and signals can be displayed as described herein.

It may be desirable to provide the ability for the subject to monitor their own capillary related edema status. Many subjects may be inflicted with a chronic medical condition or involved in a long medical treatment. In these types of settings, as well as others, the invention offers systems with an ultrasound probes that can be secured on the surface of the skin to allow the operator to perform self measurement of capillary related edema without holding the probes. Preferably, the subject can read the display while the subject is determining their capillary edema status.

#### *Calculations and Standards*

Calculation and standards can be performed as described herein for other embodiments of the invention.

### **7.0 METHODS AND DEVICES FOR MULTI-SITE MONITORING OF VASCULAR PERFORMANCE**

The vascular system performs essential physiological processes, including maintaining tissue fluid balance, tissue perfusion, tissue oxygenation and nutrient and metabolite transport. Although many current techniques can be used to evaluate vascular performance, such as pulse oxymetry, conventional angiography after intravascular injection of iodinated contrast agents, B-scan ultrasound imaging of vascular structures, Doppler ultrasound, computed tomography after intravenous injection of iodinated contrast agents, and magnetic resonance angiography, these techniques, unfortunately, suffer from a number of shortcomings. Many currently available techniques are either invasive, require complicated or costly procedures, or fail to account for tissue perfusion, especially capillary perfusion of a particular tissue. In addition, these techniques seldom assess fluid regulation as a function of vascular performance.

One aspect of the present invention circumvents many of the disadvantages of the current techniques by evaluating fluid regulation as a function of vascular performance. The present invention provides for a noninvasive assessment of fluid regulation as a function of vascular performance that is relatively inexpensive, easily performed by a clinician (not necessarily a physician trained in ultrasound techniques), and can integrate tissue effects into the assessment, especially capillary related tissue effects. The present invention can be applied to monitoring the venous, as well as the arterial system, for disorders or function that compromise fluid regulation. For example, the invention may be applied (a) to diagnose presence or absence of vascular disorders that compromise fluid regulation, (b) to detect a malfunction of aspects of vascular system that compromises fluid regulation, (c) to differentiate disorders or malfunction of the vascular system from other causes of capillary related edema, and (d) to monitor various types of medical treatments of vascular disorders or malfunction that that may improve fluid regulation.

Typically, a test of fluid regulation as a function of vascular performance, includes two basic steps: reducing or increasing blood flow (or pressure) to a tissue in a subject in need of fluid regulation assessment as a function of vascular performance (step (a)), and monitoring a capillary related interstitial layer thickness (or ILT) in multiple anatomical regions (step (b)). Monitoring capillary related interstitial layer thickness or ILT with ultrasound probe(s) can be before, after, or concurrent with reducing or increasing blood flow in step (a).

Without providing a limiting mechanism by which the invention operates, increasing or decreasing blood flow (or pressure) to the tissue will change the physical forces on the capillaries supplying the tissue thereby affecting fluid balance in the tissue, particularly the blood pressure and amount of blood flow. By reducing or increasing the blood pressure in the capillaries, the hydrostatic gradient across the capillary cells will change and typically drive fluid from the tissue and into the capillary or fluid out of the capillary and into the tissue. By reducing or increasing the blood flow (or pressure) in the capillaries, the amount of fluid and solute transport per unit of time through the tissue will change and typically increase accumulation of tissue metabolites or decrease accumulation of tissue metabolites, respectively.

Usually a test of fluid regulation as a function of vascular performance will include increasing the blood flow (or pressure) to the tissue after the reducing the blood flow in step (a) and monitoring in step (b) or decreasing the blood flow (or pressure) to the tissue after the increasing the blood flow in step (a) and monitoring in step (b). By monitoring before, after, or concurrent with controlled, predetermined maneuvers that change blood flow (or pressure) to the tissue, the change in capillary related interstitial layer thickness or ILT can provide a diagnostic evaluation of the level of fluid regulation as a function of vascular performance. Typically, a first controllable maneuver controllably reduces blood flow (or pressure) to the tissue for a clinically relevant period of time in step (a). A subsequent, second controllable maneuver to increase blood flow (or pressure) increases in blood flow (or pressure) to the tissue for a clinically relevant period of time in step (a). Monitoring typically occurs after each maneuver.

Alternatively, the first controllable maneuver increases blood flow (or pressure) and permits a controllable increase in blood flow (or pressure) to the tissue for a clinically relevant period of time in step (a). A second controllable maneuver reduces blood flow (or pressure) to reduce blood flow (or pressure) to the tissue for a clinically relevant period of time in step (b). Again, monitoring occurs after each maneuver.

For example, the first maneuver increases blood flow by the administration (e.g., local) of a vasodilator (step (a)), monitoring ILT (step (b)), then decreasing blood flow by the administration (e.g., local) of a vasoconstrictor (step (c)), then monitoring ILT (step (d)). Steps (b) and (d) may be concurrent with steps (a) and (c), respectively.

A number of physiological challenges can be used to enhance testing of fluid regulation as a function of vascular performance. Typically such challenges are controllable, predetermined maneuvers that result in changes to blood pressure, blood flow or blood velocity. For instance, ILT can be measured in the pretibial regions before and after the subject has been standing for 15 min or longer. Prior or after such a maneuver, the subject's leg can be raised above the level of the subject's chest, for instance at an angle of about  $30^{\circ}$  or greater to reduce blood pressure in the leg. The leg can be maintained in this position for 15 min, 30 min, or longer. Monitoring can



optionally occur continuously during this maneuver. ILT is typically remeasured in the same locations. If non-elevated, baseline ILT is markedly greater than the ILT with leg elevation, the result is suggestive of a venous disorder, such as incompetent venous valves. If ILT is unchanged or has only slightly decreased with leg elevation, especially at shorter time frame of elevation, the result suggests that a disorder other than incompetence of venous valves or venous insufficiency is responsible for the patient's capillary related edema, such as hepatic failure.

Another potential maneuver to change blood flow or pressure is application of a tourniquets to extremities. ILT will be measured prior to application of the tourniquet as well after, for instance at about 15 minutes, 30 minutes, and 1 hour after application of the tourniquet. Time intervals can be changed depending on the clinical situation, such as the age of the subject or suspected medical condition (e.g., to prevent deleterious side effects). Tourniquet pressure may be adjusted so that the superficial veins, such as the greater saphenous vein, are occluded. Communicating veins and deep veins, however, typically remain open. With occlusion of superficial veins, both healthy subjects as well as subjects with malfunction of vascular performance will develop capillary related edema of the extremity measured as an increase in ILT. The amount of capillary related edema and resultant measured ILT, however, will be larger in subjects with incompetent valves of the communicating veins and the deep veins, since venous drainage is even further impaired by the presence of valvular incompetence.

Additional maneuvers with application of a tourniquet or other devices can be performed at multiple different sites and with the extremity positioned above the level of the right atrial heart chamber, at the level of the right atrial heart chamber, and below the level of the right atrial heart chamber. For instance, the increase in blood flow (or blood pressure) in step (c) or (a) occurs with either 1) the tibial region elevated at a level approximately above the heart of the subject, 2) the tibial region at approximately the same level as the heart of the subject or 3) the tibial region located at a level approximately below the heart of the subject. The elevation changes in an appendage region (e.g., tibial region) can be induced by tilting the examination table to induce changes in appendage blood pressure. A tourniquet can be applied optionally to reduce blood flow. Differential effects of blood flow versus blood

pressure can be evaluated using such combination maneuvers and applied to determining the type of impairment of vascular performance. Blood flow alterations are generally related to capillary impairments and arteriole impairments. Blood pressure alterations are generally related to venous impairments, as well as arteriole impairments. Evaluations of particular subjects can be cross-verified to place greater clinical certainty on the diagnosis.

Additionally, maneuvers can be performed or modified using physiological challenges such as a fluid challenge with isotonic saline or using drug-induced manipulations. Other maneuvers can also be applied such as local administration of a vasodilator, invasive tamponade, gravitational challenge, rapid changes in distal limb blood pressure, and shunting (artificial and natural).

Other maneuvers can be used to diagnose fluid regulation as a function of the malfunction of vascular performance of the arterial tree. ILT can be measured in the pretibial region prior to administration (preferably local administration) of vasoactive substances that preferentially affect the arterial system, such as hydralazine or tolazoline. ILT can then be remeasured at various time intervals after drug administration, e.g. 30 minutes, 1 hour and 2 hours later. A significant decrease in ILT after drug administration, i.e. a decrease in capillary related edema owing to improved peripheral perfusion, is indicative of a disorder of the arterial tree, such as atherosclerosis that effect fluid regulation. Bilateral difference can also indicate whether different branches of the tree are more or less impaired. If ILT remains unchanged, other conditions such as venous insufficiency are likely to account for the capillary related edema.

The presented maneuvers are only exemplary. One skilled in the art can easily apply many other maneuvers that can be used to diagnose the presence and severity of malfunction of vascular performance. ILT measured in patients can be compared to normal reference values for each provocative maneuver in the various anatomic regions obtained in age, sex, race, and weight-matched controls and can also be compared to the contralateral side.

In another embodiment of the invention, ultrasound measurements of ILT and capillary related edema can be used to predict the possibility of venous thrombosis affecting fluid regulation. Traditionally, venous thrombosis is diagnosed using

conventional venography after intravenous injection of iodinated contrast media, Doppler ultrasound interrogation of the veins, or magnetic resonance angiography. Conventional venography is invasive and as such is hampered by multiple, even fatal, side effects such as contrast reaction. Conventional venography, Doppler ultrasound, and MR angiography require advanced technical skills for image acquisition as well as subsequent interpretation. Typically, these techniques can only be performed by trained physicians. Venous thrombosis, in particular deep venous thrombosis, is associated with high morbidity and mortality. Frequent complications include pulmonary embolism and cardiorespiratory arrest. Venous thrombosis reduces or interrupts local blood flow resulting in venous stasis with increased hydrostatic gradient across capillary cells. It often occurs in patients after surgery, stroke, catheter treatments or trauma. The increased hydrostatic gradient across capillary cells will drive fluid from the capillary into the tissue with resultant capillary related edema.

Capillary related edema secondary to venous thrombosis can be diagnosed using ultrasound measurements of ILT. The presence of venous thrombosis can be suggested, if ILT is elevated and particularly elevated beyond a certain threshold value. Threshold values can be defined based on the contra-lateral, healthy extremity. Threshold values can also be defined on the basis of reference values for healthy age, sex, weight, and race matched control subjects in a given anatomic location. The percent change in ILT per unit time can also provide diagnostically useful information about presence or absence of venous thrombosis as well as chronicity of thrombosis which is a diagnostic dilemma for the other techniques. Ultrasound measurements of ILT have several unique advantages over Doppler ultrasound interrogation of the venous structures and conventional venography and magnetic resonance angiography. Specifically, unlike the other techniques, ultrasound measurements of ILT do not require high technical skills for diagnosing the presence of venous thrombosis. The technique is simple and can be performed by an untrained physician, a nurse, or the patient.

Ultrasound measurement of ILT may also be used to differentiate the effects disorders or malfunction of vascular performance on fluid regulation from other diseases such as cardiac, renal or hepatic disorders. Capillary related edema induced

by malfunction of the vascular system may be more prominent at distal sites, such as the foot and calf. While capillary related edema induced by compromised hepatic function, for instance, may induce a more uniform increase at proximal and distal sites. Similarly, capillary related edema induced by malfunction of the vascular system may preferentially affect dependent body regions (regions subjected to fluid accumulation due to gravity), while capillary related edema induced by compromised hepatic function may induce a more homogeneous increase in ILT in dependent and non-dependent body portions (regions not subjected to fluid accumulation due to gravity). Furthermore, unlike capillary related edema induced by compromised hepatic function, capillary related edema induced by malfunction of the vascular system may be anatomically limited to the region with impaired vascular performance. Often additional diagnostic tests of vascular performance, as well as hepatic, cardiac and renal function, can be used in parallel with the methods described herein to cross correlate findings for improved differential diagnosis and enhanced diagnosis based on integrative assessments of patient physiological function. Multi-site monitoring at such anatomical regions will assist in pinpointing the abnormality.

While each clinician may find particular anatomical regions of interest for multi-site monitoring as described herein for particular patients or medical treatments related to the effects of vascular performance on fluid regulation, a number of anatomical regions are suggested for monitoring. Anatomical regions suggested for such multi-site monitoring include: the mid anterior tibia, the distal tibia, the ankle, the distal radius, the ulna, the mid axillary line, the presternal region, the sacral region, and the buttocks region. It is also suggested to compare left side and right of the body differences for assisting in diagnosing asymmetric effects on fluid regulation in the body, particularly the appendages and anatomical dependent regions. Contralateral differences in ILT or fluid regulation may also help distinguish between the effects of cardiac performance and vascular performance on fluid regulation. Because multi-site monitoring is non-invasive, easy to use, and is an extremely powerful diagnostic tool of cardiac function, additional anatomical regions may readily be discovered to assist in assessing the effect of vascular performance on fluid regulation.

In another embodiment of the invention, longitudinal ultrasound measurements of ILT, optionally in conjunction with maneuvers to change blood flow

or pressure, can be used to monitor and quantify a response to a treatment of vascular performance on fluid regulation. In subjects with a malfunction of vascular performance, ILT may be measured at multiple sites with ultrasound prior to initiation of a new treatment regimen, e.g. topical application of venoactive substances. ILT will then be remeasured at several intervals after initiation of treatment, e.g. 2 weeks, 4 weeks and 2 months later. If ILTs at multiple sites have decreased significantly when compared to the baseline value, the result indicates that treatment is effective and should be continued. If ILTs are not significantly changed, the result is indicative of treatment failure and treatment should be changed. In this fashion, longitudinal ultrasound measurement of ILT and assessment of capillary related edema can be used (a) to improve subject management and improve the patient's quality of life, and (b) to decrease health care costs by identifying ineffective treatment modalities and discontinuing them early. Medical treatments will typically include cardiovascular agents. Such measurements will be particularly important with subjects diagnosed with hypertension or diabetes.

Another particularly interesting aspect of testing fluid regulation as a function of vascular performance as it relates to the effect of weightlessness and gravity on the physiology of mammals, particularly humans. Continuous monitoring of air and space traveling subjects is a desirable feature of the invention. For air travel, particularly fighter pilots that are subjected to intense G-forces, monitoring (e.g. continuous) of ILT at multiple locations can be applied. Optionally, fluid shifts can be part of a feedback system and flight suit that would increase externally applied pressure to tissues using a flight suit with a mechanical pressure means. For space travel ultrasound monitoring of ILT at multiple sites can indicate critical times to take precautionary measures to minimize fluid shifts resulting from changes in vascular performance.

Depending on the clinically relevant time period for these applications, ultrasound measurements of ILT may be performed at a single time point, at time intervals of at least about 15 minutes, at time intervals of several days, or at time intervals of several weeks. Additionally, diagnostic information may be enhanced by measuring ILT prior to and after maneuvers or physiological challenges. Presence of a vascular disorder or malfunction of vascular performance can be diagnosed using

ultrasound measurement of ILT at a single time point. If ILT in a given anatomic location, such as the pretibial region, is elevated above the reference value (e.g. that of age, sex, race, or weight-matched controls), presence of a malfunction of vascular performance is suggested. This is a particularly strong diagnosis if the subject has no  
5 clinical or laboratory findings or diagnosis indicating an underlying cardiac, renal, hepatic or other non-vascular disorder.

Tests of fluid regulation as a function of vascular performance can be conducted using either A scan or B scan devices. For dedicated systems for tests of vascular performance A scan is preferred. Typically, such devices can detect a 15%  
10 or less change in interstitial layer thickness. Preferred embodiments for detecting ILT for this application can be ascertained by examining other embodiments of the invention described herein. Preferably, the ultrasound probe is adapted to measure interstitial layer thickness. Preferably, the monitoring can detect about a 1% or more change in leg diameter arising from changes in interstitial layer thickness.

15 Another aspect of the present invention is the assessment of vascular performance in disorders with pathologically increased capillary permeability. Pathologically increased capillary permeability can be observed in a large number of disorders such as bacteremia, burns, electric injury, exposure to systemic toxins, poisoning, or sepsis. Increased capillary permeability is another cause of capillary  
20 related edema. Ultrasound measurements of ILT from multiple sites can provide information on (a) the presence of capillary related edema in patients with pathologically increased capillary permeability, (b) the severity of capillary related edema, (c) response to treatment of pathologically increased capillary permeability or response to treatment of the underlying condition, and (d) changes in capillary  
25 permeability due to physiologic or pharmacologic interventions. By comparing different interrogation sites a map of increased capillary permeability can be created with respect to the body. In general, ILT or other assessments of fluid regulation can be analyzed as an anatomical map.

The presence of capillary related edema can be diagnosed in patients with  
30 pathologically increased capillary permeability, if ILTs at given anatomic sites such as the pretibial region is elevated above a reference value (e.g. that of age, sex, race, or weight-matched controls). The severity of the pathologic increase in capillary

permeability can be assessed using ultrasound measurements of ILTs. Slightly elevated values of ILT when compared to an age, sex, race, and weight-matched healthy reference population indicate a mild increase in capillary permeability. High ILT values at a given anatomic site are indicative of a severe increase in capillary permeability. A severe increase in capillary permeability can lead to intravascular volume depletion and hypovolemia with resultant shock and possible cardiorespiratory arrest. The risk of severe intravascular volume depletion and hypovolemia in patients with pathologically increased capillary permeability can be assessed by comparing ultrasound measured ILT with reference values of healthy control subjects and by analyzing changes in ILT of the individual patient longitudinally over time.

Patients who are being treated medically for disorders resulting in pathologically increased capillary permeability can be monitored using ultrasound measurements of ILTs. ILTs are measured at multiple sites with ultrasound prior to initiation of therapy. ILTs are then remeasured at several intervals after initiation of treatment at the substantially the same sites. A decrease in ILT during medical treatment indicates a decrease in abnormal capillary permeability either secondary to successful treatment of the underlying condition or of abnormal capillary permeability. If ILT does not change significantly during treatment, treatment of the underlying condition or of increased capillary permeability is ineffective and another therapeutic approach should be chosen.

Multiple new drugs, hormones, tissue and blood factors, and other substances are currently being developed that can alter capillary permeability. These include but are not limited to tumor necrosis factor, vascular endothelial growth factor, and substance P. Additionally, other treatments such as hyperthermia and radiation therapy are available that can modulate capillary permeability. Ultrasound measurements of ILT provide a diagnostic gauge to evaluate changes in capillary permeability in subjects treated in such fashion. If ILT increases, the increase is an indication of increased capillary permeability. Conversely, decreases in ILT indicate decreased capillary permeability, possibly due to modulation of the capillary endothelial wall. The amount of change in ILT provides a quantitative measure for the amount of change in capillary permeability induced by the treatment. Such

information is clinically extremely useful in evaluating new therapies that can decrease or, if clinically desirable, increase capillary permeability.

## 8.0 METHODS AND DEVICES FOR MULTI-SITE MONITORING OF CARDIAC

### 5 PERFORMANCE

Heart failure can often lead to decreased cardiac output or increased systolic and/or diastolic pressures that induce systemic effects. Among these systemic effects is edema, especially capillary related edema. Capillary related edema due to heart failure can lead to deleterious systemic effects, such as tissue ischemia, capillary  
10 breakdown, and, in extreme instances, necrosis of tissue subjected to prolonged or sudden ischemia.

Current methods of evaluating cardiac performance focus on direct measurements of cardiac function. Methods include auscultation, EKG, myocardial scintigraphy, exercise stress test (e.g., EKG measurements in the absence or presence  
15 of exercise), other forms of stress test (e.g. EKG or myocardial scintigraphy after injection of dipyridamole, adenosine, or other cardiac drugs) catheter related techniques (e.g. right heart catheterization such as Swan-Gantz catheter methods, wedge pressures, and cardiac output and flow studies, left heart catheterization, and measurements of ejection fraction) and imaging techniques (e.g., MRI, CT, and  
20 ultrasound). While such techniques enjoy a large measure of success in many subjects, these techniques focus in on the heart, rather than on the heart as an integrated component of the circulatory system or as a key component in the physiological process of regulating fluid balance. Currently, no techniques are available for evaluating cardiac performance as a component of systemic fluid  
25 balance.

The inventors, for the first time, present a method of evaluating cardiac performance associated with, or as a function of, capillary edema or interstitial fluid balance. Because heart function is intimately associated with, and modified by, systemic effects, it can be advantageous to test for, or monitor, capillary related edema  
30 or fluid regulation. The present invention offers a number of advantages that can reduce health care costs, improve patient quality of life and provide for more reproducible and facile tests of cardiac function. Testing for capillary related edema or



monitoring ILT can provide early signs of cardiac failure. Testing for capillary related edema or monitoring ILT can also be combined with current techniques of cardiac function to provide powerful diagnostic tools that evaluate the heart both as an isolated component and as an integrated component of maintaining fluid balance.

- 5 Described herein for the first time are a number of techniques that alter cardiac function and monitor its affect on fluid balance, both short and long-term effects of dynamic cardiac performance can be evaluated.

Heart failure refers to the pathophysiologic state in which an abnormality of cardiac function is responsible for the failure of the heart to pump blood at a rate commensurate with the requirements of the metabolizing tissues and/or in which the heart can do so only from an abnormally high filling pressure. Without providing a limiting mechanism by which the invention operates, the inability to pump a sufficient amount of blood per unit time or a compromised cardiac output can lead to capillary related edema. Because tissues may receive insufficient blood flow in the early stages of heart failure, capillary related edema can occur due to a variety of effects including ischemic tissue damage, increased afterload, capillary breakdown due to an increase in tissue metabolites, or tissue acidosis. By testing for capillary related edema or monitoring ILT, early signs of heart failure can be detected prior to or during compensatory adjustment of heart function, which can ultimately lead to irreversible and often deleterious effects on heart muscle. Once the heart attempts to compensate for insufficient blood flow to the systemic tissue by pumping more blood less efficiently, the ventricular performance begins to decline and capillary related edema can actually intensify.

Single and multiple myocardial and non-myocardial disorders and conditions can lead to heart failure. These include, but are not limited to, myocardial infarction, myocardial ischemia, myocardial infections, arrhythmias, valvular dysfunction, hypoxia, cardiotoxic substances, pericardial effusion, hypertension, recent initiation of a  $\beta$ -blocking agent, discontinuation of anti-hypertensive agents, cardiovascular drugs, diuretics, or anticoagulants. Many such heart disorders can lead to abnormally high filling pressures that can result in systemic increases in capillary pressure.

Right heart failure causes an increase in venous pressure and venous distension in the superior and inferior vena cava and the peripheral venous system

with resultant venous stasis and elevated intra-capillary pressures. Elevated capillary pressure increases the hydrostatic gradient for fluid movement out of the capillaries and the elevated pressure increases the capillary permeability to large molecular weight molecules. Either condition or both can lead to capillary related edema.

5           Left heart failure can cause decreased renal perfusion resulting in decreased glomerular filtration and urinary excretion, as well as fluid retention. Patients in whom the left ventricle is mechanically overloaded or weakened develop dyspnea and orthopnea as a result of pulmonary vascular congestion and, ultimately, pulmonary edema. When left heart failure is more chronic and has existed for months and years,  
10       patients will often develop ankle edema, congestive hepatomegaly, or systemic venous distension, i.e. signs and symptoms of right heart failure, even though the abnormal hemodynamic burden was initially placed on the left ventricle. This is, in part, the result of secondary pulmonary hypertension and resultant right-sided heart failure, as well as the effect of the persistent retention of salt and water.

15           Ultrasound measurements of ILT at multiple sites can be used to (a) diagnose presence of capillary related edema in patients with heart failure, (b) assess the severity of capillary related edema in patients with left and right ventricular failure, and (c) monitor response to treatment of heart failure, e.g. with positive inotropic or chronotropic drugs or diuretics. Such monitoring of ILT can include any temporal  
20       method, including periodic, intermittent, predetermined and continuous. Preferably such monitoring will be continuous in relation to the clinical relevant time period using multiple probes.

          The presence and severity of capillary related edema can be assessed in patients and can lead to the early diagnosis of progressive heart failure. For instance,  
25       if ILT at a given anatomic site, such as the anterior tibial region, is elevated above the reference value of a healthy reference population (e.g., an age, sex, race, or weight-matched healthy reference population) heart failure is implicated. In addition, the reference values may be based on a historic value of the patient or in relation to another interrogation site such as the distal radius. Typically, the patient will then be  
30       subjected to additional tests of cardiac function either separately or in conjunction with ILT measurements. Slightly elevated values of ILT can be compared to historic records of the same patient or when compared to a healthy reference population (e.g.,

an age, sex, race, and weight-matched healthy reference population) may indicate mild heart failure. High values of ILT values at a given anatomic site are indicative of more advanced and severe heart failure. Multiple high values at different interrogation sites will indicate higher probability of heart failure. Changes in cardiac function can be assessed by longitudinal or continuous monitoring of ILT at different anatomic sites. Often, the patient will be suspected of having a medical condition that compromises heart function or is need of heart function testing.

In another embodiment of the invention, ultrasound measurements of changes in ILT over time can be used to diagnose progression of heart failure from a compensated to a decompensated state. Such information is clinically useful in many situations, e.g. hospitalized patients after myocardial infarction with heart failure or patients with chronic heart failure. For example, if ILT increases above a certain threshold value, this change can be indicative of decompensation of cardiac function that can indicate a serious threat to the patient's life. Threshold values can be defined by comparing measured ILT at a given time point with the patient's baseline ILT, e.g. ILT measured at the time of hospital admission or at the time of a previous outpatient visit. Threshold values can also be defined by comparing measured ILT at a given time point with the patient's baseline ILT and/or normal reference values of ILT (e.g. ILT values in an age, sex, race, or weight-matched healthy reference population). ILT can be measured continuously or in an intermittent fashion, e.g. every 30 minutes or at intervals greater than 1, 2, 5, and 24 hours. Threshold values in evaluating changes in ILT can also be based on the calculation of the slope of the curve of ILT plotted against time or of the slope of the curve of change in ILT plotted against time. The slope of the ILT-time-curve or the  $\Delta$ ILT-time-curve can yield useful diagnostic information on progression of heart failure from a compensated to a decompensated state. One skilled in the art will readily recognize substitute methods and equations for assessing changes in ILT. In addition, physiological challenges as described herein may be used in conjunction with such monitoring for more complete evaluation of cardiac performance.

By monitoring such changes in ILT, systemic effects of cardiac performance can be assessed continuously or during clinically relevant time periods. Unlike other cardiac monitoring techniques, such as EKG methods, ILT changes provide an

assessment of the ability of cardiac performance to adequately maintain systemic tissue perfusion. For instance, continuous EKG monitoring may provide information concerning damaged heart tissue, or comprised electrical conduction, however, the clinician can only infer the systemic effects of such compromised heart function. In the present invention, the monitoring of compromised heart function provides additional information on the heart's ability to supply tissues with sufficient amounts of blood to prevent or minimize tissue perfusion effects, such as metabolite build up, insufficient oxygenation or insufficient nutrient delivery.

While each clinician may find particular anatomical regions of interest for multi-site monitoring as described herein for particular patients or medical treatments related to heart failure, a number of anatomical regions are suggested for monitoring. Anatomical regions suggested for multi-site monitoring include: the mid anterior tibia, the distal tibia, the ankle, the distal radius, the ulna, the mid axillary line, the presternal region, the sacral region, and the buttocks region. It is also suggested to compare left side and right of the body differences for assisting in diagnosing heart failures that result in asymmetric effects on fluid regulation in the body, particularly the appendages and anatomical dependent regions. Contra-lateral differences in ILT or fluid regulation may also help distinguish between the effects of cardiac performance and vascular performance on fluid regulation. Because multi-site monitoring is non-invasive, easy to use, and is an extremely powerful diagnostic tool of cardiac function, additional anatomical regions may readily discovered to assist in assessing cardiac function.

In addition, because ILT can be exquisitely sensitive in monitoring rapid or small changes, changes in cardiac function may be detected systemically by changes in ILT before changes in EKG or other techniques demonstrate a clinically important change. For example, a small change in EKG pattern might be readily detectable, but go unnoticed. The effect of such a change on the patient's homeostasis may often not be detected clinically. Such a change, however, may lead to systemic effects that will complicate the patient's homeostasis or be indicative of progressive effects systemically, particularly fluid regulation. Such a small change in heart function may negatively synergize with other bodily functions (e.g. respiratory, renal or hepatic functions) that manifest in an increase in ILT but not a direct measurement of cardiac

function. ILT changes may occur prior to a clinically definable intervention point based solely on a measurement of cardiac function (e.g., EKG). Consequently, the present invention can detect changes in cardiac function that are useful in defining a clinical intervention point, particularly a clinical intervention point defined in advance of changes in cardiac function detected using measurements of cardiac function alone.

If ILT increases above a predefined threshold value or at an accelerated rate exceeding a predefined range of clinically acceptable values of change in ILT over time, a device may alert the patient and/or the physician with an alarm such as a bell, a flashing light, or a message indicating that the patient is at risk for decompensation of heart failure.

In another embodiment, the invention provides for risk assessment of pulmonary edema in patients with left heart failure. As outlined above, patients with left heart failure will often develop capillary related edema. The severity of capillary related edema is directly related to the severity of heart failure. For example, if ILT increases above a certain threshold value, this change can indicate an increased risk for pulmonary edema or, if high enough, can be indicative of the development of pulmonary edema.

The slope of the curve of ILT plotted against time or change in ILT plotted against time can also provide useful information for assessing the risk of pulmonary edema. If the slope of the ILT-time-curve or the  $\Delta$ ILT-time-curve exceeds a predefined value, the patient is at increased risk for pulmonary edema. This information is extremely useful in situations where it is difficult to monitor the patient's cardiac function closely, e.g. during surgery, or in situations where frequent or continuous monitoring is required.

Another embodiment of the invention includes a method for non-invasively estimating dynamic cardiac performance in a human, comprising: (a) monitoring capillary related interstitial fluid content with ultrasound probes positioned on the skin of a human in need of such monitoring and in regions suitable for monitoring changes in capillary related interstitial fluid content during a clinically relevant time period and (b) measuring capillary related interstitial fluid content prior to and after pharmacologic interventions, exercise, and other current and future types of stress induction designed to evaluate cardiac performance.

If ILT is measured in conjunction with cardiac stress testing, changes in ILT can be compared to reference values obtained from a healthy reference population (e.g., an age, sex, race, and weight-matched healthy reference population).

5      Impairment of cardiac function is diagnosed if changes in ILT exceed a predefined reference range. Testing of dynamic cardiac performance using ultrasound measurements of ILT prior to and after stress induction can also be used to evaluate the patient's risk for progressing from a compensated to a decompensated state of heart failure.

10      Calculations and Standards can include those described herein, known in the art or developed in the future. Standards can be used to qualitatively or quantitatively compare capillary related interstitial fluid content to a predetermined standard value for capillary related interstitial fluid content, wherein the comparison provides a useful diagnostic measure of cardiac performance.

## 15      **9.0 METHODS AND DEVICES FOR MULTI-SITE MONITORING OF RENAL DISORDERS AND FUNCTION**

Compromised renal function can be observed with multiple disorders, such as urinary obstruction, vasculitides, diabetes, glomerulonephritis, interstitial nephritis, chronic pyelonephritis, ischemic kidney damage, or, in transplant patients, transplant malfunction, e.g. from transplant rejection. Compromised renal function will lead to electrolyte disturbances and fluid retention resulting in capillary related edema. The present invention can be applied to monitoring the renal system for disorders or to evaluating renal function. For example, the invention may be applied (a) to diagnosing presence of capillary related edema in patients with compromised renal function, (b) to assess the severity of capillary related edema, and (c) to monitor a subject's response to the treatment of compromised renal function or capillary related edema, e.g. diuretic therapy.

25      Presence of capillary related edema can be diagnosed in patients with compromised renal function, if ILT at selected, multiple anatomical sites. For example measurements at the anterior tibial region can be compared to the reference values as described herein (e.g. the values in age, sex, race, or weight-matched controls). Ultrasound measurements of ILT provide also information on the severity

of the compromise of renal function. Slightly elevated values of ILT when compared to a healthy reference population indicate mild compromise of renal function. High values of ILT values at a given anatomic site are indicative of severe compromise of renal function. The risk of acute renal failure and anuria can be assessed by comparing  
5 ultrasound measured ILT with reference values of healthy control subjects (or historic values from the same patient) and by analyzing changes in ILT of the individual patient longitudinally over time.

To enhance distinguishing between renal failure and compromised cardiac or vascular performance, ILT can be measured in the face of different physiological  
10 challenges as described herein for different organ systems. Typically, either by specific pharmacological manipulation or specific physical stresses effects on renal function can be separated from effects on cardiac or vascular function. For instance, renal function can be further assessed by measuring ILT prior to and after physiologic challenges, such as saline administration and/or administration of drugs, such as  
15 angiotensin converting enzyme inhibitors or antidiuretic hormone. In addition, a stress test for cardiac function may be performed as described herein for multi-site monitoring. Reference values for changes in ILT following such physiologic challenges and/or drug administration obtained in healthy control subjects (e.g., age, sex, race, and weight-matched healthy control subjects) can be compared to the  
20 change in values measured in a patient. If the change in ILT measured in the patient differs significantly from the change in the reference population, it is a diagnostic indicator of compromised renal function. The difference in change in the patient and change in the reference population is a diagnostic gauge of the severity of impairment of renal function. Furthermore, the rate of change of ILT post-administration of IV  
25 saline or isoosmotic solution can give a further indication of renal function. If ILT changes rapidly, especially in nondependent sites, due to such maneuvers impaired renal function is suggested.

Generally, compromised renal function will relatively effect all or a substantially larger percentage of the interrogation sites in a more uniform fashion  
30 compared to compared to compromised cardiac performance or vascular performance. Without providing a limiting mechanism by which the invention operates, compromised renal solute filtration/uptake/secretion will typically increase or

decrease total fluid or salt retention and/or the amount of protein in the blood which may change the physical forces on the capillaries supplying a tissue thereby affecting fluid balance in the tissue, particularly acid/base regulation (including changes in . blood and tissue buffering), the hydrostatic pressure, and the oncotic pressure. For instance, by increasing salt and water retention total fluid retention will increase typically increasing blood pressure in the capillaries. This in turn will increase the hydrostatic gradient across the capillary cells and typically drive fluid from many tissues and into the capillary or fluid out of the capillary and into of many tissues. Typically, this will occur at most if not all interrogation sites.

Such renal disfunctions will typically manifest themselves in global anatomical changes in ILT or fluid regulation that can be readily monitored. In most instances, while there may be an expected increase in ILT in most anatomical sites, the absolute change in ILT for each tissue is not typically expected to be the same. For instance, five sites are measured the right and left distal radius, the right and left mid tibia and the left presternal region. Although, it is typically expected that the ILT at each of the five sites will increase, the percent increase in each tissue is likely to vary. Because each of these tissues will typically have different ILT values, and different degrees of sensitivity to changes in renal performance, ILT increases at each of the sites are likely to be different. Typically, contra-lateral differences are not expected to be as great with compromised renal performance, as compared to compromised cardiac performance.

Patients who undergo medical treatment of compromised renal function can be monitored using aspects of the present invention. ILT can be measured prior to initiation of therapy, e.g. diuretic therapy. ILT can then be re-measured at several intervals after initiation of treatment, e.g. 2 weeks, 4 weeks and 2 months later. A decrease in ILT during medical treatment indicates improvement in renal function and/or successful diuretic treatment. If ILT does not change significantly during treatment, therapy is ineffective and another therapeutic approach should be considered.

Noninvasive ultrasound measurements of ILT are particularly advantageous when frequent monitoring of the status of kidney function is necessary as is often the case in patients with compromised renal function. In this setting, ultrasound



measurements of ILT may help avoid frequent blood draws for laboratory analysis of renal function, since treatment can be tightly monitored by following ILT.

Furthermore, ultrasound assessment of ILT in conjunction with laboratory tests and urine output can provide a more complete and physiologic assessment of renal

5 function than was previously possible.

Continuous or intermittent ultrasound monitoring of ILT is particularly useful in dialysis patients. Frequently, excess plasma fluid is removed during dialysis, in particular hemodialysis. However, if too much fluid is removed or fluid is removed too rapidly, patients can develop hypovolemia with the potential for shock and cardio-  
10 respiratory arrest. ILT can be monitored at intervals of approximately 15 minutes for the duration of dialysis and an observation period of 1-2 hours after dialysis. If ILT decreases below a certain threshold value, such as a defined based on the baseline value of the patient's ILT measured immediately prior to dialysis, or if ILT decreases at an accelerated rate greater than a predefined maximum value of change in ILT per  
15 unit time, the device may alert the patient and/or the physician with an alarm such as a bell, a flashing light, or a message indicating that the patient is at risk for hypovolemia.

Similarly, if infusion or transfusion therapy or other types of treatment with intravenous fluid administration is performed in renal patients, as well as patients with  
20 other disorders (including medical conditions), ultrasound measurements of ILT can be obtained to monitor the patient's fluid balance closely. In this setting, ILT will be measured prior to initiation of intravenous treatment and at intervals of approximately 15-30 minutes after initiation of therapy. If ILT increases above a certain threshold value defined based on the baseline value of the patient's ILT measured immediately  
25 prior to treatment or if ILT increases at an accelerated rate exceeding a predefined maximum range of change in ILT per unit time, fluid administration may need to be slowed down or discontinued or the patient has to be treated with a diuretic drug in order to avoid complications of overhydration, such as pulmonary edema. Continuous or intermittent measurements of ILT during intravenous fluid administration can also  
30 be used to estimate the risk of pulmonary edema.

In another embodiment of the invention, patients with chronic compromise of renal function, e.g. patients with diabetes mellitus or dialysis patients, can monitor

ILT at home on a daily basis using the devices described herein. The device can store results of ILT measurements and compare them over a period of several months. If the measured ILT has increased significantly when compared to previous measurements, an alarm such as a bell, a flashing light, or a message will be generated by the device and the patient will be asked to repeat the measurement. If the repeat measurement confirms the increase in ILT, the device can generate a message informing the patient to consult his physician who may then intensify medical treatment.

Ultrasound monitoring of ILT can also be used to monitor renal transplant function both in the early postoperative period as well as days, weeks, months, and years after successful transplantation. ILT measurements can be used to identify transplant complications, such as acute or chronic rejection and other forms of transplant compromise.

### **Examples**

#### **General Materials and Methods:**

The following materials and methods are exemplary of the materials and methods that can be used to achieve the results described herein. One skilled in the art will readily recognize substitute materials and methods.

*In vitro* and *in vivo* ultrasound measurements were performed using an Ultramark 9 HDI ultrasound system (Advanced Technologies Laboratories ("ATL"), 22100 Bothell Everett Hwy, Bothell, WA 98041-3003). All examinations were performed using a 5 MHz linear array transducer manufactured by ATL. An acoustic coupling gel was applied to the transducer surface and the object to be examined in order to reduce the impedance mismatch between the transducer surface and the object surface, usually skin. Data were acquired in B-scan mode. Two-dimensional gray-scale images of the various tissue/edema layers were obtained. Images were displayed on a computer monitor attached to the scanner hardware and capable of displaying the full gray scale range. Distance measurements were performed by saving a representative image displaying the various tissue layers, e.g. skin, subcutaneous fat and bone, on the display monitor. A trained physician identified the various tissue interfaces visually and placed cursors manually at the probe/skin, soft-tissue/bone, and

other interfaces. Software provided with the ultrasound scanner was then used to calculate the distance between the calipers. All measurements were expressed in mm.

To maintain the anatomic location of the selected sites, a dye was used to mark the sites on the skin of the human subjects. Similarly, in the *in vitro* experiments, a dye was used to mark the measurement site on the external tissue surface.

### **Example 1: Ultrasonographic Measurement of Tissue Thickness in an *In Vitro* Model of Capillary Related Edema**

In order to evaluate the accuracy of ultrasonographic measurements for detecting edema and measuring interstitial fluid, experiments were performed with a sample of porcine muscle tissue creating a model of capillary related edema. Ultrasound measurements were correlated to results of anatomic examination. Ultrasonographic measurements were performed in a large piece of muscle tissue obtained from the gluteal region of a pig. The tissue was cut into thin sections using a rotating electric blade.

Two fluid-filled polymer film bags that were approximately 7 mm-thick when fully filled were prepared for insertion between the cut, separated muscle tissue layers. The surfaces of the polymer film bags and tissue were covered with a thin film of acoustic coupling gel. One or two bags were then placed in a sandwich-like fashion between the superior and the inferior muscle tissue layers thereby simulating an interposed fluid layer(s). A region of interest was defined at the external surface of the superior muscle tissue layer centered over the area where the bags had been placed and the region was marked with a dye. The ultrasound transducer was placed flush with the tissue surface in this region. An ultrasonographic image covering the total thickness of the tissue, defined as the distance from the outer surface of the superior muscle tissue layer to the outer surface of the inferior muscle tissue layer, was obtained. Both total tissue thickness as well as the thickness of the interposed fluid layer were measured on the image. Additionally, total tissue thickness with an empty polymer film bag inserted that was not filled with fluid and the thickness of the empty bag were measured with ultrasound. Total thickness and thickness of the interposed fluid layer were also determined anatomically with use of a ruler. The results of these experiments are set forth in Tables 6 and 7.

**Table 6** compares the total tissue thickness measured by 1) anatomic measurement and 2) ultrasound measurements.

**Table 6**

Interposed Layers	Anatomic Measurement of Total Tissue Thickness (in mm)	Ultrasound Measurement of Total Tissue Thickness (in mm)
Empty	17	16.7
1 layer	24	23.6
2 layers	32	31.2

5

**Table 7** compares the thickness of the interposed fluid layer measured by 1) anatomic measurement and, 2) ultrasound measurements.

**Table 7**

Interposed Layers	Anatomic Measurement of Interposed Fluid Layer (in mm)	Ultrasound Measurement of Interposed Fluid Layer (in mm)
Empty	0.8	0.7
1 layer	7.0	7.0
2 layers	14.0	14.3

10

Ultrasound and anatomic measurements were compared and the absolute and relative error of ultrasound measurements of total tissue thickness and of the thickness of the interposed fluid layer were calculated. The absolute error is defined as:

$$AE = US - AN, \quad [Eq. 4],$$

15

where AE is the absolute error of the ultrasound measurement in mm, US is the ultrasonographic measurement of tissue thickness in mm, and AN is the tissue thickness determined by anatomic measurement in mm.

The relative error is defined as:

$$RE = \{(US - AN) / AN\} \times 100 \quad [Eq. 5]$$

20

**Table 8** shows the absolute values of the absolute and relative errors of ultrasound measurements of total tissue thickness for different interposed fluid layers when compared to anatomic measurement.

**Table 8**

Interposed Layers	Absolute Error (in mm)	Relative Error (in %)
Empty	0.3	1.8
1 layer	0.4	1.7
2 layers	0.8	2.5

**Table 9** shows the absolute values of the absolute and relative errors of ultrasound measurements of the thickness of the interposed fluid layers when compared to anatomic measurement.

**Table 9**

Interposed Layers	Absolute Error (in mm)	Relative Error (in %)
Empty	0.1	12.5
1 layer	0.0	0.0
2 layers	0.3	2.1

**Table 10** shows the mean absolute and mean relative errors of ultrasound measurements averaged over all measurements of 1) total tissue thickness and 2) thickness of the interposed fluid layer.

**Table 10**

Ultrasound Measurements	Mean Absolute Error (in mm)	Mean Relative Error (in %)
Total Tissue Thickness	0.5	2.0
Thickness of Interposed Fluid Layer	0.1	4.9

15

The data generated in this *in vitro* model of pretibial edema demonstrate that ultrasound is a highly accurate technique for measuring thickness of a tissue with interposed fluid layers and for measuring the thickness and severity of the edema layer. Based on the results presented in **Tables 6-10**, the mean absolute error for measuring total tissue thickness and measuring the thickness of the interposed fluid layers ranged between 0.2 and 0.5 mm. Relative errors ranged between 2 and 4.9%.

20

These results indicate that ultrasound techniques can monitor edema accurately and non-invasively *in vitro*, as well as *in vivo*.

**Example 2: Ultrasonographic Measurement of Thickness of Capillary Related Edema in a Model of Venous Insufficiency and Right Ventricular Cardiac Failure**

This example documents, among other things, that ultrasound can be used *in vivo* to:

- 1) document rapid interstitial fluid shifts,
- 2) detect presence or progression of capillary related edema, e.g., capillary related edema secondary to impairment of cardiac or vascular function and
- 3) monitor presence or modulation of capillary related edema as a result of therapeutic intervention.

Two healthy male volunteers aged 36 and 34 years were studied. Distances between the knee joint space and the medial malleolus of the right calf were measured in each individual. The following landmarks were defined and marked in the right calf along the anterior aspect of the tibia:

- 1.) anterior aspect of the proximal third of the tibia,
- 2.) anterior aspect of the mid-tibia,
- 3.) anterior aspect of the distal third of the tibia, and
- 4.) medial aspect of the medial malleolus.

Measurement sites were marked on the skin with a pen. The circumference of the extremity was measured at these sites using a tape measure in both volunteers. Ultrasound measurements were then obtained at these sites. In the medial malleolus, the most protuberant portion was selected for scanning. A baseline measurement of tissue thickness was obtained at all four sites in both individuals prior to intervention. Individuals were in an upright and standing position before and during the experiments. Tissue thickness was defined as the distance from the probe/skin interface to the soft-tissue/bone interface. The soft-tissue/bone interface was prominently displayed on the B-scan images as a bright, echogenic reflector.

After a baseline was established, a tourniquet was applied to the distal thigh as a controllable maneuver to reduce blood flow. The tourniquet was sufficiently tight to

retard venous drainage. Arterial pulses in the region of the posterior tibial and dorsalis pedis artery were, however, intact and preserved. Ultrasound measurements of tissue thickness were repeated at each site 15 min, 30 min, and 1 hour after application of the tourniquet. The tourniquet was removed after 1 hour and measurements were  
 5 repeated at each site 30 min and 1 hour after release of the tourniquet.

In addition to the ultrasound measurements of capillary related edema, a trained physician examined both volunteers clinically for visual or palpatory evidence of edema at each time interval, i.e. prior to application of the tourniquet, 15 min, 30 min, and 1 hour after application of the tourniquet, as well as 30 min and 1 hour after  
 10 removal of the tourniquet. Edema was clinically evaluated at the mid-tibial site by visual inspection and manual palpation. Using standard clinical techniques (see Bates et al., J.B. Lippincott, 1995), edema was subdivided into 5 grades:

- O.) absent,
- I.) slight,
- 15 II.) mild,
- III.) moderate, and
- IV.) severe.

One skilled in the art can readily recognize that the techniques described herein can be applied to measuring changes in interstitial fluid in any other body  
 20 region as well as in other living organisms *in vivo*.

Table 11 shows the ultrasound measurement of the thickness of the pretibial tissue/capillary related edema layer in the region of the proximal third of the tibia for different time intervals after application of the tourniquet.

25

**Table 11**

Duration of Impaired Venous Drainage (in hr)	Ultrasound Measurements of Thickness of Pretibial Tissue/Capillary Related Edema Layer in the Proximal Third of the Tibia (in mm)	
	Subject 1	Subject 2
0*	3.0	3.4
0.25	3.1	4.8
0.5	4.4	5.1
1	5.5	5.5

\*: measured immediately prior to application of tourniquet.

**Table 12** shows the ultrasound measurement of the thickness of the pretibial tissue/capillary related edema layer in the region of the mid-tibia for different time intervals after application of the tourniquet.

5

**Table 12**

Duration of Impaired Venous Drainage (in hr)	Ultrasound Measurements of Thickness of Pretibial Tissue/Capillary Related Edema Layer in the Mid-Tibia (in mm)	
	Subject 1	Subject 2
<b>0*</b>	2.3	2.3
<b>0.25</b>	2.3	4.0
<b>0.5</b>	2.9	3.8
<b>1</b>	4.0	4.5

\*: measured immediately prior to application of tourniquet.

**Table 13** shows the ultrasound measurement of the thickness of the pretibial tissue/capillary related edema layer in the region of the distal third of the tibia for different time intervals after application of the tourniquet.

10

**Table 13**

Duration of Impaired Venous Drainage (in hr)	Ultrasound Measurements of Thickness of Pretibial Tissue/Capillary Related Edema Layer in the Distal Third of the Tibia (in mm)	
	Subject 1	Subject 2
<b>0*</b>	2.5	3.3
<b>0.25</b>	2.5	4.5
<b>0.5</b>	3.8	4.0
<b>1</b>	3.5	3.8

\*: measured immediately prior to application of tourniquet.

15

**Table 14** shows the ultrasound measurement of the thickness of the pretibial tissue/capillary related edema layer in the region of the medial malleolus of the tibia for different time intervals after application of the tourniquet.



**Table 14**

Duration of Impaired Venous Drainage (in hr)	Ultrasound Measurements of Thickness of Tissue/Capillary Related Edema Layer in the Region of the Medial Malleolus (in mm)	
	Subject 1	Subject 2
<b>0*</b>	1.6	2.3
<b>0.25</b>	1.8	2.7
<b>0.5</b>	1.7	2.7
<b>1</b>	2.7	3.5

\*: measured immediately prior to application of tourniquet.

**Table 15** shows the results obtained with clinical assessment of pretibial edema in the region of the mid-tibia for different time intervals after application of the tourniquet.

**Table 15**

Duration of Impaired Venous Drainage (in hr)	Clinical Assessment of Pretibial Edema	
	Subject 1	Subject 2
<b>0*</b>	0	0
<b>0.25</b>	0	0
<b>0.5</b>	0	0
<b>1</b>	1	1

\*: measured immediately prior to application of tourniquet.

10

**Tables 16-19** present the data obtained after release of the tourniquet.

**Table 16** shows the ultrasound measurement of the thickness of the pretibial tissue/capillary related edema layer in the region of the proximal third of the tibia for different time intervals after removal of the tourniquet.

**Table 16**

Duration of Restoration of Venous Drainage (in hr)	Ultrasound Measurements of Thickness of Pretibial Tissue/Capillary Related Edema Layer in the Proximal Third of the Tibia (in mm)	
	Subject 1	Subject 2
0*	5.5	5.5
0.5	4.2	4.9
1	3.6	3.9

\*: measured immediately prior to removal of tourniquet.

5      **Table 17** shows the ultrasound measurement of the thickness of the pretibial tissue/capillary related edema layer in the region of the mid-tibia for different time intervals after removal of the tourniquet.

**Table 17**

Duration of Restoration of Venous Drainage (in hr)	Ultrasound Measurements of Thickness of Pretibial Tissue/Capillary Related Edema Layer in the Mid-Tibia (in mm)	
	Subject 1	Subject 2
0*	4.0	4.5
0.5	3.5	3.3
1	2.9	2.4

\*: measured immediately prior to removal of tourniquet.

10      **Table 18** shows the ultrasound measurement of the thickness of the pretibial tissue/capillary related edema layer in the region of the distal third of the tibia for different time intervals after removal of the tourniquet.

**Table 18**

Duration of Restoration of Venous Drainage (in hr)	Ultrasound Measurements of Thickness of Pretibial Tissue/Capillary Related Edema Layer in the Distal Third of the Tibia(in mm)	
	Subject 1	Subject 2
0*	3.5	3.8
0.5	3.4	3.5
1	3.4	3.1

15      \*: measured immediately prior to removal of tourniquet.

**Table 19** shows the ultrasound measurement of the thickness of the pretibial tissue/capillary related edema layer in the region of the medial malleolus of the tibia for different time intervals after removal of the tourniquet.

5

**Table 19**

Duration of Restoration of Venous Drainage (in hr)	Ultrasound Measurements of Thickness of Tissue/Capillary Related Edema Layer in the Region of the Medial Malleolus (in mm)	
	Subject 1	Subject 2
0*	2.7	3.5
0.5	1.4	2.3
1	1.6	2.0

\*: measured immediately prior to removal of tourniquet.

**Table 20** shows the results obtained with clinical assessment of pretibial edema in the region of the mid-tibia for different time intervals after removal of the

10

**Table 20**

Duration of Restoration of Venous Drainage (in hr)	Clinical Assessment of Pretibial Edema	
	Subject 1	Subject 2
0*	1	1
0.5	1	1
1	1	1

\*: measured immediately prior to removal of tourniquet.

Based on the data presented in **Tables 11-14** and **16-19** percent change in thickness of the pretibial tissue/capillary related edema layer was calculated for the four different sites for measurements obtained after application and after removal of the tourniquet. Percent increase after application of the tourniquet was calculated as:

15

$$\% \text{increase} = \{(US_{ts} - US_{\text{PreTourniquet}}) / US_{\text{PreTourniquet}}\} \times 100 \quad [\text{Eq. 6}].$$

Percent decrease after removal of the tourniquet was calculated as:

20

$$\% \text{decrease} = \{(US_{ts} - US_{\text{Tourniquet}}) / US_{\text{Tourniquet}}\} \times 100 \quad [\text{Eq. 7}],$$

where  $US_{ts}$  is the ultrasonographic measurement of the thickness of the pretibial tissue/capillary related edema layer for a given time point "t" and a given

measurement site.  $US_{PreTourniquet}$  is the thickness of the pretibial tissue/edema layer prior to application of the tourniquet for the experiments in which the tourniquet had been applied.  $US_{Tourniquet}$  is the thickness of the pretibial tissue/capillary related edema layer prior to removal of the tourniquet for the experiments in which the

5 tourniquet had been removed.

The percent change in thickness of the pretibial tissue/capillary related edema layer after application of the tourniquet, e.g. to simulate onset of diseased state, and after removal of the tourniquet, e.g. to simulate medical intervention and treatment of diseased state, is shown in **Tables 21** and **22** and is averaged for both volunteers.

10 **Table 21** shows the mean percent increase in thickness of the pretibial tissue/edema layer from baseline ( $US_{PreTourniquet}$ ) compared to the different time intervals after application of the tourniquet measured by ultrasound at all four sites.

**Table 21**

Duration of Impaired Venous Drainage (in hr)	Mean Percent Increase in Thickness of Pretibial Tissue/Capillary Related Edema Layer after Application of Tourniquet*			
	Proximal Third of Tibia (in %)	Mid-Tibia (in %)	Distal Third of Tibia (in %)	Medial Malleolus (in %)
<b>0.25</b>	22.3	37.0	18.2	14.9
<b>0.5</b>	48.3	45.7	36.6	11.8
<b>1</b>	72.5	84.8	27.6	60.5

15 \*data averaged for both volunteers.

**Table 22** shows the mean percent decrease in thickness of the pretibial tissue/capillary related edema layer from baseline ( $US_{Tourniquet}$ ) compared to the different time intervals after removal of the tourniquet measured by ultrasound at all

20 four sites.

Table 22

Duration of Restoration of Venous Drainage (in hr)	Mean Percent Decrease in Thickness of Pretibial Tissue/Capillary Related Edema Layer after Removal of Tourniquet*			
	Proximal Third of Tibia (in %)	Mid-Tibia (in %)	Distal Third of Tibia (in %)	Medial Malleolus (in %)
0.5	17.3	19.6	5.4	41.2
1	31.8	37.1	10.7	41.8

\*data averaged for both volunteers.

To assess the sensitivity of the technique in relation to the size of the leg, anatomical regions were measured. The circumference of the calf was measured in both volunteers at each measurement site using a tape measure. Based on measurements of the circumference, the radius R of the calf was calculated for each site as:

$$R = C / 2\pi \quad [\text{Eq. 8}],$$

where C is the circumference of the calf at a given measurement site.

Table 23 shows circumference and radius of the calf in both volunteers for all four measurement sites.

Table 23

Anatomic Site	Calf Circumference (in mm)		Radius (in mm)	
	Subject 1	Subject 2	Subject 1	Subject 2
Prox. Third of Tibia	366	380	58.2	60.5
Mid-Tibia	334	345	53.1	54.9
Distal Third of Tibia	228	260	36.3	41.4
Medial Malleolus	250	260	39.8	41.4

Based on the data presented in Tables 21-23, percent change in thickness of the pretibial tissue/capillary related edema layer relative to the radius or the circumference of the calf at the different measurement sites was calculated for measurements obtained after application and after removal of the tourniquet. Percent increase after application of the tourniquet relative to the *radius* was calculated for each individual as:

$$\% \text{Increase}_{\text{Edema/Radius}} = \{ | (US_{ts} - US_{\text{PreTourniquet}}) | / R \} \times 100 \quad [\text{Eq. 9}].$$

Percent increase after application of the tourniquet relative to the *circumference* was calculated for each individual as:

$$\% \text{Increase}_{\text{Edema/Circumference}} = \{ | (US_{ts} - US_{\text{PreTourniquet}}) | / C \} \times 100 \quad [\text{Eq. 10}].$$

5 Similarly, percent decrease after removal of the tourniquet relative to the *radius* was calculated for each individual as:

$$\% \text{Decrease}_{\text{Edema/Radius}} = \{ | (US_{ts} - US_{\text{Tourniquet}}) | / R \} \times 100 \quad [\text{Eq. 11}]$$

Percent decrease after removal of the tourniquet relative to the *circumference* was calculated for each individual as:

$$10 \quad \% \text{Decrease}_{\text{Edema/Circumference}} = \{ | (US_{ts} - US_{\text{Tourniquet}}) | / C \} \times 100 \quad [\text{Eq. 12}]$$

**Table 24** shows the mean percent increase in thickness of the pretibial tissue/capillary related edema layer relative to the calf radius averaged over both volunteers at the different time intervals after application of the tourniquet. The method described herein is quite sensitive, as it can detect changes in calf radius less  
15 than about 1.0 to 1.5% of the calf radius. Larger changes of about 5 or 10 percent or greater can also be measured as described herein.

**Table 24**

Duration of Impaired Venous Drainage (in hr)	Mean Percent Increase in Thickness of Pretibial Tissue/Capillary Related Edema Layer after Application of Tourniquet Relative to Calf Radius*			
	Proximal Third of Tibia (in %)	Mid-Tibia (in %)	Distal Third of Tibia (in %)	Medial Malleolus (in %)
<b>0.25</b>	1.2	1.6	1.5	0.7
<b>0.5</b>	2.6	1.9	2.6	0.6
<b>1</b>	3.9	3.6	2.0	2.8

\*data averaged for both volunteers.

20

**Table 25** shows the mean percent increase in thickness of the pretibial tissue/capillary related edema layer relative to the calf circumference averaged over both volunteers at the different time intervals after application of the tourniquet. The method described herein is quite sensitive, as it can detect changes in calf

circumference less than about 0.2 to 0.5% of the calf circumference. Larger changes of about 5 or 10 percent or greater can also be measured as described herein.

**Table 25**

Duration of Impaired Venous Drainage (in hr)	Mean Percent Increase in Thickness of Pretibial Tissue/Capillary Related Edema Layer after Application of Tourniquet Relative to Calf Circumference*			
	Proximal Third of Tibia (in %)	Mid-Tibia (in %)	Distal Third of Tibia (in %)	Medial Malleolus (in %)
<b>0.25</b>	0.2	0.3	0.2	0.1
<b>0.5</b>	0.4	0.3	0.4	0.1
<b>1</b>	0.6	0.6	0.3	0.5

5 \*data averaged for both volunteers.

**Table 26** shows the mean percent decrease in thickness of the pretibial tissue/capillary related edema layer relative to the calf radius averaged over both volunteers at the different time intervals after removal of the tourniquet.

10

**Table 26**

Duration of Restoration of Venous Drainage (in hr)	Mean Percent Decrease in Thickness of Pretibial Tissue/Capillary Related Edema Layer after Removal of Tourniquet Relative to Calf Radius*			
	Proximal Third of Tibia (in %)	Mid-Tibia (in %)	Distal Third of Tibia (in %)	Medial Malleolus (in %)
<b>0.5</b>	1.6	1.6	0.5	3.1
<b>1</b>	3.0	3.0	1.0	3.2

\*data averaged for both volunteers.

**Table 27** shows the mean percent decrease in thickness of the pretibial tissue/capillary related edema layer relative to the calf circumference averaged over both volunteers at the different time intervals after removal of the tourniquet.

15

**Table 27**

Duration of Restoration of Venous Drainage (in hr)	Mean Percent Decrease in Thickness of Pretibial Tissue/Capillary Related Edema Layer after Removal of Tourniquet Relative to Calf Circumference*			
	Proximal Third of Tibia (in %)	Mid-Tibia (in %)	Distal Third of Tibia (in %)	Medial Malleolus (in %)
<b>0.5</b>	0.3	0.3	0.2	0.5
<b>1</b>	0.5	0.5	0.2	0.5

\*data averaged for both volunteers.

The results presented in **Tables 11-15** and **Table 21** demonstrate that

5 ultrasound is a sensitive technique to detect interstitial fluid shifts and quantitate the amount of interstitial fluid. Ultrasound also appears to be extremely useful for early or rapid detection of changes in capillary related interstitial fluid. Significant increases in interstitial fluid can be detected as early as 15 minutes after alteration of venous drainage. The mean percent increase in thickness of pretibial capillary related edema

10 15 minutes after impairment of venous drainage was 22.3% at the proximal tibia and 37.0% at the mid-tibia (**Table 21**). After 1 hour of impaired venous drainage, the tissue thickness in the mid-tibia measured by ultrasound had almost doubled. Clinical examination, i.e. combined visual inspection and manual palpation, did not detect any changes during the 15 minutes and 30 minutes observation periods. Only a slight

15 change (grade I) could be detected at the 1 hour interval (**Table 15**). These results demonstrate that ultrasound is substantially more sensitive than clinical examination in detecting interstitial fluid shifts, which can be seen with venous insufficiency and cardiac disease, as well as other disease states and therapeutic interventions.

When the tourniquet was removed (**Tables 16-20 & 22**), the model can

20 clinically correspond to therapeutic intervention, e.g. administration of cardiac or other drugs. Significant changes could be observed as early as 30 minutes after removal of the tourniquet. Thirty minutes after removal of the tourniquet, the mean decrease in pretibial interstitial fluid layer thickness amounted to 17.3% in the proximal third of the tibia and 19.6% in the mid-tibia (**Table 22**). Clinical

25 examination, however, showed no change even 1 hour after removal of the tourniquet confirming that clinical examination is unreliable in assessing the presence and the



amount of edema (Table 20). These results show that, unlike clinical examination, ultrasound, can be used for early or continuous monitoring and quantification of the efficacy of therapeutic interventions in medical conditions that lead to interstitial edema.

5           The data presented in Tables 24-27 indicate that ultrasound is extremely sensitive in detecting subtle shifts in interstitial fluid. The changes in thickness of the soft-tissue/edema layer that were detected with ultrasound ranged between 0.5 and 3.9% when compared to the radius of the calf and between 0.1 and 0.6% when compared to the circumference of the calf.

10

**Example 3: Ultrasonographic Measurement of Thickness of Pretibial Edema in a Model of Capillary Related Edema Secondary to Abnormal Colloid Osmotic Pressure and/or Renal Failure**

          This example documents that ultrasound can be used *in vivo* to detect subtle  
15   changes in interstitial fluid. The example shows that changes in pretibial interstitial fluid layer thickness relate directly to the volume of interstitial fluid. Two healthy volunteers aged 36 and 34 years were examined with ultrasound. The distance between the medial knee joint space and the medial malleolus of the left calf was measured in each individual. Using these measurements, the mid-region of the  
20   anterior tibia was identified for ultrasound measurements. The measurement site was marked on the skin with a pen. A baseline measurement of tissue thickness was obtained with ultrasound at the marked site in both individuals prior to intervention. Tissue thickness was defined as the distance from the probe/skin to the soft-tissue/bone interface. The soft-tissue/bone interface was prominently displayed on the  
25   B-scan images as a bright, echogenic reflector.

          The measurement site was then cleaned with iodine solution for disinfection. A 10cc syringe was filled with 1% Xylocaine solution (Astra Pharmaceuticals, Westborough, MA 01581). A sterile 25 Gauge needle was attached to the syringe and small volumes of Xylocaine were injected into the pretibial soft-tissues. The total  
30   injected volume was recorded. After each injection, an ultrasonographic measurement of pretibial interstitial fluid layer thickness was obtained. Injected volumes were 0.5cc, 1.5cc, and 2.5cc.

**Table 28** shows the ultrasound measurement of the thickness of the pretibial edema layer in the region of the mid-tibia after local injection of 1% Xylocaine solution for different injection volumes.

**Table 28**

Amount of Fluid injected (in cc)	Ultrasound Measurements of Thickness of Pretibial Edema Layer (in mm)	
	Subject 1	Subject 2
0*	2.6	2.4
0.5	7.2	4.8
1.5	9.0	6.8
2.5	9.5	7.6

5 \*: measured prior to injection.

Once 2.5 cc of 1% Xylocaine solution had been injected, injection was stopped and serial ultrasound measurements of pretibial fluid/edema layer thickness were obtained immediately after injection, and 30 min, 1 hour, 1.5 hours, and 2 hours after  
10 injection.

**Table 29** shows the ultrasound measurement of the thickness of the pretibial edema layer in the region of the mid-tibia for different time intervals after injection of 2.5cc 1% Xylocaine solution.

**Table 29**

Time Interval since Injection of 2.5cc (in hr)	Ultrasound Measurements of Thickness of Pretibial Edema Layer (in mm)	
	Subject 1	Subject 2
0*	9.5	7.6
0.5	5.5	5.0
1	5.0	5.7
1.5	4.4	4.5
2.0	-	4.3

15 \*: measured immediately after completion of injection; -: not obtained.

**Table 30** shows the percent decrease in thickness of the pretibial edema layer measured by ultrasound in the region of the mid-tibia for different time intervals after injection of 2.5cc 1 % Xylocaine solution.

**Table 30**

Time Interval since Injection (in hr)	Percent Decrease in Thickness of Pretibial Edema Layer*	
	Subject 1 (in %)	Subject 2 (in %)
0.5	42.1	34.2
1	47.4	25.0
1.5	53.7	40.8
2.0	-	43.4

\*: data compared to baseline thickness measured immediately after completion of injection; -: not obtained.

- 5           The data presented in **Table 28** indicate that ultrasound is a very sensitive technique in detecting very small changes in interstitial fluid volume. Injection of as little as 0.5cc resulted in an ultrasonographic change in the thickness of the pretibial soft-tissue/edema layer of 100% and greater. These results demonstrate that ultrasound has very high sensitivity in measuring subtle interstitial fluid shifts.
- 10   Moreover, as seen in **Table 28**, ultrasonographic measurement of pretibial interstitial fluid layer thickness correlated well with the volume of injected fluid. This demonstrates that ultrasonographic measurement of the thickness of the interstitial fluid layer in the pre-tibial area as well as potentially other anatomic regions represents a new diagnostic parameter that relates directly to the interstitial fluid
- 15   volume. The data presented in **Tables 29** and **30** show that ultrasound cannot only be used to detect edema, but also to monitor interstitial fluid longitudinally over time and to assess resolution of edema, for example secondary to medical treatment.

**PUBLICATIONS****U.S. PATENT DOCUMENTS**

	4,658,827	Dec. 21, 1987	He, P., et al.
	4,446,737	May 8, 1984	Hottier, F.
5	4,920,966	May 1, 1990	Hon, E. H.
	4,224,829	Sep. 30, 1980	Kawabuchi, M., et al.
	08/731,821	Filed Oct. 21, 1996	Lang, P., et al.
	4,242,911	Jan. 6, 1981	Martin, H. E.
	4,688,428	Aug. 25, 1987	Nicolas, J.-M.
10	4,702,258	Oct. 27, 1987	Nicolas, J.-M., et al.
	4,043,181	Aug. 23, 1977	Nigam, A. K.
	4,830,015	May 16, 1989	Okazaki, K.
	5,271,403	Dec. 21, 1993	Paulos, J. J.
	4,833,323	May 23, 1989	Scholze, C.
15	5,303,708	Apr. 19, 1994	Stouffer, J. R.
	5,316,003	May 31, 1994	Stouffer, J. R.
	5,617,864	Apr. 8, 1997	Stouffer, J. R., et al.

**FOREIGN PATENT DOCUMENTS**

20	PCT WO 93/12419	June 24, 1993	Lake, R. J., et al.
----	-----------------	---------------	---------------------

**OTHER PUBLICATIONS**

- Physician's 1991 drug handbook, pp. 1099-1103, 1991.
- Agner, T., et al., Contact Dermatitis, vol. 20, pp. 352-359, 1989.
- 25 Agner, T., et al., Clin Exp Dermatol, vol. 15, pp. 29-33, 1990.
- Agner, T., et al., J Invest Dermatol, vol. 95 (5), pp. 543-547, 1990.
- Alexander, H., et al., J Invest Dermatol, vol. 72 (1), pp. 17-19, 1979.
- Barnes, M., et al., Phlebology, vol. 7, pp. 31-35, 1992.
- Bates, B., et al., in: "A guide to physical examination and history taking, 6th edition",
- 30 Bates, B., et al., eds., pp. 427-447, 1995.
- Bhagat, P. K., et al., Ultrasound Med Biol, vol. 6, pp. 369-375, 1980.
- Braunwald, E., in: "Harrison's Principles of Internal Medicine", Isselbacher, K. J., Braunwald, E., et al., eds., pp. 183-187, 1994.
- Brazier, S., et al., Contact Dermatitis, vol. 15, pp. 199-201, 1986.
- 35 Bushberg, J. T., et al. "The essential physics of medical imaging", 1994.
- Campbell, I. T., et al., Am J Clin Nutr, vol. 62, pp. 533-539, 1995.
- Carpenter, D. A., et al., Radiology, vol. 195 (2), pp. 563-567, 1995.
- Cohen, J. S., et al., Arthritis & Rheumatism, vol. 27, pp. C65, 1984.
- Ciocon, J. O., et al., Angiology, vol. 46, pp. 19-25, 1995.
- 40 deRigal, J., et al., J Invest Dermatol, vol. 93 (5), pp. 621-625, 1989.
- Dykes, P. J., et al., J Invest Dermatol, vol. 69, pp. 275, 1977.
- Escoffier, C., et al., Bioeng Skin, vol. 2, pp. 87-94, 1986.
- Fornage, B., et al., J Clin Ultrasound, vol. 14, pp. 619-622, 1986.
- Fornage, B., et al., Radiology, vol. 189, pp. 69-76, 1993.
- 45 Fornage, B. D., Radiologia Medica, vol. 85 (5 Suppl. 1), pp. 149-155, 1993.
- Fornage, B. D., Clinics in Diagnostic Ultrasound, vol. 30, pp. 85-98, 1995.
- Gniadecka, M., et al., Br J Dermatol, vol. 131, pp. 849-855, 1994.

- Gniadecka, M., et al., *J Invest Dermatol*, vol. 102 (3), pp. 362-364, 1994.  
Gniadecka, M., *Acta Derm Venereol*, vol. 75, pp. 120-124, 1995.  
Gniadecka, M., *Skin Res Technology*, vol. 1, pp. 55-60, 1995.  
Gniadecka, M., *J Am Acad Dermatol*, vol. 35, pp. 37-41, 1996.  
5 Gottlieb, S. H., in: "Principles of ambulatory medicine", Barker, L. R., et al., eds., pp. 736-754, 1991.  
Goss, S. A., et al., *J Acoust Soc Am*, vol. 64 (2), pp. 423-457, 1978.  
Hermann, R. C., et al., *Skin Pharmacol*, vol. 1, pp. 128-136, 1988.  
Killewich, L. A., et al., *Archives of Surgery*, vol. 120 (4), pp. 424-426, 1985.  
10 Krijnen, R. M. A., et al., *Dermatology*, vol. 194, pp. 121-126, 1997.  
Ludwig, M., et al., *Schweizerische Rundschau fuer Medizin Praxis*, vol. 78 (37), pp. 987-992, 1989.  
Milner, S. M., et al., *Dermatologic Surgery*, vol. 23 (1), pp. 43-35, 1997.  
Munson, P. L. "Principles of pharmacology. Basic concepts and clinical applications",  
15 1995.  
Querleux, B., et al., *Dermatologica*, vol. 177, pp. 332-337, 1988.  
Reali, U., et al., *Plast Reconstr Surg*, vol. 93, pp. 1050-1055, 1994.  
Richard, S., et al., *J Invest Dermatol*, vol. 100 (5), pp. 705-709, 1993.  
Salmi, A., et al., *Plastic and Reconstr Surg*, vol. 97, pp. 1443-1450, 1995.  
20 Seidenari, S., et al., *Contact Dermatitis*, vol. 24, pp. 216-222, 1991.  
Seidenari, S., et al., *Contact Dermatitis*, vol. 25, pp. 329, 1991.  
Seidinari, S., et al., *Contact Dermatitis*, vol. 26, pp. 171-176, 1992.  
Seidenari, S., et al., *Acta Derm Venereol*, vol. Suppl. 175, pp. 3-7, 1992.  
Seidenari, S., et al., *Acta Derm Venereol*, vol. Suppl. 175, pp. 9-13, 1992.  
25 Seidenari, S., et al., *Contact Dermatitis*, vol. 27, pp. 331-332, 1992.  
Serup, J., et al., *Contact Dermatitis*, vol. 10, pp. 88-93, 1984.  
Serup, J., *Acta Derm Venereol*, vol. 64, pp. 214-219, 1984.  
Serup, J., et al., *Contact Dermatitis*, vol. 17, pp. 80-84, 1987.  
Sondergaard, J., et al., *Acta Dermatovenerol*, vol. 65, suppl. 120, pp. 76-82, 1985.  
30 Tan, C. Y., et al., *Br J Dermatol*, vol. 106, pp. 657-667, 1982.  
Tan, C. Y., et al., *J Invest Dermatol*, vol. 76, pp. 126-128, 1981.  
Tan, C. Y., et al., in: "Bioengineering and the skin", Marks, R., et al., eds., pp. 215-225, 1981.  
Williams, P., et al. "Gray's anatomy, 36th British Edition" , 1980.  
35

All documents and publications, including patents and patent application documents, are herein incorporated by reference to the same extent as if each publication were individually incorporated by reference, including U.S. patent application 08/914,527, filed August 19, 1997 by the inventors of the present  
40 application.

## We claim:

1. A method of multi-site monitoring of capillary related edema in a subject, comprising:
  - a) positioning an ultrasound probe on an epidermal surface of at least two anatomical regions of a subject in need of capillary related edema detection,
  - b) applying at least one ultrasound pulse to a subcutaneous layer of said at least two anatomical regions,
  - c) recording a least one ultrasound signal from each of said at least two anatomical locations, and
  - d) detecting the presence or absence of a capillary related edema layer in said subcutaneous layer of said at least two anatomical regions from said ultrasound signals of step (c).
2. The method of claim 1, wherein said subject is a human.
3. The method of claim 2, wherein one anatomical region of said at least two anatomical regions is a tibia region.
4. The method of claim 2, wherein said detecting of said capillary related edema layer extends from an inner surface of skin to either a bone or fat surface in said tibia region.
5. The method of claim 4, wherein said recording does not determine the degree of skin echogenicity.
6. The method of claim 5, further comprising calculating a distance from said inner surface to said bone or fat surface of said tibia region.
7. The method of claim 3, wherein said applying step further includes at least three ultrasound probes positioned at three or more anatomical regions.
8. The method of claim 3, wherein said human has diabetes, compromised renal function or compromised cardiac function.
9. The method of claim 8, further comprising:
  - a) administering a diuretic agent, a cardiac agent or a diabetic agent,
  - b) positioning an ultrasound probe on at least one anatomical region of a subject in need of capillary related edema detection after said administration, and

- c) recording ultrasound signals with said ultrasound probe from said at least one anatomical region;
  - d) wherein said ultrasound signals can be used to measure a capillary related edema layer in said at least one anatomical region after said administration.
- 5 10. The method of claim 2, wherein said positioning step further includes positioning at least four ultrasound probes at four or more anatomical regions.
11. The method of claim 10, wherein said four or more anatomical regions include a tibial region, an arm region and a chest region.
12. The method of claim 8, further comprising measuring said capillary related edema layer at three or more anatomical regions based on said ultrasound signals.
- 10 13. The method of claim 12, wherein said measuring further comprises measuring skin thickness with said at least one ultrasound signal.
14. The method of claim 12, further comprising comparing said capillary related edema layer to a standard subcutaneous layer thickness for said tibia region.
- 15 15. The method of claim 1, wherein said steps (a), (b), (c) and (d) are repeated at least about 24 hours later.
16. The method of claim 1, further comprising comparing an ILT from each of said at least two anatomical regions to assess the relative amount of capillary related edema in said at least two anatomical regions.
- 20 17. The method of claim 1, further comprising:
- a) positioning an ultrasound probe on each of said at least two anatomical regions of said subject in need of capillary related edema detection 24 or more hours after detecting said capillary related edema layers, and
  - 25 b) recording ultrasound signals from each of said at least two anatomical regions;
  - c) wherein said ultrasound signals can be used to measure a change of said capillary related edema layers in each of said at least two anatomical regions after detecting said capillary related edema layer.

18. A multi-site ultrasound system for monitoring capillary related edema, comprising at least two ultrasound probes comprising at least two connections to separately and concurrently connect said at least two ultrasound probes to a computational unit and each of said at least two connections permit signals to pass between said at least two ultrasound probes and said computational unit; and said computational unit comprises at least one chip to process signals from said at least two ultrasound probes, send instructions to said at least two ultrasound probes, and monitor capillary related edema from at least two anatomical locations.
19. The multi-site ultrasound system of claim 18, wherein said at least two ultrasound probes comprises at least three ultrasound probes.
20. The multi-site ultrasound system of claim 19, wherein said at least three ultrasound probes comprises at least four ultrasound probes.
21. The multi-site ultrasound system of claim 19, wherein said computational unit can measure an ILT.
22. The multi-site ultrasound system of claim 18, wherein said computational unit has instructions for concurrently monitoring from said at least two anatomical locations during clinically relevant time periods.
23. The multi-site ultrasound system of claim 19, wherein said computational unit has instructions for continuously monitoring from said at least two anatomical locations during clinically relevant time periods.
24. The multi-site ultrasound system of claim 19, wherein said computational unit comprises a computer program to calculate capillary related edema layer thickness.
25. The multi-site ultrasound system of claim 19, wherein said computer program comprises a standard thickness for skin layer thickness.
- 
26. A therapeutic kit, comprising:
- a) a multi-site ultrasound system for monitoring capillary related edema, comprising at least two multi-site ultrasound probes, and



- b) a computational unit for estimating capillary related edema based on monitoring of capillary related edema based at two or more anatomical regions; and
  - c) a health care product in at least one dosage;
- 5 wherein said multi-site ultrasound system can monitor for a therapeutic effect of said at least one dosage.
27. The therapeutic kit of claim 26, wherein said health care product enhances water loss.
28. The therapeutic kit of claim 27, wherein said health care product is a drug  
10 selected from the group consisting of antiarrhythmics, anticholinergics, antihypertensives, alpha- and beta-adrenergic blockers, calcium channel blockers, cardiac glycosides, hydantoin derivatives, and nitrates.
29. The therapeutic kit of claim 26, wherein said at least two multi-site ultrasound probes comprises at least three multi-site ultrasound probes.
- 15 30. The therapeutic kit of claim 27, wherein said health care product is a drug selected from the group consisting of diuretics such as aldosteron antagonists, carbonic anhydrase inhibitors, loop diuretics and thiazides or thiazide-like agents
31. The therapeutic kit of claim 26, wherein said health care product enhances  
20 cardiac function.
32. The therapeutic kit of claim 27, wherein said health care product is a drug selected from the group consisting of anticoagulants and vasoactive substances.
- 
- 25 33. A method of multi-site monitoring of capillary related interstitial layer thickness, comprising:
- a) transmitting at least one ultrasound pulse to at least two anatomical regions in a subject in need of capillary related interstitial fluid assessment,
  - b) recording at least one ultrasound signal from each of said at least two  
30 anatomical regions, and
  - c) determining a capillary related interstitial layer thickness from a first reflective surface to an internal reflective surface from each of said at least

two anatomical regions, wherein said capillary related interstitial layer thicknesses are an assessment of capillary related interstitial fluid.

34. The method of claim 33, wherein said first reflective surface is a probe-skin interface and said internal reflective surface is from a bone.

5 35. The method of claim 34, wherein one of said at least two anatomical regions is located in an appendage and said subject is a human.

36. The method of claim 35, wherein said steps (a), (b), and (c) are performed prior to a medical treatment and a first capillary related interstitial layer thickness is determined for each of said at least two anatomical regions and further comprising repeating said steps (a), (b), and (c) after, or simultaneous to, said medical treatment and during a clinically relevant time period, and further comprising comparing a second capillary related interstitial layer thickness for each of said at least two anatomical regions to said first interstitial layer thickness for each of said at least two anatomical regions, wherein if said second capillary related interstitial layer thickness for a particular anatomical region is larger than said first capillary related interstitial layer thickness for the corresponding anatomical region then said medical treatment failed or induces an increase in capillary related interstitial fluid for said particular anatomical region or if said second capillary related interstitial layer thickness for a particular anatomical region is smaller than said first capillary related interstitial layer thickness for the corresponding anatomical region then said medical treatment induces a decrease in capillary related interstitial fluid for said particular anatomical region or if said second capillary related interstitial layer thickness for a particular anatomical region is approximately equal to said first capillary related interstitial layer thickness for the corresponding anatomical region then said medical treatment produces no change in capillary related interstitial fluid for said particular anatomical region.

37. The method of claim 36, wherein said medical treatment comprises administration of a drug to said subject.

30

38. The method of claim 37, wherein said steps (a), (b), and (c) are repeated at predetermined intervals as an assessment of capillary related interstitial fluid balance of said subject over a clinically relevant time period.
39. The method of claim 38, wherein said drug is a cardiovascular agent.
- 5 40. The method of claim 38, wherein said drug is a renal agent.
41. The method of claim 35, wherein said steps (a), (b), and (c) are performed prior to and during surgery.
42. The method of claim 33, wherein said steps (a), (b), and (c) are repeated at predetermined intervals as an assessment of capillary related interstitial fluid  
10 balance of said subject over a clinically relevant time period and said subject is a human.
43. The method of claim 42, wherein said method further comprises administration of a general anesthetic.
44. The method of claim 42, wherein said method further comprises intubation.
- 15 45. The method of claim 33, wherein said steps (a), (b), and (c) are repeated at predetermined intervals as an assessment of capillary related interstitial fluid balance of said subject over a clinically relevant time period at least three anatomical locations and said subject is a human.
46. The method of claim 34, wherein said subject is a human and said steps (a),  
20 (b), and (c) are initiated within 36 hours of a trauma to said subject and an initial capillary related interstitial layer thickness is determined and said steps (a), (b), and (c) are repeated during a clinical relevant time period after said trauma and sequential capillary related interstitial layer thicknesses are determined, wherein a progressive increase in capillary related interstitial layer  
25 thickness indicates an increase in capillary related interstitial fluid and a progressive decrease in capillary related interstitial layer thickness indicates a decrease in capillary related interstitial fluid.
47. The method of claim 33, further comprising positioning at least two ultrasound probes on the skin of said at least two anatomical regions and said subject is a  
30 human.
48. The method of claim 47, wherein said at least two ultrasound probes positioned, either continuously or intermittently, at approximately the same

anatomical site, and said transmitting and recording occur at clinically relevant time intervals over at least about a 4 hour time period.

49. The method of claim 47, wherein said at least two ultrasound probes are secured to said subject with an adhesive.

5 50. The method of claim 49, wherein each of said at least two ultrasound probes has a surface area no more than about 2 cm<sup>2</sup>.

51. The method of claim 49, wherein said at least two ultrasound probes comprises at least three ultrasound probes.

---

10 52. A method of multi-site monitoring of vascular performance, comprising:

a) reducing or increasing blood flow to at a first anatomical region in a human need of vascular performance evaluation,

b) monitoring a capillary related interstitial layer thickness of said first anatomical region and a capillary related interstitial layer thickness of at least one additional anatomical region with at least one ultrasound probe  
15 after or concurrent with said step (a), and

c) increasing said blood flow to said tissue after said reducing in step (a) and said monitoring as in step (b) or decreasing said blood flow to said tissue after said increasing in step (a) and said monitoring as in step (b), and

20 wherein said reduction in blood flow controllably reduces blood flow to said tissue for a clinically relevant period of time in step (a) and said increase in blood flow controllably increases blood flow to said tissue for a clinically relevant period of time in step (c), or

25 wherein said increase in blood flow controllably increases blood flow to said tissue for a clinically relevant period of time in step (a) and said reduction in blood flow controllably reduces blood flow to said tissue for a clinically relevant period of time in step (c).

53. The method of claim 52, wherein said first anatomical region is in an appendage and step (a) further comprises applying a tourniquet to said  
30 appendage to reduce blood flow to said appendage.

54. The method of claim 53, wherein said at least one ultrasound probe is a part of an A scan ultrasound system.

55. The method of claim 54, wherein said monitoring in either said steps (b) or (c) uses at least three ultrasound probes, including two ultrasound probes contralaterally located.
56. The method of claim 52, wherein said monitoring can detect a 15% change in interstitial layer thickness.
57. The method of claim 56, wherein said first anatomical region is located in the pretibial region of said leg and said steps (a) through (c) are performed before a medical treatment and either after or concurrent with said medical treatment.
58. The method of claim 55, wherein said monitoring in either said steps (b) or (c) occurs continuously for at least about thirty minutes.
59. The method of claim 52, wherein said monitoring can detect about a 1% or more change in leg diameter arising from changes in interstitial layer thickness.
60. The method of claim 52, wherein said first anatomical region is a tibial region and said increase in blood flow in step (c) occurs with either 1) said tibial region elevated at a level approximately above the heart of said human, 2) said tibial region at approximately the same level as the heart of said subject or 3) said tibial region located at a level approximately below the heart of said subject.
61. The method of claim 60, wherein said tibial region is located at a level approximately below the heart of said subject and said monitoring detects an increase in capillary related interstitial layer thickness during said reduction in blood flow and said monitoring detects a decrease in capillary related interstitial layer thickness during said increase in blood flow, wherein less than about 50% decrease in the change in the capillary related interstitial layer thickness after 60 minutes of said increase in blood flow indicates venous insufficiency.
- 
62. A method for multi-site monitoring of resting or dynamic cardiac performance in a human, comprising:
- a) monitoring interstitial fluid content with an ultrasound probe positioned on the skin of at least two anatomical regions of a human in need of cardiac performance evaluation and said at least two anatomical regions are

suitable for monitoring changes in interstitial fluid content during a clinically relevant time period, and

- 5           b)    comparing said capillary related interstitial fluid content monitored at each of said at least two anatomical regions in step (a) and optionally comparing said capillary related interstitial fluid content monitored at each of said at least two anatomical regions in step (a) with either a standard value for capillary related interstitial fluid content or a previous measurement of capillary related interstitial fluid content in said human.

63.    The method of claim 62, wherein said comparing qualitatively compares  
10       interstitial fluid content to a predetermined standard value for interstitial fluid content, wherein said comparison provides a diagnostic measure of cardiac performance.

64.    The method of claim 62, wherein said human is suspected of having a medical condition that increases interstitial fluid content.

15    65.    The method of claim 62, wherein monitoring occurs before and after one or all of the following: 1) elevating legs of said human, 2) exercise challenge, 3) application of a tissue compression appendage stocking, and 4) administration of a sufficient amount of isotonic saline to cause a temporary interstitial fluid challenge.

---

20    66.    A method of multi-site detection of rapid changes in capillary related interstitial fluid volume in a human, comprising:

- a)    positioning a first ultrasound probe on a skin surface of a first anatomical region of said human in need of capillary related interstitial fluid volume detection during a clinically relevant time period,
- 25       b)    positioning a second ultrasound probe on a skin surface of a second anatomical region of said human in need of capillary related interstitial fluid volume detection during said clinically relevant time period,
- c)    interrogating said first anatomical region with first ultrasound pulses from said first ultrasound probe,
- 30       d)    interrogating said second anatomical region with second ultrasound pulses from said second ultrasound probe,

- e) detecting a first capillary related interstitial fluid volume between an inner surface of skin and either a bone or fat surface in said first anatomical region with ultrasound signals from said first ultrasound pulses, wherein said first capillary related interstitial fluid volume is an indicator of capillary related interstitial fluid volume of said first anatomical region or optionally is an indicator of systemic capillary related interstitial fluid volume and
- f) detecting a second capillary related interstitial fluid volume between an inner surface of skin and either a bone or fat surface in said second anatomical region with ultrasound signals from said second ultrasound pulses, wherein said second capillary related interstitial fluid volume is an indicator of capillary related interstitial fluid volume of said second anatomical region or optionally is an indicator of systemic capillary related interstitial fluid volume.
67. The method of claim 66, further comprising the step of comparing said first capillary related interstitial fluid volume to a predetermined value for capillary related interstitial fluid layer volume.
68. The method of claim 66, wherein said first anatomical region is selected from the group consisting of a tibial region, a humerus region, a chest region, an abdominal region, and a cranial region.
69. The method of claim 68, wherein said measuring is a quantitative measurement of capillary related interstitial fluid volume comprising determining a capillary related interstitial layer thickness or a capillary related interstitial layer volume.
70. The method of claim 66, wherein said detecting in either step (e) or (f) can detect about a 1 millimeter or greater change in interstitial layer thickness.
71. The method of claim 66, wherein said interrogating in either step (c) or (d) occurs during at least two predetermined monitoring times during said clinically relevant time period or occurs continuously during said clinically relevant time period.
72. The method of claim 71, wherein said interrogating occurs over more than a 20 minute time frame.

73. The method of claim 66, wherein said first and second ultrasound probes remain in approximately the same position during said measuring and said measurements occur no less than 1 per minute at regularly spaced intervals.
74. The method of claim 66, further comprising:
- 5       positioning a third ultrasound probe on a skin surface of a third anatomical region of said human in need of capillary related interstitial fluid volume detection during a clinically relevant time period,
- interrogating said third anatomical region with third ultrasound pulses from said third ultrasound probe,
- 10       detecting a third capillary related interstitial fluid volume between an inner surface of skin and either a bone or fat surface in said third anatomical region with ultrasound signals from said third ultrasound pulses, wherein said third capillary related interstitial fluid volume is an indicator of capillary related interstitial fluid volume of said third anatomical region or optionally is an indicator of systemic
- 15       capillary related interstitial fluid volume.
75. The method of claim 74, wherein said second and third ultrasound probes comprises a left tibial region probe, and a right tibial region probe, and wherein said interrogating steps (a) through (c) are performed concurrently.
76. The method of claim 66, wherein said method further comprises interrogating
- 20       said human with a plurality of probes greater than two and includes interrogating at least one of the following anatomical regions: the humerus, the cranium, the chest probe, and the abdomen.
77. A compact ultrasound probe for in situ ultrasound measurements, comprising:
- 25       a) at least one ultrasound crystal in acoustic communication with an acoustic coupling material,
- b) an ultrasound crystal holder adapted for securing said acoustic coupling material to a surface of an object or subject for in situ ultrasound measurements,
- c) a connection for connecting said at least one ultrasound crystal to an
- 30       ultrasound output or recording system, wherein said connection is compatible with securing said ultrasound probe for in situ ultrasound measurements, and



- d) a chip for facilitating interrogation or background noise reduction or management or both.

78. The compact ultrasound probe of claim 77, wherein said at least one ultrasound crystal is a plurality of crystals.

5 79. The compact ultrasound probe of claim 78, wherein said chip facilitates signal processing or transmission.

80. The compact ultrasound probe of claim 78, wherein said acoustic coupling material has an adhesive coating or adhesive properties.

10 81. The compact ultrasound probe of claim 78, wherein said ultrasound probe is adapted for ILT interrogation.

82. The compact ultrasound probe of claim 78, wherein said connection comprises a an electrical coupling for transmitting electrical signals to an ultrasound computational unit that can calculate ILT or a capillary related interstitial thickness and said electrical coupling is sufficiently light to permit said  
15 ultrasound probe to rest on said subject without substantial interference with ultrasound interrogation and ultrasound probe placement and said subject is a human.

83. The compact ultrasound probe of claim 78, wherein said connection comprises an infra red coupling for transmitting signals to an ultrasound computational  
20 unit that can calculate ILT or a capillary related interstitial thickness and said infra red coupling is sufficiently light to permit said ultrasound probe to rest on said subject without substantial interference with interrogation and ultrasound probe placement and said subject is a human.

25 84. The compact ultrasound probe of claim 78, wherein said wherein said connection comprises a radio frequency coupling for transmitting signals to an ultrasound computational unit that can calculate ILT or a capillary related interstitial thickness and said radio frequency coupling is sufficiently light to permit said ultrasound probe to rest on said subject without substantial interference with interrogation and ultrasound probe placement and said  
30 subject is a human.

85. The compact ultrasound probe of claim 78, wherein said connection comprises a radio frequency coupling for transmitting signals to an ultrasound computational unit.
86. The compact ultrasound probe of claim 72, wherein said coupling material has a surface area of about  $1\text{cm}^2$  or less.
87. The compact ultrasound probe of claim 83, wherein said coupling material has a surface area of about  $2\text{cm}^2$  or less.
88. The compact ultrasound probe of claim 85, wherein said coupling material has a surface area of about  $2\text{cm}^2$  or less.
89. The compact ultrasound probe of claim 78, wherein said probe is not adapted for Doppler measurements.
90. The compact ultrasound probe of claim 78, wherein said probe is not adapted for positioning on the surface of a body cavity.
- 
91. A wireless, micro-transducer, comprising a continuous acoustic surface acoustically coupled to an ultrasound source and detector, wherein said continuous acoustic surface and said ultrasound source and detector are disposed in a structure or frame adapted for directly or indirectly securing said micro-transducer to a skin, and a output port for transmission to an ultrasound signal processing or transmitting unit.
92. The micro-transducer of claim 91, wherein said micro-transducer is adapted for monitoring interstitial thickness.
93. The micro-transducer of claim 92, wherein said micro-transducer has a surface area of about  $.5\text{cm}^2$  or less.
94. The micro-transducer of claim 93, wherein said micro-transducer is 1 cm or less in thickness.
95. The micro-transducer of claim 92, wherein said out-put port further comprises a radio frequency coupling for transmitting signals to an ultrasound computational unit.
96. The micro-transducer of claim 95, wherein said micro-transducer has a surface area of about  $2\text{cm}^2$  or less.

97. The micro-transducer of claim 92, wherein said micro-transducer further comprises an infra red coupling for transmitting signals to an ultrasound computational unit.
98. The micro-transducer of claim 95, wherein said micro-transducer includes a  
5 chip to either filter signals, transmit pulses in a predetermined manner, control activation of said micro-transducer or control deactivation of said micro-transducer or a combination thereof.
99. The micro-transducer of claim 93, wherein said micro-transducer is sterile and further comprises a covering to protect said micro-transducer from  
10 contamination.
- 
100. A multi-probe set, comprising a first ultrasound probe comprising a first output port, said first ultrasound probe adapted for continuous or in situ monitoring at a first anatomical region and a second ultrasound probe  
15 comprising a second output port, said second ultrasound probe adapted for continuous or in situ monitoring at a second anatomical region.
101. The multi-probe set of claim 100, further comprising an ultrasound system to concurrently process first signals from said first ultrasound probe and second signals from said second ultrasound probe.
- 20 102. The multi-probe set of claim 100, wherein said first and second ultrasound probes are for in situ monitoring.
103. The multi-probe set of claim 102, wherein an anatomical region is selected from the group consisting of the forehead region, anterior tibia region, foot region, distal radius region, elbow region, presternal region and temporal bone  
25 region.
104. The multi-probe set of claim 102, wherein said first ultrasound probe is a micro-transducer adapted for monitoring interstitial layer thickness.
105. The multi-probe set of claim 102, further comprising a third ultrasound probe comprising a third output port, said third ultrasound probe adapted for in situ  
30 monitoring at a third anatomical region.

106. The multi-probe set of claim 100, wherein each of said first and second ultrasound probes further comprises a radio frequency coupling for transmitting signals to an ultrasound computational unit.
107. The multi-probe set of claim 106, wherein said micro-transducer has a surface area of about  $1\text{cm}^2$  or less.
108. The multi-probe set of claim 100, wherein each of said first and second ultrasound probes further comprises an infra red coupling for transmitting signals to an ultrasound computational unit.
109. The multi-probe set of claim 108, wherein said micro-transducer has a surface area of about  $1\text{cm}^2$  or less.
- 
110. A method of multi-site monitoring, comprising:
- a) transmitting an ultrasound pulse from a first ultrasound probe to a first anatomical region,
  - b) transmitting an ultrasound pulse from a second ultrasound probe to a second anatomical region,
  - c) recording ultrasound signals from a first ultrasound probe to a first anatomical region,
  - d) recording ultrasound signals from a second ultrasound probe to a second anatomical region, and
  - e) monitoring interstitial layer thickness of said first and second anatomical regions.
111. The method of claim 110, wherein said monitoring from said first anatomical region is concurrent with said monitoring from said second anatomical region.
112. The method of claim 110, wherein said step (a) is within about 10 seconds of step (b) and is automatically controlled by a computational unit.
113. The method of claim 110, wherein said steps (a) through (e) are repeated about every 30 to 600 seconds.
114. The method of claim 112, wherein said first and second ultrasound probes are micro-transducers.
115. The method of claim 114, further comprising interrogating with a third micro-transducer.

116. The method of claim 110, further comprising a step of comparing interstitial layer thickness from said first and second anatomical regions.
117. The method of claim 110, further comprising a step determining the rate of change over time of an interstitial layer thickness from said first and second anatomical regions.
118. The method of claim 114, wherein said micro-transducers are secured to the skin for continuous monitoring during at least about a 1 to 24 hour period.
119. The method of claim 118, wherein an anatomical region is selected from the group consisting the forehead region, anterior tibia region, distal radius region, presternal region and temporal bone region.
120. The method of claim 114, wherein said micro-transducers are secured to the skin for continuous monitoring during a clinically relevant time period.
121. A multi-probe set, comprising:  
a first ultrasound probe comprising a first output port, a first chip for controlling operation of said first ultrasound probe and said chip may optionally include a program for multi-site monitoring and A scan and a first housing or frame for said first ultrasound probe and said chip, wherein said first ultrasound probe adapted for continuous or in situ monitoring at a first anatomical region, and  
a second ultrasound probe comprising a second output port and a second chip for controlling operation of said second ultrasound probe and said chip may optionally include a program for multi-site monitoring and A scan and a second housing or frame for said first and second ultrasound probes and said chip, wherein said second ultrasound probe adapted for continuous or in situ monitoring at a second anatomical region.
122. The multi-probe set of claim 121, wherein first ultrasound probe further comprises a power feedback system and said second ultrasound probe further comprises a power feedback system.
123. The multi-probe set of claim 121, wherein said first ultrasound probe further comprises an oxymeter and said second ultrasound probe further comprises an oxymeter.

124. The multi-probe set of claim 121, wherein first ultrasound probe further comprises a thermometer and said second ultrasound probe further comprises a thermometer.
- 5 125. The multi-probe set of claim 121, wherein an anatomical region is selected from the group consisting of the forehead region, anterior tibia region, foot region, distal radius region, elbow region, presternal region and temporal bone region and said first and second ultrasound probes are adapted for automated monitoring.
- 10 126. The multi-probe set of claim 125, wherein said ultrasound probe is a micro-transducer adapted for monitoring interstitial layer thickness.
127. The multi-probe set of claim 125, further comprising a third ultrasound probe comprising a third output port and an ultrasound source and detector, said third ultrasound probe adapted for continuous or in situ monitoring at a third anatomical region.
- 15 128. The multi-probe set of claim 127, wherein said ultrasound system comprises a computational unit for concurrent monitoring of ultrasound signals from said first, and second ultrasound probes and first, second and third anatomical regions, respectively, during a clinical relevant time period.
- 20 129. The multi-probe set of claim 128, wherein said first output port is connected to said ultrasound system by lightweight electrical connections that permit automated in situ monitoring, and said second output port is connected to said ultrasound system by lightweight electrical connections that permit automated in situ monitoring.
- 25 130. The multi-probe set of claim 129, wherein said first ultrasound probe is securable to skin of said first anatomical region for continuous, uninterrupted monitoring and said second ultrasound probe is securable to skin of said second anatomical region for continuous, uninterrupted monitoring.
- 30 131. The multi-probe set of claim 121, wherein said first ultrasound probe is securable to said skin with an in situ probe holder and said second ultrasound probe is securable to said skin with an in situ probe holder.

132. The multi-probe set of claim 121, wherein said first output port is connected to said ultrasound system by a first radio frequency transmitter and said second output port is connected to said ultrasound system by a second radio frequency transmitter,

5                wherein said first radio frequency transmitter can identify said first ultrasound probe and second radio frequency transmitter can identify said second ultrasound probe.

133. The multi-probe set of claim 121, wherein said first ultrasound probe has a surface area less than about 4 centimeters squared and said second ultrasound probe has a surface area less than about 4 centimeters squared.

10

---

134. A multi-probe set, comprising:

              a first ultrasound probe comprising a first output port and an ultrasound source and detector, said first ultrasound probe adapted for in situ monitoring at a first anatomical region, and

15

              a second ultrasound probe comprising a second output port and an ultrasound source and detector, said second ultrasound probe adapted for in situ monitoring at a second anatomical region,

              a third ultrasound probe comprising a third output port, said third ultrasound probe adapted for in situ monitoring at a third anatomical region,

20

              wherein first and second ultrasound probes are adapted for multi-site monitoring to permit recording of ultrasound signals during clinically relevant time periods and are securable to a subject's skin at predetermined anatomical regions, further wherein said first, second and third ultrasound probes are adapted for either imaging or measurements of an anatomical distance.

25

135. The multi-probe set of claim 134, wherein said first ultrasound probe is securable to said skin with an in situ probe holder, said second ultrasound probe is securable to said skin with an in situ probe holder and said third ultrasound probe is securable to said skin with an in situ probe holder.

136. A multi-probe set, comprising:
- a first ultrasound probe comprising a first output port and an ultrasound source and detector, said first ultrasound probe adapted for in situ monitoring at a first anatomical region, and
- 5 a second ultrasound probe comprising a second output port and an ultrasound source and detector, said second ultrasound probe adapted for in situ monitoring at a second anatomical region,
- wherein first and second ultrasound probes are adapted for multi-site monitoring, further wherein said first output port comprises a first radio frequency
- 10 transmitter for connecting said first ultrasound probe to a signal processing unit and said second output port comprises a second radio frequency transmitter for connecting said second ultrasound probe to said signal processing unit,
- wherein said first radio frequency transmitter can identify said first ultrasound probe and second radio frequency transmitter can identify said second ultrasound
- 15 probe.
137. The multi-probe set of claim 136, wherein said first ultrasound probe transmits a first coded signal to said signal processing unit, said first coded signal comprises an ultrasound signal information, first anatomical region identification and patient information and said second ultrasound probe
- 20 transmits a second coded signal to said signal processing unit, said second coded signal comprises ultrasound signal information, second anatomical region identification and patient information.
138. The multi-probe set of claim 136, further comprising a RF relay station.
139. The multi-probe set of claim 136, wherein said first radio frequency
- 25 transmitter is a separate, reusable unit that mechanically engages said first ultrasound probe and said second radio frequency transmitter is a second separate, reusable unit that mechanically engages said second ultrasound probe, wherein said first and second ultrasound probes are contained in sanitary, sealed packages prior to engaging said radio frequency transmitters.



140. A remote, medical probe that emits wave form energy into, or receives wave form energy from, a tissue, comprising  
a medical probe selected from the group consisting of a MRI probe, an  
ultrasound probe, radioactivity probe and a photon probe,  
5 and optionally a probe of human physiology, such as a temperature, oxygen, pH, conductivity, electrical or salinity probe,  
a first radio frequency transmitter,  
and whereby said first radio frequency transmitter can connect said medical probe to a signal processing unit.
- 10 141. The remote, medical probe of claim 140, wherein said medical probe is an ultrasound probe for diagnostic applications.
142. The remote, medical probe of claim 141, wherein said first radio frequency transmitter is a passive system and is electronically connected to said medical probe.
- 15 143. The remote, medical probe of claim 142, wherein said first radio frequency transmitter is an active system.
144. The remote, medical probe of claim 140, wherein said first radio frequency transmitter can identify and provide instruction to said medical probe.
145. The remote, medical probe of claim 140, wherein said first radio frequency  
20 transmitter transmits signals to said signal processing unit and said signal processing can transmit at least one instruction signal to first radio frequency transmitter and said medical probe responds to said at least one instruction signal.
146. The remote, medical probe of claim 141, wherein said medical probe  
25 comprises an energy unit.
147. The remote, medical probe of claim 140, further comprises a signal processing unit, wherein said signal processing unit is programmably controllable to monitoring signals from said medical probe or to control the operation of said medical probe.
- 30 148. The remote, medical probe of claim 140, wherein said signal processing unit can receive a plurality of signals from a plurality of medical probes, each said medical probe disposed on a plurality of subjects.

149. A computer program product, comprising instructions for creating an anatomical map based on fluid regulation information from ultrasound signals.
150. A computer program product, comprising instructions for interrogating multiple anatomical sites with multiple ultrasound probes.

1/8




FIG. 1A




FIG. 1B




FIG. 1C

3/8




FIG. 2A




FIG. 2B

4/8






FIG. 2C

**FIG. 3**



**FIG. 4**



7/8




FIG. 5A




FIG. 5B

8/8




FIG. 6

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/17240

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61B 8/00

US CL : 600/449

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 600/449

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
600/437, 438, 450, 454, 459Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Extra Sheet.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,622,177 A (BREIMESSER et al) 22 April 1997, col. 3 line 1-14.	77-81, 89, 90
Y	US 5,598,845 A (CHANDRARATNA et al) 04 February 1997, col. 4 lines 12-59.	77-81, 89, 90, 134, 135
Y	US 4,807,635 A (OPHIR) 28 February 1989, col. 2 lines 40-68, and col. 7 line 25 to col. 8 line 29.	100-105, 107, 110-116, 134, 135
X	US 4,413,629 A (DURLEY, III) 08 November 1983, col. 2 lines 39-57.	140, 141, 143, 144, 146

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

21 OCTOBER 1998

Date of mailing of the international search report

03 NOV 1998

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

FRANCIS J. JAWORSKI

Telephone No. (703) 308-3061

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/17240

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 149, 150  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
The claims are drawn to a computer program product, i.e., a program per se as opposed to a program resident on a computer readable medium.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐  
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/17240

## B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS

Search Terms: (interstitial layer)(3a)(measur? or detect? or determin?)  
(ultraso?) and edema; and peripheral(w)edema